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Abstract 
 
Breast cancer is the most common cancer in women worldwide and afflicts about 30 % of all 
women between 35 and 50 years. The majority of breast cancers are estrogen dependent. 
This means that they need estrogen for their development and growth. Estrogen dependent 
breast cancers can be treated with hormone therapy to block estrogen action and prevent 
cancer growth. Unfortunately, there are many side effects associated with this treatment and 
therefore, there is a great need for the development of new therapies for breast cancer. Liver 
receptor homologe-1 (LRH-1) is a nuclear receptor that recently came into focus for its 
implications in breast cancer development and growth. Targeting LRH-1 could present an 
alternative approach for the treatment of breast cancer. There are two potential sites to target 
nuclear receptors: the ligand binding pocket or the co-activator binding site. Both sites are 
known to be crucial for the transcriptional activity of nuclear receptors.  
 
This thesis gives an overview about breast cancer and the role of nuclear receptors in this 
disease. In particular, approaches to the regulation of nuclear receptors using small molecule 
antagonists are discussed both in terms of traditional “ligand binding pocket” inhibitors and 
the more recently explored “co-activator binding inhibitors”. Both approaches are explained 
generally and in the context of LRH-1. 
The work described here is divided into two parts: The first part describes the synthesis and 
evaluation of a library of benzimidazole-based potential antagonists of LRH-1. These 
molecules are expected to bind into the ligand binding pocket and act as traditional 
antagonists.   
The second part of this thesis explains the synthesis of an α-helix mimetic. A previous PhD 
student in the group developed a route for the synthesis of an α-helix mimetic. The mimetic 
targeted here was anticipated to bind competitively to the co-activator binding site of LRH-1 
and prevents co-activators from binding and consequently blocks transcriptional activity.  
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thesis are acknowledged by means of references. 	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1. Introduction 
1.1 Introduction to Breast Cancer 
1.1.1 The Normal Breast  	  
The breast consists of fat, connective tissue and glandular tissue. The glandular tissue 
contains the lobes (milk glands), where the milk is produced, and milk ducts, which connect 
the lobes to the nipple (figure 1.1). 
 
	  
Figure 1.1: Structure of the breast (illustrations from Macmillan Cancer Support). [1] 
 
The area of breast tissue extends into the axilla, the breast bone and the collar bone, where 
lymph nodes can be found that connect the breast to the lymphatic system. [2] 
 
1.1.2 Breast Cancer 
 
Breast cancer is a malignant tumour that originates in the breast tissue, most commonly in 
the ducts or lobes. [2] 
In the western world, the incidences of breast cancer have doubled since 1940. [3] World-
wide, a yearly incidence rate of nearly one million new cases has been estimated. Breast 
cancer constitutes 30% of all cancers in women between 35 and 55 years of age. [3] 
 
1.1.2.1 Types of Breast Cancer 
 
Traditionally, breast cancers are classified according to their origin. There are 5 main types of 
breast cancer subdivided into 3 classes: ductal carcinomas, lobular carcinomas and rare 
types.  
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Ductal Carcinomas 
 
Ductal carcinoma in situ (DCIS) 
 
20% of breast cancers are DCISs. This type of cancer is made of 
irregular cells found in the ductal system of the breast (figure 1.2).  
DCISs are the most common non-invasive breast cancer. It is a 
non-metastatic breast cancer, but around 50% of DCISs progress 
to become malignant. Between 50 and 75% are ER/PR positive 
and have a good prognosis. The remaining 30-50% are HER2 
positive with a worse prognosis than the ER/PR positive cancers. [4] 
 
 
Invasive ductal breast cancer (IDC) 
 
With about 80% of cases, IDCs are the most common type of invasive breast cancers. 
Originated in the milk ducts, this cancer invades the surrounding tissue. IDCs move to other 
parts of the body through the blood stream or the lymphatic system. Women over 40 years 
have an increased risk of developing invasive ductal carcinomas. [4] 	  	  
Lobular Carcinoma 
 
Lobular carcinoma in situ (LCIS) 
 
LCIS is a benign type of breast cancer, which starts in the milk producing glands. It is often 
referred to as lobular neoplasia. Unlike the DCIS, it does not progress to its invasive type. 
LCIS are most commonly found in pre-menopausal women aged 40-50. They are usually 
HER2 negative but ER/PR positive and can therefore be treated with hormone therapy. [4] 
 
Invasive lobular breast cancer (ILC) 
 
This type develops in the milk-producing glands of the breast (figure 
1.3). Like the IDCs, it invades the surrounding tissue and has the 
ability to metastasise. It presents as an abnormal feeling in the 
breast. ILCs are most common in women between 45 and 56 years. 
[4] 
 
 
Figure 1.2: Illustration of DCIS (Image used with 
kind permission from breastcancer.org) [4] 
Figure 1.3: Illustration of ILC: Breast profile: A: ducts; B: lobules; C: dilated section of duct 
to hold milk; D: nipple; E: fat; F: pectoralis major muscle; G: chest wall/ rib cage; 
Enlargement: A: normal cells; B: lobular cancer cells breaking through basement membrane; 
C: basement membrane (Image used with kind permission from breastcancer.org) [4] 
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1.1.2.2 Rare Types of Breast Cancer 	  
Inflammatory Breast Cancer (IBC) 	  
In inflammatory breast cancer, the cancer cells grow along small lymph vessels in the skin of 
the breast and block these vessels. The body reacts to this blockage with symptoms similar to 
an inflammation: the breast becomes swollen sore and often develops an orange-peel like 
skin.  
With only 1-4% of breast cancer patients affected by IBC, it is a rare but aggressive form of 
breast cancer. [1] 	  	  
Paget’s Disease 
 
Paget’s disease affects less than 5% of breast cancer patients and shows with an eczema- 
like change of the nipple and areola. The majority of patients with Paget’s disease have 
underlying DCISs or a type of invasive cancer. [4] 
 
 
Breast Cancer in Men 
 
Breast cancer in men is very rare. As for women, age is a major risk factor. Additional risk 
factors are exposure to estrogen, radiation to the chest and Klinefelter’s syndrome. This 
syndrome is a set of symptoms that result from the presence of an additional of X 
chromosome, which can cause an increased concentration of circulating estrogen and hence 
more feminie body features and a higher risk to develop brest cancer. 
 
1.1.2.2 Molecular Classification of Breast Cancers 
 
More modern classification methods also take other relevant information such as the grade 
and receptor status into account. The grade is determined by microscopic analysis and gives 
information about the appearance of the breast cancer cells. A low grade corresponds to well 
differentiated cancer cells, that appear similar to healthy cells in shape and organisation. Low 
grade cancers are associated with slowly growing tumours and a good prognosis. In contrast, 
high grade breast cancer cells are not differentiated and exhibit an abnormal shape and a 
non-tissue like organisation. High grade breast cancers are associated with fast growing 
tumours and a worse prognosis.  
The receptor status defines which receptors are expressed in the breast cancer. Nuclear 
receptors are transcription factors that regulate the expression of their target genes. In the 
context of breast cancer, there are three important nuclear receptors: the estrogen receptor 
(ER), the progesterone receptor (PR) and HER2 (Human Epidermal Growth Factor Receptor 
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2). ER/PR positive breast cancers express the estrogen receptor and the progesterone 
receptor. ER/PR positive breast cancers are estrogen dependent tumours and require 
estrogen for their growth. Due to this dependency, ER positive tumours can be treated by 
hormone therapy, which generally improves the prognosis. Tumours that express HER2 are 
termed HER2 positive. This can be in conjunction with ER/PG, so that all three receptors are 
present. Breast cancers which express the HER2 receptor have a worse prognosis than the 
only ER/PR positive cancers as they tend to be of higher grade and more proliferative.  
Additionally, there are breast cancers where none of the mentioned receptors are expressed. 
These “triple negative“ cancers are generally associated with a bad prognosis. 
By taking into account more factors, a more accurate classification of the breast cancer is 
possible which allows for a more individual treatment and can prevent over- or under-
treatment of breast cancer patients. 
 
1.1.3 Risk Factors for Breast Cancer 
 
The greatest risk factor for breast cancer is gender. The occurrence of breast cancer in 
women is 100 times higher than in men. [5] The risk to develop breast cancer increases 
steadily with age. The vast majority of patients are women over 50 years of age.  
Although only 5-10% of cases are considered hereditary, genetics are a risk factor. [3] 
Alterations in the BRCA-1 and BRCA-2 genes are the most common mutations accounting for 
the development of breast cancer. Closely related to the hereditary risk factor is the family 
history. The risk increases the more close relatives developed breast cancer.  
An important risk aspect is the hormonal history. The exposure to estrogen and progesterone 
for a long period of time has been linked to an increased risk of developing breast cancer. 
The use of hormone replacement therapy or the contraceptive pill increases estrogen levels 
and contributes to this hormonal history. Further aspects include early menarche, late 
menopause, having no children or having children late in life and not having breastfeed 
children. [6]  
After the menopause, when the ovary has stopped the production of estrogen, adipose tissue 
is the major source of estrogen. It is produced from androgens by the aromatase enzyme. 
Therefore, obesity is a risk factor for the development of breast cancer. There is evidence that 
a lack of physical activity increases the risk of breast cancer, independent of the menopausal 
status. [7] Other common risk factors are smoking and excessive alcohol consumption.  
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1.1.4 Treatments for Breast Cancer 
 
The first line of treatment is surgery where parts of the breast (lumpectomy) or the whole 
breast (mastectomy) are removed. To reduce the risk of reoccurrence, radiation therapy is 
routinely used as adjuvant therapy after the surgical removal of the tumour. Chemotherapy is 
only indicated for invasive types of cancer. [6] Another adjuvant therapy is hormone therapy. In 
ER positive breast cancers, where estrogen is required for the tumour growth, blocking 
estrogen from binding to the estrogen receptor or reducing estrogen production are important 
methods of treatment. This can be achieved with selective estrogen receptor modulators, 
which prevent estrogen from binding to the estrogen receptor or aromatase inhibitors that 
reduce the local estrogen production.  
In HER2 positive breast cancers, adjuvant therapy can also consist of treatment with a 
monoclonal antibody which blocks HER2 action such as Trastuzumab (Herceptin®).  
 
1.1.4.1 Hormone Therapy-Estrogen and the Estrogen Receptor 
 
Estrogen is a steroidal hormone that is produced by the female ovaries. It is involved in cell 
proliferation in the breast inner lining and the uterine inner lining (endometrium) to prepare the 
female body for a possible pregnancy. At the end of the menstrual cycle the concentration of 
circulating estrogen decreases dramatically and the endometrium is shed out as 
menstruation. Additionally, estrogen is involved in maintaining bone density, lowers LDL-
cholesterol and increases HDL-cholesterol. Estrogen has been shown to slow down the 
development of dementia and has a positive effect on cognitive functions (figure 1.4).  
 
	  
Figure 1.4: Sites of estrogen action. [8] 
 
The actions of estrogen are mediated by the ER, a nuclear receptor of the family of ligand-
activated transcription factors. Upon estrogen binding the estrogen receptor is activated and 
controls the expression of its target genes.  
	  
Breast 
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(sexual reproduction) 
Brain  
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Heart 
Liver 
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increases LDL cholesterol) 
Bone 
(maintains bone density) 
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Selective Estrogen Receptor Modulators (SERMs) 
 
SERMs stimulate or inhibit the action of estrogen in different tissues. The most famous 
example is Tamoxifen (Nolvadex®). It has anti-estrogenic properties in breast tissue and 
prevents cell growth and therefore reduces the risk of breast cancer (figure 1.5).  
	  
Figure 1.5: Structures of selected SERMs. 
 
Additionally, Tamoxifen has beneficial estrogen-like properties in the bone, where it preserves 
bone mineral density, and in the liver, where it affects cholesterol metabolism. [9] In 1977 the 
FDA approved Tamoxifen for the treatment of advanced breast cancer and in 1998 
Tamoxifen was approved for the reduction of risk of breast cancer in pre-and postmenopausal 
women. [9, 10] To date, Tamoxifen is the most prescribed anti-cancer drug. However, it exhibits 
severe side effects. Due to its estrogen-like behaviour, Tamoxifen increases the risk of 
uterine endometrial cancer and causes thromboembolic events in postmenopausal women.  
Another problem occurring with Tamoxifen is that a high population of tumours that express 
the ER develop a resistance to Tamoxifen. This can lead to the rapid reoccurrence of the 
breast cancer when undetected. There are many possible explanations for this resistance. 
Some of which are mutations in the ER, limited ER saturation by Tamoxifen due to a reduced 
intracellular concentration, alterations in the co-regulator proteins or increased metabolism of 
Tamoxifen to its agonistic metabolites (e.g. 4-hydroxy-N-desmethyltamoxifen). [11, 12,13] 
 
Raloxifene (Evista®) is a second generation SERM. It works in a similar fashion to Tamoxifen 
by acting as an anti-estrogen in breast tissue, and estrogen-like in bone and liver (figure 1.6).  
 
	  
Figure 1.6: Structure of Raloxifen and analogues- second generation SERMs. 
 
After being originally approved for preventing osteoporosis in postmenopausal women, 
Raloxifene is now also approved for reduction of risk of breast cancer in postmenopausal 
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patients. Because of its poor bioavailability and short half life, the efficacy of Raloxifen in 
preventing breast cancer is slightly lower than of Tamoxifen.  On the other hand, Raloxifen 
does not increase the risk of endometrial cancer.  
 
 
Aromatase Inhibitors 	  
Aromatase is an enzyme of the P-450 superfamily. It is responsible for the final step in the 
conversion of androgens to estrogen. After the menopause the ovaries stop the production of 
estrogen. The residual estrogen production is solely from non-glandular sources, in particular 
subcutaneous fat.  
Aromatase inhibitors are designed to reduce the risk of breast cancer in postmenopausal 
women. They act via the inhibition of aromatase and prevent the synthesis of estrogen. 
Aromatase inhibitors affect the estrogen production in the whole body and do not profit from 
the positive effects on the bones density of the SERMs. The most serious side effects include 
loss of bone density, an increased fracture rate and heart problems. There are two types of 
third generation aromatase inhibitors: the steroidal and non-steroidal type (figure 1.7).  
 
	  
Figure 1.7: Structures of aromatase inhibitors. 
 
The steroidal aromatase inhibitors such as Exemestane (Aromasin®), bind irreversibly to the 
aromatase enzyme and deactivate the enzyme. The non-steroidal aromatase inhibitors such 
as Letrozole (Femara®) or Anastrozole (Arimidex®) also bind to aromatase to prevent its 
actions, but do so in a reversible manner. Current trials are evaluating the use of aromatase 
inhibitors as first line adjuvant therapy in breast cancer.  
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Estrogen Receptor Downregulators 
 
Estrogen receptor downregulators are used in patients with metastatic breast cancers and 
where other hormone therapies have stopped working. Fulvestrant (Faslodex®) is one of 
these downregulators (figure 1.8).  
	  
Figure 1.8: Structure of estrogen downregulator Fulvestrant. 
Fulvestrant acts in two different ways: as an anti-estrogen, it binds to the ER and prevents 
estrogen from binding. This deactivates both co-activator binding sites (AF-1 and AF-2) and 
prevents dimerisation, both required for the receptor’s action. Additionally, it destroys the ER 
and consequently decreases the concentration of the ER. 
 
 
Antibody Therapy 
 
Breast cancers, where HER2 is overexpressed can be treated with Trastuzumab 
(Herceptin®). This drug consists of a monoclonal antibody that blocks the action of a growth-
promoting protein HER2/neu and prevents cell division and therefore, cancer growth.  
 
The work presented in this thesis concerns the development of molecules designed to inhibit 
the action of nuclear receptors. For a better understanding of the action of nuclear receptors, 
a brief introduction into nuclear receptors is given here.  
 
1.2 Nuclear Receptors 
 
Nuclear receptors are the largest super family of intracellular transcription factors with 48 
members identified in the human genome. [14] From these, 25 nuclear receptors are classified 
as orphan, [15] which means that no ligand has yet been identified. Nuclear receptors play 
important roles in key biological processes, ranging from development and reproduction to 
homeostasis and metabolism. [16] The nuclear receptor super family is divided into three 
classes. The steroid receptor class includes the progesterone receptor, estrogen receptor and 
androgen receptor, the thyroid/retinoid class that includes the thyroid receptor, vitamin D 
receptor and the orphan receptor class. [17] As indicated above, in the context of breast 
cancer, there have traditionally been considered three nuclear receptors of importance: the 
estrogen receptor, progesterone receptor and HER2. Recently, however, a fourth nuclear 
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receptor involved in breast cancer came into focus: Liver receptor homologue-1 (LRH-1 or 
NR5A2). 
LRH-1 is a monomeric nuclear receptor that belongs to the Ftz-F1 subgroup of nuclear 
receptors. [18, 19] Its closest mammalian homolog is steroidogenic factor-1 (SF-1) Both LRH-1 
and SF-1 are considered orphan nuclear receptors. However, recent studies suggest 
phosphatidyl inositols [20, 21] and phospholipids such as dilauryl phosphatidylcholine (DLPC) 
and diundecanoly phosphatidylcholine (DUPC) could be its endogenous ligands (figure 1.9). 
[22] 	  
	  
Figure 1.9: Structures of phospholipids DLPC and DUPC. 	  
SF-1 expression is mainly restricted to steroidogenic tissue such as found in the ovary and 
adrenal cortex, [23] where it regulates the synthesis of various steroids. In adult mammals, 
LRH-1 is expressed in the liver, pancreas and intestine, [19] where it plays a key role in 
metabolic pathways, [24] which include the regulation of cholesterol metabolism, reverse 
cholesterol transport to the liver and bile acid synthesis. LRH-1 is also expressed at high 
levels in the ovaries, more specifically in the granulosa cells and corpora lutea, [18] where it is 
involved in steroid synthesis. [25] Additionally, LRH-1 is vital in early development by 
maintaining undifferentiated embryonic stem cells [26, 27] via controlling the expression of two 
transcription factors: Oct4 and Nanog. [21] 
Recent studies showed that LRH-1 is also expressed in colon, gastric and breast cancers 
where, it is involved in tumour development and progression. [18, 28–31] 
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1.2.1 Structure of Nuclear Receptors 
 
Like all nuclear receptors, members of the Ftz-F1 subfamily share a highly conserved domain 
structure (figure 1.10). [19] 
	  
Figure 1.10: Domain structure of nuclear receptors: [16] A/B domain: contains the ligand independent activation 
function (AF-1); C domain: Contains the DNA binding domain, the CTE and the Ftz-F1 box; D domain: flexible hinge 
between DBD and LBD; E domain: contains ligand-dependent activation function (AF-2). (PDBs for zinc finger: 
2A66, LRH-1: 3PLZ) 
 
A/B domain 
 
The N-terminal regions of nuclear receptors are highly variable in sequence and size and 
harbour potent transcription activation functions, known as activation function-1 (AF-1). [32] 
This function assists in the regulation of transcriptional activity and is independent from ligand 
binding. The AF-1 region of the protein is one of two sites involved in co-regulator binding. 
Additionally, it is an important site for posttranslational modification by processes such as 
phosphorylation and sumoylation. [15] 
 
 
C domain 
 
The C domain includes the DNA binding domain (DBD), which targets specific DNA 
sequences known as hormone response elements. [33] The DBD consists of two cysteine rich 
zinc fingers that mediate DNA binding. This region is also important for regulating the 
dimerisation of the nuclear receptor either to give a homodimer or a heterodimer. [15] Located 
at the C-terminal end of the zinc finger module, is the carboxy-terminal extension (CTE), 
which extends the contact surface between the receptor and the DNA (figure 1.11).  
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Figure 1.11: Crystal structure of zinc fingers (PDB: 2A66). [34] 
 
Most nuclear receptors bind to DNA as dimers: either as homodimers, like the ER, or as 
heterodimers with retinoid X receptor. By contrast, LRH-1 and other members of the Ftz-F1 
subfamily bind to DNA as monomers. Here, the specificity of DNA binding is dictated by the 
Ftz-F1 box, a unique feature of the members of the Ftz-F1 subfamily. This box is a sequence 
of 20 amino acids located immediately after the CTE. [34] 
 
 
D domain 
 
The region between the DBD and the ligand binding domain (LBD) is a flexible hinge region. 
This region allows for the accommodation of rotational differences, [35] but is also an important 
site for posttranslational modifications. [15] 
 
 
E domain 
 
The E domain or ligand binding domain (LBD) is located at the carboxy-terminal end of the 
protein and can be seen as a molecular switch, which, upon ligand binding shifts the receptor 
to a transcriptionally active state. [33] 
 
The LBD of most nuclear receptors shows a common structure consisting of 12 α-helices and 
a short β turn, which form 3 antiparallel helical sheets that shape the so-called α-helical 
sandwich that forms the ligand binding pocket (LBP). [16] The ligand binding domain also 
includes a ligand-dependent activation function (AF-2), which is located at the carboxy-
terminus of the LBD. Both the LBP and the AF-2 function are essential for the regulation of 
the transcriptional function of the nuclear receptor (figure 1.12). 
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Figure 1.12: Left: Crystal structure of LRH-1 with extended helix 2 (yellow) and the AF-2 function in an active 
conformation; Right: Crystal structure of LBD ER with helix 2 (yellow) (PBD LRH-1: 3PLZ, ER: 2QZO). [36] 
 
The Crystal structure of mouse LRH-1 LBD shows a stable monomer with a large but empty 
LBP (blue crystal structure). [36] Additionally, at the N-terminal region of the LBD, the rigid 
structure of helix 2 (yellow) forms a fourth layer in the canonical fold of the LBD. In contrast, 
the LBD of the ER (red crystal structure) has a short helix 2 which does not form an additional 
layer. This difference in structure relative to most nuclear receptors confers LRH-1 with 
constitutional activity by indirectly stabilising the active position of helix 12 (purple) and so of 
the AF-2 function. This constitutional activity is also common among orphan receptors.  
 
 
Co-Factors  
 
Co-activators positively regulate a nuclear receptor and enable its transcriptional activity, 
whereas co-repressors dampen the transcriptional activity of nuclear receptors. Analysis of 
numerous nuclear receptors has revealed that the ligand dependent transcriptional activation 
function (AF-2) consists of a short LXXLL motif (where L is leucine and X is any amino acid) 
in a hydrophobic cleft on the surface of the ligand binding pocket. Residues adjacent to the 
LXXLL core encode domains with specificity for different nuclear receptors. [37]  
The hydrophobic cleft is flanked by charged residues, the “charge clamp” on either side, that 
contributes to the orientation of the co-factor towards the LBD and its specificity. [37] In ligand-
activated nuclear receptors, binding of ligands induces a conformational change that alters 
the orientation of several helices, in particular helix 12, which contains the AF-2 domain. This 
repositioning uncovers the hydrophobic binding cleft and enables co-activator binding, which 
results in an enhancement of transcriptional activity (figure 1.13). [15] 
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Figure 1.13: Schematic diagram of a ligand-dependent nuclear receptor: [38] Upon Ligand binding a conformational 
change is induced that leads to release of the co-repressor and recruitment of a co-activator and results in 
transcriptional activity. 
 
Orphan receptors, such as LRH-1 and SF-1 are constitutively active and therefore exhibit 
slight differences in the LBD structure and mode of action. As their helix 12 is prepositioned 
for optimal co-activator binding, orphan receptors are particularly sensitive to co-activator 
proteins. Differential co-regulator binding can therefore directly affect the activity of the 
nuclear receptor (figure 1.14). [15] 
 
	  
Figure 1.14: Schematic representation of orphan receptors: [38] Competitive binding of co-factors can lead to binding 
of a co-activator and transcriptional activity. 
 
The transcritptional activity of LRH-1 strongly depends on the presence or absence of co-
activators. They are expressed in a tissue specific manner and regulate the activity of LRH-1 
by competitive binding to the receptor.  
 
1.3 Implications of LRH-1 in Breast Cancer 
 
As detailed above, estrogen is known to play a critical role in the development and 
progression of breast cancer. [39] Its action is mediated by the ER, which is expressed in the 
majority of breast cancers. [39] In healthy women, aromatase expression in adipose tissue is 
low and originates mainly from activation of the promoter called I.4. [39] In breast cancer 
surrounding adipose tissue, the gonadal type promoter pII is used. The most potent factor 
identified that stimulates the activity of promoter pII is prostaglandin E2 (PGE2), [30] which is 
produced by the breast tumour itself. Interestingly, LRH-1 is co-expressed with aromatase in 
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undifferentiated adipose stromal cells and has the ability to bind to the promoter pII and thus 
stimulate aromatase expression. At the same time, PGE2 stimulates aromatase activity by 
inducing the expression of LRH-1. [30] As aromatase is a crucial factor for the conversion of 
androgens into estrogen, this results in an increase in estrogen levels in breast cancer 
surrounding adipose tissue.  
In addition to these implications of LRH-activity in aromatase expression, LRH-1 is directly 
involved in the regulation of the expression of ERα. Furthermore, Annicotte et al. [18] have 
reported that LRH-1 contains a near perfect palindromic estrogen response element to which 
ERα binds and stimulates LRH-1 expression (figure 1.15). [25] 
 
	  
Figure 1.15: Connection between LRH-1, aromatase and the estrogen receptor. 
 
Clyne et al. [40] showed that LRH-1 is directly implicated in cell migration and increases cell 
invasiveness in normal and malignant breast tissue, independent of the ER status. 
Cell migration is important for cancer progression and is the initial step in tumour metastasis. 
The cells subsequently invade into adjacent tissue and start growing. [40] 
 
In summary, LRH-1 locally induces the production of estrogen via the regulation of the 
expression of aromatase in adipose stromal cells. Within the tumour, LRH-1 regulates 
estrogen dependent cell proliferation [41] and is directly involved in the expression of ER, 
which in turn, regulates the expression of LRH-1. [24,39,40] These two properties of LRH-1 
cause a steep increase in the local estrogen levels of the tumour surrounding tissue, which 
ultimately results in tumour growth. Additionally, LRH-1 is involved in cell migration and 
increases cell invasiveness in breast cancer. These implications make LRH-1 a very 
interesting target for the treatment of breast cancer.  
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1.4 History of Nuclear Receptors as Therapeutic Targets 
 
Nuclear receptors are implicated in a variety of functions ranging from embryonic 
development to homeostasis. [42] Dysfunction of the nuclear receptor signalling can result in 
many pathological processes such as diabetes, cancer, rheumatoid arthritis and hormone 
resistance. [42] Therefore, nuclear receptors are of great interest in the development of new 
drugs.  
The first drugs to target nuclear receptors were discovered before the discovery of the 
nuclear receptors themselves. One of these examples started as a treatment of Addinson’s 
disease (glucocorticoid deficiency). [42] Extracts from adrenal glands had been shown to bring 
relief from stress-related disease and reduce inflammatory conditions; cortisone was 
identified as the active component of these extracts and used as a therapeutic.  
With this early success further evolution of the first generation of steroidal glucocorticoids was 
started which led to the modern glucocorticoid steroids such as Prednisolone, 
Dexamethasone and Fluocotolone (figure 1.16). [42, 43] 
 
	  
Figure 1.16: Examples of modern glucocorticoids. 	  
In 1929 estrone was isolated independently by Doisy and Butenandt. The latter elucidated its 
structure in 1932.  [44] Six years later, Inhoffen and Hohlweg [45] published the first synthesis of 
ethinyl-estradiol, which later became a cornerstone of modern female fertility control (figure 
1.17).  
 
	  
Figure 1.17: Structures of estrogens. 
 
In the 1960s anti-estrogens were developed as contraceptives. Among these compounds 
were the non-steroidal anti-estrogens Ethamoxytriphetol, Clomiphene and Tamoxifen, which 
later became the gold standard of treatments for ER positive breast cancers.  
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1.4.1 Targeting Nuclear Receptors 
 
Nuclear receptors have been studied for decades due to their interest as potential drug 
targets. Therefore it is not surprising that nuclear receptor agonists and antagonists such as 
Tamoxifen (ER), thiazolidinediones (PPARγ) and dexamethasone (glucocorticoid receptor) 
are amongst the most commonly used drugs. [46] The challenge for finding novel drugs is to 
generate a compound that addresses one or only a few physiological nuclear receptor 
functions to achieve the desired effects without causing side effects from the 
activation/deactivation of other nuclear receptor functions. To date, the vast majority of drug 
discovery programs have aimed to find structures that bind to the LBD of the NR and prevent 
transcriptional activity.  
 
1.4.1.1 Targeting the Ligand Binding Pocket of Estrogen- SERMs 
 
SERMs are a type of conventional anti-estrogens, with Tamoxifen as the most famous drug 
for the treatment of breast cancer. They bind to the ligand binding domain, more specifically 
in the ligand binding pocket, and cause a conformational change that prevents the binding of 
co-activators and therefore transcriptional activity of the receptor. However, as noted above it 
is known that that the efficiency of Tamoxifen decreases with time and can also result in 
Tamoxifen promoting breast cancer.  
 
	  
Figure 1.18: Left: The crystal structure of the ER in a active conformation; Middle: structure of ER bound to 
tamoxifen (blue), where helix 12 is shifted into a slightly different position; Right: Structure of the ER bound to 
raloxifene (teal), with position of helix 12 altered but still allowing for limited co-activator binding (PBD left: 2QZO; 
middle: 3ERT; right: 1QKN). 
 
The anti-tumour effect of Tamoxifen is mediated by its competitive binding to the ER. This 
causes a conformational change (figure 1.18). [47] This change is different to the 
conformational change caused by estrogen binding. In the case of estrogen, the binding to 
the ER results in a change that seals the ligand binding domain and activates the AF-2 
function of the ER. When Tamoxifen binds to the ER, the structure of Tamoxifen prevents the 
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sealing of the ligand binding domain and activation of the AF-2 function. [13] Similar 
conformational changes can be observed upon binding of Raloxifen.  
 
1.4.1.2 The LRH-1 Ligand Binding Domain as Drug Target 
 
As LRH-1 plays a vital role in a variety of biological functions and pathological processes 
which include early embryonic development, cholesterol metabolism, and steroidogenesis, 
[19,29,48–52] a great number of applications for both agonists and antagonists in medicine can be 
envisioned (figure 1.19).  
 
	  
Figure 1.19: Summary of potential therapeutic applications of LRH-1. [25] 
 
The major sites of action of LRH-1 are summarised in the chart above and some of them 
have been used as targets for potential drugs. Recent studies by Ortlund et al. [22] discovered 
that dilauroyl phosphatidylcholine (DLPC) and diundecanoyl phosphatidylcholine (DUPC) are 
potent selective agonists for LRH-1 and have a positive effect in diabetic and obese disease 
models. [20,53] Similarly, Whitby et al. [54,55] published two series of LRH-1 agonists aimed at 
the treatment of metabolic diseases (figure 1.20).  
 
	  
Figure 1.20: Whitby's LRH-1 agonists. [55, 54] 
 
Earlier this year, Fletterick et al. [56] reported on the discovery of the first LRH-1 small 
molecule antagonists by virtual screening of a database of compounds (figure 1.21). 
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Figure 1.21: Most effective LRH-1 antagonists. [56] 
 
These compounds have been shown to selectively inhibit the transcriptional activity of LHR-1 
and exhibit no cytotoxicity. Additionally, these compounds have demonstrated anti-
proliferative properties in breast, pancreatic, and colon cancer cells and could therefore be 
used as a molecular tool to further explore the involvement of LRH-1 in the development and 
growth of these types of cancer. [56] 
 
1.4.2 Targeting the Co-Activator Binding Site 
 
Co-activators bind with high selectivity to the AF-2 function of nuclear receptors. As indicated 
above, this selectivity is due to an amphipathic α-helix that contains the LXXLL motif and 
additional charged residues, which constitute the “charge clamps”. [37] 
McDonnell et al. [59, 60] noted that these well-defined features raise the possibility for the 
development of small synthetic molecules that bind to this AF-2 function and directly disrupt 
the nuclear receptor–co-factor interaction. [59] To fulfil all criteria mentioned above, the ideal 
co-activator binding inhibitor (CBI) would be a short α-helical sequence that constitutes the 
LXXLL motif as well as the polar functional groups that make the charge clamp. Initial 
approaches have employed short helical peptides, constrained peptides and peptidomimetics. 
[60] 
 
1.4.2.1 The AF-2 Function of the Estrogen Receptor 
 
In 2003, Leduc et al. [59] reported on a helix-stabilised cyclic peptide as a selective co-
activator binding inhibitor for the estrogen receptor. Their results support the idea to design α-
helical peptide fragments that contain the LXXLL motif as potential new antagonists for the 
estrogen receptor. Katzenellenbogen et al. [12] used a very similar approach. They established 
a FRET assay with streptavidin-europium labelled estrogen receptor ligand binding domain 
and a Cy5 dye labelled sequence of SRC3, a known co-activator for the estrogen receptor, to 
verify the possibility of peptides to function as CBIs (figure 1.22). 
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Figure 1.22: Schematic representation of time-resolved fluorescence resonance energy transfer (FRET)–based 
coactivator binding inhibitor (CBI) assay: A: ER in the presence of agonist estradiol (center), with a competing CBI 
(right), and with a competing conventional antagonist (CA; left). B: Schematic representation of FRET-based CA-
binding assay. LBD, ligand-binding domain; SRC, steroid receptor co-activator. [12] 	  
In the same year they published the synthesis and initial testing of proteomimetics as 
estrogen receptor co-activator binding inhibitors, which were tested using the FRET assay 
described above (figure 1.23). [60] 
 
	  
Figure 1.23: Structures of proteomics by Katzenellenbogen et al. [60] 
The main features of peptide mimetics are their low molecular weight and their relative ease 
of modification to improve binding, selectivity, solubility and bioavailability. [59–61] 
 
1.4.2.2 Targeting LRH-1’s Co-Activator Binding Site 
 
As an orphan receptor, LRH-1 is constitutively active and hence, primarily regulated by 
transcriptional co-regualtors. This feature suggests that it could be fruitful to selectively target 
the LRH-1 AF-2 site and regulate its transcriptional activity. Clyne et al. [23] started a project 
looking for an α-helical peptide as a potential CBI. Using phage display technology they found 
a series of peptides modulating the transcriptional activity of LRH-1. 
 
It could be anticipated that LRH-1 agonists could have positive effects in the activation of 
LRH-1 in the liver as drugs for non-insulin dependent diabetes and obesity and in the ovary 
as potential agents to treat infertility. On the other hand, the activation of LRH-1 would cause 
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severe effects in various cancer types. At the same time, LRH-1 antagonists could be a key 
treatment for breast cancer, but the downregulation of LRH-1 could cause dramatic changes 
in lipid metabolism and cholesterol efflux. To address all implications of LRH-1 it is essential 
to find selective and tissue specific modulators, which act as agonists e.g. in the liver but 
antagonise LRH-1 in cancer.  
 
The remainder of this chapter outlines our strategy to develop such agents. 
 
1.5 Scientific Aims and Objectives 
1.5.1 Synthesis of a Benzimidazole-based Compound Library and SAR 
Studies 
 
The first half of this thesis describes a project based on the idea to find conventional 
antagonists that bind to the ligand binding pocket of LRH-1. In a previous project, Andrew 
Bayly (Spivey Group 2007-2011) [62] found through in silico screening that benzimidazole 
thioethers exhibit similar properties in terms of charge distribution, size and hydrogen bonds 
to the known LRH-1 agonists published by Whitby et al. [54,55] This benzimidazole scaffold was 
taken further by Andrew Bayly and displayed a good EC50 and no toxicity in cells (scheme 
1.1).  
 
	  
Scheme 1.1: Andrew Bayly’s Approach towards a benzimidazole series. [62] 
 
Therefore, this scaffold was to be employed as a new lead with the plan to synthesise a 
library of benzimidazoles to study the structure-activity relationship (SAR) of these 
compounds.   
 
In the first instance we chose to explore three distinct sites in the benzimidazole structure that 
could be modified (figure 1.24): 
	  
Figure 1.24: Sites of possible modifications on the benzimidazole structure. 
 
	  Virtual screening &  biological testing 
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The first position selected for substitution on the benzimidazole core was at the R1 position. 
These derivatives were envisaged to be prepared using transition metal catalysed cross-
coupling of an appropriate aryl halide precursor. The second position for modification was on 
the benzyl ring. These analogues could be envisaged to be obtained by reacting an 
appropriate 2-substituted benzimidazole with a range of commercially available substituted 
benzyl bromides or benzyl alcohols.  
As there was no evidence that the originally included thioether is required for the binding 
properties of the lead compound it was decided also to synthesise a series of analogues 
which an ether linkage instead of a thioether.  
 
A retrosynthetic analysis for the synthesis of the envisaged compound library could start from 
the diamine and form the 2-mercapto or 2-hdroxy benzimidazole using carbon disulfide or 
CDI, which in the final step of the synthesis could be the converted to the corresponding 
benzyl ethers (scheme 1.2). 
 
	  
Scheme 1.2: Retrosynthetic analysis of the benzimidazole synthesis. 
 
It was decided to select the substitution patterns on the benzyl ring according to the Topliss 
series of analogues. [63] This series is designed to empirically optimise the substitution pattern 
of substituents on aromatic rings when, no structural information about the mode of binding is 
available and takes steric factors, hydrophobicity and electronic effects into account.  
To obtain an SAR, the second part of the research described in this thesis is dedicated to the 
testing of the synthesised compound library for binding to the ligand binding domain of LRH-
1. Achieving this required the expression and purification of the ligand binding domain of 
LRH-1, the optimisation of the assay conditions and finally the testing of the compounds.  
 
1.5.2 Towards the Synthesis of an α-Helix Mimetic 
 
The final piece of research described in this thesis is based on the idea to design and 
synthesise nuclear receptor antagonists by targeting the co-activator binding site and 
consequently inhibit nuclear receptor action. 
A prior PhD student in the research group, Andrew Bayly, had designed an α-helix mimetic 
which could potentially contain the required LXXLL motif for co-activator binding. [62] He had 
also conducted preliminary synthetic studies towards its synthesis. The aim of the research 
described herein was therefore to improve and continue of the synthesis of the α-helix 
mimetic (scheme 1.3).  
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Scheme 1.3: Synthetic route towards α-helix mimetic. [62] 
 
The first part of the synthetic pathway involves the synthesis of a substituted N-phenyl 
maleimide. In the second part of the synthesis a 1,6-dihydropyridine will be formed. Both 
parts will be combined via a hetero Diels-Alder reaction to give the scaffold of the α-helix 
mimetic. Then, further modification will give the final α-helix mimetic.  
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2. Results and Discussion 
2.1 Synthesis of Potential LRH-1 Antagonists 
2.1.1 Previous Work on Cresset Virtual Screen- Design of a New Lead 
 
Previous PhD student in the research group Andrew Bayly (Spivey Group 2007-2011), in 
collaboration with Caroline Low (Drug Discovery Centre, Imperial College London) started the 
search for a new lead as potential LRH-1 antagonists or inverse agonists. [62] The search 
began by using the most active compound of a series of LRH-1 agonists published by Whitby 
et al. (figure 2.1). [54]  
 
	  
Figure 2.1: Structure of 5l and energy minimised structure of 5l as implemented by Andrew Bayly. [62] 
 
This compound is a cis-fused [3.3.0] bicyclooctane derivative having an aniline substituent at 
the ring junction. Compounds of this type have been shown by X-ray crystallography to bind 
to the ligand binding pocket of LRH-1 and behave as agonists with EC50 values between 2 
and 0.06 µM. [54] 
Energy minimisation of the structrure of 5l in the gas phase using the XED force field™ within 
the Cresset VS™ software suite gave a conformation very similar to the active conformation 
of this compound, as revealed in the aforementioned X-ray co-crystal structure. This energy 
minimised conformation was used as query to find a new series of agonists. By applying the 
Cresset FieldViewTM Software (now TorchLiteTM) field points for that structure were generated 
(figure 2.2).  
 
	  
Figure 2.2: TorchLite™ field point structure of 5l as generated by Bayly. [62] 	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The field points represent different areas of interactions within and around the molecule. The 
yellow field points correspond to van der Waals interactions, positive electrostatic interactions 
are represented as red field points and negative electrostatic interactions as blue field points. 
Hydrophobic areas are indicated as golden field points. The field points were then used to 
screen through a database of commercially available compounds using Cresset VS.  
From the 200 obtained ranked hit compounds, those compounds, which were deemed to be 
unsuitable as medicinal chemistry leads, were discarded. Among the discarded structures 
were nitro and nitroso compounds, phosphines, organometallics, entirely hydrocarbon based 
compounds and compounds that did not match the positive field point derived from the 
aniline. After this library reduction process, the 143 compounds left were further refined by 
removal of potentially metabolically unstable primary amines and aniline-containing structures 
that exhibited a high structural and field point similarity to compounds with a higher score. 
This refinement resulted in 110 final compounds, of which 100 were purchased or 
synthesised by Andrew Bayly and tested in vivo for their ability to modulate LRH-1. The assay 
used was a cell-based luciferase and renilla reporter assay and was carried out by Dr Fiona 
Kyle (Department of Oncology, Hammersmith Campus, Imperial College London). The 
analysis showed 7 compounds with better agonistic properties than Whitby’s 5a compound, 
which is another LRH-1 agonist (figure 2.3). 
 
	  
Figure 2.3: Structures of potential new lead compounds discovered by Bayly. [79] 
 
One of these hits was AB_WC057. This compound showed a good EC50 in the µM range and 
most importantly, no toxicity as evidenced by a luciferase and renilla reporter assay (figure 
2.4). 
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Figure 2.4: Activity of 5a and AB_WC057 in a cell-based assay as determined by Bayly. [62] 
 
Overlapping the structure of AB_WC057 with the field points of Whitby’s 5l compound shows 
a good similarity index of 0.69 (figure 2.5).  
 
	  
Figure 2.5: Overlapped structure of compounds 5l and AB_WC057. 
 
Due to its field points similarity to compound 5l, its good EC50 and its non-toxicity, compound 
AB_WC057 was selected as the new lead for the discovery of potential new LRH-1 
antagonists.  
 
From the overlapped structures of compound 5l and the lead benzimidazole AB_WC057, we 
hoped that the benzimidazole would bind in a similar fashion to the LRH-1 LBD (figure 2.6).  
 
	  
Figure 2.6: Left: compound 5a (pink) bound to LRH-1 LBD (PDB: 3PLZ) [54,55], Right: overlapped structures 5l and 
AB_WC057. 	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In this scenario the benzimidazole core takes the position of the aniline of compound 5l and 
could point towards the β-sheet (green). The thioether bridge aligns with the bicyclic core of 
compound 5l and would be positioned in the centre of the ligand binding pocket. The benzyl 
ring of the benzimidazole lead is in the same position as the phenyl ring of compound 5l and 
would point towards the bottom of the ligand binding pocket. 
 
The first task therefore was to devise a robust synthesis of benzimidazoles like AB_WC057 
that would allow the preparation of analogues varying in both the benzyl ring and phenyl core.  
 
2.1.2 Benzimidazoles 
2.1.2.1 Synthesis of Benzimidazoles 
 
Historically, the first benzimidazole was synthesised by Hoebrecker et al. [64] in 1872 who 
obtained 2,5- and 2,6-dimethylbenzimidazole by reducing 2-nitro-4-methylacetanilide 
(scheme 2.1). [65] 
 
	  
Scheme 2.1: Hoebrecker’s synthesis of 2,6-dimethyl benzimidazole. [64] 
 
Several years later, Ladenburg obtained the identical products by heating of 3,4-
diaminotoluene and acetic acid to reflux (scheme 2.2). [66] 
 
	  
Scheme 2.2: Ladenburg's synthesis of 2,6-dimethylbenzimidazole. [66] 
 
There are many other ways to synthesise benzimidazoles and therefore it is only possible to 
show a fraction of syntheses here (scheme 2.3). 
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Scheme 2.3: An overview of modern syntheses of benzimidazoles. [67–73] 
 
The majority of syntheses start from the o-phenyl diamine and carboxylic acids or aldehydes. 
[67,74] Other methods use amidines, that react intramolecularly with a halide to close the ring 
and form the benzimidazole. Another method for the synthesis of substituted benzimidazoles 
was reported by Zhu et al. [71] This reaction employs a Chan-Lam-Evans N-arylation and C-H 
activation/C-N bond formation process to form the substituted benzimidazole.  
 
2.1.2.2 Applications of Benzimidazoles 
 
Reflecting the variety of syntheses, there is a diverse range in different applications for 
benzimidazoles. Benzimidazoles have a broad range of applications in medicinal chemistry 
and as pharmaceuticals for instance as anthelmintic, fungicides, antiviral, anticancer or 
antimicrobial agents [74] and are valuable precursors for the synthesis of ligands [75] and more 
complex structures (figure 2.7).  
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Figure 2.7: Selected examples of pharmaceutical relevant benzimidazoles as anticancer agent [76], treatment on 
breast cancer [77], as antiamoebial [78], anthemintic, or fungicide. 
 
2.1.2.3 2-Mercaptobenzimidazoles 
 
Important derivatives of benzimidazoles are 2-mercaptobenzimidazoles. These compounds 
have found many applications in medicine, for example as antiviral agents, [81, 82] 
anthelmintics or as luteinizing hormone-releasing hormone antagonists (figure 2.8). [81] 
 
	  
Figure 2.8: Examples of pharmaceutical relevant 2-mercaptobenzimidazoles. 
 
Murzart et al. [82] reported a copper catalysed synthesis of unsymmetrically substituted 2-
Mercaptobenzimidazoles 2 (scheme 2.4). 
 
	  
Scheme 2.4: Murzart’s synthesis of unsymmetrical substituted 2-mercaptobenzimidazole 2. [82,83] 
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Murzart’s synthesis starts with the formation of the substituted thiourea 1, which can be 
synthesised from the respective aniline and a thioisocyanate. [83] In the next step the thiourea 
undergoes S-alkylation followed by an intramolecular Cu-catalysed N-aryl amination to give 
the substituted 2-mercaptobenzimidazole 2. [82]  
 
The classical method for the synthesis of benzimidazole 2-thioethers 5 involves the reaction 
of o-phenyldiamine 3 with carbon disulfide and subsequent etherification of the 2-
mercaptobenzimidazole 4 (scheme 2.5).  
 
	  
Scheme 2.5: Classical method of S-alkylated 2-mercaptobenzimidazole synthesis 5. [84] 
 
Among many, Klimesová et al. [84] suggested a mechanism for the reaction of carbon disulfide 
with o-phenyldiamine 3 (scheme 2.6).  
 
	  
Scheme 2.6: Klimesová’s proposed mechanism of S-alkylated 2-mercaptobenzimidazole 5 formation. 
 
The reaction is initiated by the deprotonation of the diamine 3, which then attacks the carbon 
of the carbon disulfide. A proton transfer produces another amide, which attacks the carbon 
of the carbon disulfide and closes the ring. The driving force of the following step is the loss of 
H2S and the aromatisation, which gives the final 2-mercaptobenzimidazole 4. In the second 
part of the synthesis the thiol is deprotonated and reaction with the benzyl bromide via an SN2 
reaction gives the final S-alkylated 2-mercaptobenzimidazole 5.  
 
The etherification can theoretically yield 3 different products: the desired S-alkylated product 
5, the N-alkylated product 6 and the S,N-dialkylated product 7 (scheme 2.7). 
  
  Results and Discussion 	  
 30 
	  
Scheme 2.7: The three possible products of attempted alkylation of 2-mercaptobenzimidazole 4. 
 
Pearson’s hard-soft-acid-base principle is a method to predict the pathways of reactions. It 
states that soft sites prefer to react with a soft counter part and hard moieties with hard 
counter parts. Soft moieties are large and easy polarisable. A hard moiety is small and hard 
to polarise. According to Pearson’s principle the benzyl bromide is soft and threrefore should 
prefer to react with the soft thiol rather than the hard nitrogen. Additionally, the sulfur is 
sterically slightly less hindered and therefore should react faster.  
 
2.1.3 Synthesis of AB_WC057 Analogues 
 
With a plan for the synthetic approach in place, the synthesis of a compound library based on 
the lead benzimidazole was undertaken.  
 
2.1.3.1 Analogues with Different Core Substituents 
 
For the first analogues, different commercially available 4-substituted benzenediamines 8 
were procured and used for the synthesis of a small series of core-substituted benzimidazole 
thioethers 10 (table 2.1).  
 
 
R Yield benzimidazole Yield thioether Overall yield 
H 51% 53% 27% 
tBu 89% 66% 59% 
Br 43% 30% 13% 
 
Table 2.1: Synthesis of different core substituted benzimidazoles 10a-b. 
 
The synthesis was carried out following a procedure adapted from Klimesová et al. [84] As 
described above, the first step involved the formation of the 2-mercaptobenzimidazoles 9a-b. 
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This product could be obtained in satisfactory yields. In the next reaction the sulfur was 
alkylated using 2-methylbenzyl bromide. There is a great variance in the yields for the 
individual compounds with the tert-butyl substituted benzimidazole 10a giving the highest 
yield. It could be that the electron donating properties of the tert-butyl group result in a less 
stable but more nucleophilic thiol, which reacts faster with the benzyl bomide. This electron 
donation derives from hyperconjugation of the alkyl C-H bonds with the aromatic system. 
At the same time, the deprotonation of the ring nitrogen is more difficult, due to the electron 
donating tert-butyl group, leading to fewer side products. The opposite appeared to be the 
case for the bromo-substituted benzimidazole 10b. The electron withdrawing bromide could 
conceivably stabilise the thiol and make it less reactive towards SN2 reactions. This is due to 
the inductive electron withdrawing effect of the bromide. At the same time the bromide 
exhibits a mesomeric donating effect which is significantly weaker than the inductive effect, 
resulting in a net electron withdrawing effect. 
 
2.1.4 Benzimidazoles with Different Benzyl Ring Substitution 
2.1.4.1 Topliss Series of Analogues 
 
For the next series of benzimidazole analogues, the substitution pattern of the benzyl ring 
was modified. To select an array of substituents that is suitable for the synthesis of a 
compound library, the Topliss scheme was used as a guide. 
The Topliss series is a tool for the optimisation of phenyl ring substitution in the context of 
medicinal chemistry. [63,85] The basis of this concept was developed by Hansch, [86] who 
established that the primary influences on activity of a compound result from lipophilic, 
electronic and steric properties of the substituents. His calculations are based on the partition 
coefficient log P of to give a substituent constant π (equation 2.1).  
 𝜋 = 𝑙𝑜𝑔𝑃! − 𝑙𝑜𝑔𝑃! 
Equation 2.1: Hansch’s substituent constant π with PH: partition coefficient of parent substituent; PX: partition 
coefficient of the derivative. 
 
These calculations were taken further by Topliss, who developed a scheme for the 
optimisation of phenyl ring substitution (figure 2.9). 
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Figure 2.9: Topliss scheme for the optimisation of aryl substitution. [64] 
 
For our series of analogues a set of 7 substituents has been chosen and include 
unsubstituted, 2-Me, 4-Me, 2-Cl, 3-Cl, 4-Cl and 3,4-Cl2.  
 
2.1.4.2. Synthesis of Benzimidazoles with Different Benzyl Ring 
Substitution Patterns 
 
After choosing the substituents, the synthesis of the first series of Topliss analogues was 
carried out (table 2.2).  
 
 
R H 2-Me 4-Me 2-Cl 3-Cl 4-Cl 3,4-Cl2 
Yield 43% 53% 39% 28% 42% 27% 75% 
 
Table 2.2: Synthesis of different benzyl substituted benzimidazole thioethers 12a-f. 
 
The syntheses were carried out as described above following the adapted procedure of 
Klimesová et al. [84] The analogues could be obtained in 27-75 % yield. The broad range in 
yields may be explained by the different electronic and steric properties of the benzyl 
bromides. The electron withdrawing property of the chloride substituent increases the 
reactivity of the benzyl bromide. The electron withdrawing effect is strong when the chloride is 
in meta position and weak in the ortho or para position. This is reflected by the obtained 
yields, where the 3-chloro substituted benzyl bromide gives a higher yield than the 2-chloro or 
4-chloro benzyl bromide. The highest yield could be observed for the 3,4-dichlorobenzyl 
bromide, where the meta and para positions are occupied by a chloride. The methyl groups 
stabilise the transition state through hyperconjugation, where the ortho position is of greater 
importance than the para position. 
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2.1.5 Synthesis of N-Phenylbenzimidazole Thioether 
 
It was also decided to target one benzimidazole having an N-phenyl substituent. This 
analogue was anticipated to allow us to evaluate if the nitrogen of the benzimidazole ring had 
any role in the binding to LRH-1.  
 
Sreedhar et al. [87] published a Chan-Lam-Evans type reaction for the arylation of azoles using 
phenylboronic acid and copper oxide under air; we adapted this approach in our first attempt 
to prepare such a derivative (scheme 2.8).  
 
	  
Scheme 2.8: Attempted synthesis of N-phenyl benzimidazole thioether 13 via Chan-Lam-Evans reaction. [87] 
 
The reaction was performed using the conditions outlined in scheme 2.8 and monitored by 
TLC. After 16 hours at room temperature no product could be detected. Therefore, it was 
decided to increase the reaction temperature to 75 °C. Since after two hours still no product 
could be detected, the catalyst loading was increased from 5 mol% to 35 mol% and more 
phenylboronic acid was added. Heating the reaction mixture for another 24 hours did not yield 
any product.  
Another method for the N-arylation of benzimidazoles is via Ullmann-type coupling. Buchwald 
et al. [88,89] have reported on a method for the arylation of this type of nitrogen heterocycles 
and so we opted to evaluate their method next (scheme 2.9). 
 
	  
Scheme 2.9: Attempted synthesis of N-phenyl benzimidazole thioether via Ullmann-type coupling. [88,89] 
 
The reaction was carried out in a sealed tube under an atmosphere of nitrogen and monitored 
periodically by TLC. After 48 hours no product has been formed. The reaction was repeated 
under the same conditions but with the more reactive iodobenzene instead of bromobenzene. 
As in the previous reaction, no product was formed. To find the best conditions for this 
arylation, the reaction conditions were optimised using benzimidazole 14 as a model system 
(table 2.3). 
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Entry  Iodobenzene CuI 1,10-phen Cs2CO3 Outcome 
1 2.0 eq. 20 mol% 40 mol% 2.0 eq. <2% product 
2 2.0 eq. 50 mol% 100 mol% 2.0 eq. 100% conversion 
3 2.0 eq. 100 mol% 200 mol% 2.0 eq. 100% conversion 
 
Table 2.3: Optimisation of Ullmann-type coupling using benzimidazole 14 as model system. 
 
Monitoring the reaction by GC showed a full conversion to N-phenylbenzimidazole 15 using 
50 mol% copper iodide, caesium carbonate and 1 equivalent of phenanthroline in DMF (table 
2.3, entry 2). The optimised conditions were transferred to the actual benzimidazole benzyl 
thioether system 12a (table 2.4).  
 
 
Entry CuI 1,10-Phen Base (2.0 eq.) Solvent Yield 
1 1.0 eq. 2.0 eq. Cs2CO3  DMF 16% 
2 0.5 eq. 1.0 eq. KOtBu  DMF 0% 
3 0.5 eq. 1.0 eq. K3PO4  Dioxane 16% 
4 2.0 eq. 4.0 eq. Cs2CO3  DMF 26% 
5 2.0 eq. 4.0 eq. Cs2CO3  DMA 16% 
6 2.0 eq. 4.0 eq. Cs2CO3  NMP 23% 
 
Table 2.4: Optimisation of Ullmann-type coupling using the benzimidazole thioether system 12a. 
 
The initial reaction conditions gave only small quantities of the product 13 (table 2.4, entry 1). 
Therefore, further optimisation using benzimidazole thioether 12a as the substrate was 
carried out. The best conditions found were using DMF with 2 equivalents copper iodide and 
4 equivalents of phenanthroline (table 2.4, entry 4). Changing the base to KOtBu resulted in 
a complex mixture with no product detectable (table 2.4, entry 2). A screening of different 
solvents gave DMF and dioxane (table 2.4, entries 3 and 4) as the best solvents for this 
transformation. DMA and NMP also worked, but gave lower yields (table 2.4, entries 5 and 
6).  
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From the results of the optimisation it is appears that the yield increases with the amount of 
catalyst used. The reason for this connection might be the ability of sulfur to form strong 
complexes with transition metals. [90] A more detailed discussion on this matter can be found 
in chapter 2.1.7. 
It is possible that this problem might be overcome by using a ligand that is able to shield the 
metal and prevent the sulfur from binding to the copper centre during the Ullmann-type 
couplings. Here, phenathroline was used as the ligand. It has a flat structure and is not 
capable of protecting the metal centre from the sulfur. A possibility could be a 6,6-
disubstituted-2,2’-bipyridyl complex, which still is flat but shields the copper ion from two 
sides.  
 
2.1.6 Benzimidazole Ethers 
 
The Cresset VS approach used to obtain the lead for this project primarily gives information 
relating to the structure and topology of potential binders and is not so prescriptive as to 
which atoms comprise these scaffolds. In order to test if the sulfur was crucial for the binding 
properties a series of oxygen analogues was synthesised. These analogues have the same 
substitution pattern as the thioether analogues. A possible retrosynthetic approach would 
follow a similar route as for the benzimidazoles thioethers (scheme 2.10). 
 
	  
Scheme 2.10: Retrosynthetic approach for benzimidazole ethers 18. 
 
It was proposed that the synthesis could start with the 3,4-diaminotoluene 16, which would be 
converted to the 2-hydroxybenzimidazole 17. The next step would be the alkylation to give 
the benzimidazole ether 18.  
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2.1.6.1 Synthesis of Benzimidazole Ethers 
 
Intending to follow the method outlined above, the 2-hydroxybenzimidazole 17 was 
synthesised using CDI in anhydrous THF (scheme 2.11).  
 
 
Scheme 2.11: Formation of 2-hydroxybenzimidazole 17. 
 
The reaction was carried out as described by Dannhardt et al. [91] The precipitated product 
was filtered and washed with THF. The reaction proceeded cleanly with no further purification 
required and gave the product in 53% yield.  
 
With the 2-hydroxybenzimidazole in hand the alkylation was attempted using sodium 
methoxide or sodium hydride and benzyl alcohol in DMF (table 2.5). 
 
 
Entry Solvent Temperature Base Additive Outcome 
1 DMF 50 °C NaOMe  No product 
2 DMF 50 °C NaOMe NaI No product 
3 DMF RT NaH  No product 
 
Table 2.5: Conditions for the synthesis of benzimidazole ether 19. 
 
Unfortunately, the reaction did not show any conversion to the product, even after heating the 
reaction mixture to 50 °C (table 2.5, entry 1). The reaction was repeated with 0.1 equivalents 
of sodium iodide to enable an in situ Finkelstein reaction and increase the reactivity of the 
benzyl bromide. Again, this attempt did not give the desired product (table 2.5, entry 2). A 
change in base to sodium hydride also was unsuccessful and no product could be detected 
(table 2.5, entry 3).  
 
The reaction of 2-hydroxybenzimidazole 17 with benzyl bromide is expected to follow a SN2 
reaction mechanism with the deprotonated hydroxy group acting as the nucleophile (scheme 
2.12).  
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Scheme 2.12: Anticipated mechanism of the benzimidazole ether 18 formation via SN2 reaction. 
 
At the same time, deprotonation of the hydroxy group could also facilitate tautomerism within 
the benzimidazole, giving a cyclic urea-type structure 20, which would be unreactive in the 
given conditions (scheme 2.13).  
 
	  
Scheme 2.13: Potential tautomerism of 2-hydroxybenzimidazole 17. [65] 
 
This tautomerism could be the main reason for the failure of the reactions.  
A change in reaction mechanism could be a possibility to circumvent the unreactivity. 
Therefore, it was planned to convert the 2-hydroxybenzimidazole 17 to the 2-
chlorobenzimidazole 21. The reaction mechanism would then change from SN2 to a 
nucleophilic aromatic substitution-type reaction, which we hoped would be successful 
irrespective of the tautomerism of the benzimidazole (scheme 2.14).  
 
	  
Scheme 2.14: Anticipated mechanism of benzimidazole ether 18 formation via nucleophilic aromatic substitution. 
 
In this reaction mechanism the nucleophile is the benzyl alcohol. After deprotonation to the 
alkoxide it attacks the position 2 of the benzimidazole 21, causing the chloride to be 
displaced.  
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2.1.6.2 Synthesis of Benzimidazole Ether via 2-Chlorobenzimidazole 
 
The conversion of 2-hydroxybenzimidazole 17 to the 2-chlorobenzimidazole 21 was carried 
out using an adaptation of a procedure by Blythin et al. (scheme 2.15). [92] 
 
	  
Scheme 2.15: Conversion of 2-hydroxybenzimidazole 17 to 2-chlorobenzimidazole 21. [92] 
 
This reaction gave the desired product in 40% yield, but it was decided not to further optimise 
the reaction conditions until the utility of the product had been established. 
The next step towards the benzimidazole ether 18 was the alkylation (table 2.6).  
 
 
Entry Solvent Temperature Additive Outcome 
1 DMF 25 °C  No product 
2 DMF 60 °C  No product 
3 DMF 25-60 °C DMAP No product 
4 DMF 25 °C AgNO3 No product 
5 THF 25 °C 18 crown 6 No product 
 
Table 2.6: Optimisation of benzimidazole ether 18 synthesis. 
 
At first, the reaction was attempted using sodium hydride as base at 25 °C. This reaction did 
not lead to the formation of the desired product (table 2.6, entry 1). The reaction was 
therefore repeated at elevated temperature, but again, no product could be detected (table 
2.6, entry 2). To increase the reactivity of the benzyl alcohol, DMAP was added to the 
reaction mixture. Even after heating the reaction to 60 °C, no product was detected (table 
2.6, entry 3). In the next attempt silver nitrate was added to the reaction mixture. This was to 
convert the chloride to a better leaving group by forming silver chloride and to act as a mild 
Lewis acid to increase the reactivity of the benzyl alcohol. Unfortunately, this also did not lead 
to the desired product (table 2.6, entry 4). In a final attempt to induce a reaction, the solvent 
was changed to THF and 18 crown 6 was added. It was thought that this crown ether should 
increase the reactivity of the benzyl alcohol by removing the sodium counter ions from the 
vicinity. As before, no product was formed (table 2.6, entry 5).  
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A potential reason for the failure of the alkylation could be that the position 2 of the 2-
chlorobenzimidazole 21 is too electron rich to allow for a nucleophilic attack of the benzyl 
alkoxide. The tautomerism of the 2-chlorobenzimidazole 21 consists of two isoforms: 21 and 
21a (scheme 2.16).  
 
	  
Scheme 2.16: Tautomerism of 2-chlorobenzimidazole 21. 
 
Superposition of the two tautomers 21 and 21a gives a situation in which a high electron 
density resides at position 2, which makes this position difficult to attack with a nucleophile.  
To minimise the possibility of tautomerism, it was decided to protect one of the nitrogens in 
the benzimidazole core. Furthermore, this measure would reduce the electron density on 
position 2, hopefully leaving it more susceptible towards nucleophilic attack.  
 
2.1.6.3 Synthesis of Benzimidazole Ethers with Protected 2-
Chlorobenzimidazole 
 
There is a plethora of protecting groups available for the protection of amines and it is crucial 
for the success of the synthesis to find one that is appropriate for the particular 
circumstances. An ideal protecting group must be introduced selectively and under mild 
conditions. The protecting group needs to be stable during the synthesis and be cleaved 
under mild conditions and in a selective manner. [93] In the case of the synthesis of 
benzimidazole ethers, the protecting group needs to be stable under basic conditions.  
Some of the most common base-stable protecting groups for amines are: Boc, Cbz, benzyl 
and trityl (figure 2.10).  
 
	  
Figure 2.10: Potentially useful base-stable amine protecting groups. 
 
The benzyl and Cbz groups would be easy to install and stable under basic reaction 
conditions. As both groups are removed via hydrogenolysis, they are unsuitable for this 
synthesis because the benzyl ether may be cleaved in the same way. 
A very common protecting group for amines is Boc. It fulfils all of the fundamental criteria, is 
stable under basic conditions and inert to many nucleophiles. The trityl group is another 
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suitable base-stable protecting group. It can be attached by using trityl chloride and removed 
under acidic conditions. 
 
 
Synthesis of Benzimidazole Ether via N-Boc-protected 2-
Chlorobenzimidazole 
 
Due to its versatility and the mild procedures for its introduction and removal, the Boc group 
was chosen as the protecting group for the synthesis of benzimidazole ethers (scheme 2.17).  
 
	  
Scheme 2.17: Boc-protection of 2-chlorobenzimidazole 21. 
 
The protection was carried out using Boc-anhydride under standard conditions and gave the 
Boc-protected benzimidazole 22 in 60% yield.  
The product was then used to find suitable reaction conditions to synthesise the Boc- 
protected benzimidazole benzyl ether 23 (table 2.7).  
 
 
Entry Base Solvent Additive Outcome 
1 NaH (1.3 eq.) DMF  No product 
2 NaH (2.6 eq.) DMF  No prduct 
3 NaH (4.0 eq.) DMF  No product,  
4 NaH (1.5 eq.) DMF DMAP No product 
5 NaH (1.5 eq.) THF DMAP Trace amounts, deprotected SM 
6 Et3N (1.3 eq.) DMF DMAP No product 
7 Et3N (1.3 eq.) THF DMAP No product 
8 No base DMF AgNO3 No product 
9 No base THF AgNO3 No product 
 
Table 2.7: Conditions tried for the synthesis of benzimidazole ether 23. 
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The optimisation was started with a series of reactions with increasing amounts of base 
employed. None of these reactions gave any amount of the desired benzimidazole 23 (table 
2.7, entries 1-3). Then, to increase the reactivity of the benzyl alcohol two reactions were 
conducted where a catalytic amount (0.1 equivalents) of DMAP was added. While the 
reaction in DMF did not yield any product, the reaction in THF showed a trace amount of 
product (table 2.7, entries 4 and 5). Unfortunately, the reaction also yielded a large quantity 
of deprotected starting material. It was hypothesised, that deprotection could occur due to the 
hydroxy group attacking the carbonyl of the Boc group (scheme 2.18).  
 
	  
Scheme 2.18: Possible mechanism for the nucleophilic deprotection of 2-chloro-N-Boc benzimidazole 22. 
 
Thus, nucleophilic attack by the alkoxide 24 on the Boc group results in the formation of a 
carbonate-amide intermediate 25 that collapses to give back the 2-chlorobenzimidazole 21 
and a tert-butyl-benzyl carbonate 26.  
 
To avoid the deprotection, the next reactions were carried out with triethylamine to neutralise 
the hydrochloric acid produced in this process. For both reactions, in THF as well as in DMF 
no conversion to the product occurred (table 2.7, entries 6 and 7). In the last trial reaction of 
this series, silver nitrate was used as an additive. This salt acts as a mild Lewis acid and 
should activate the benzyl alcohol, as well as leading to the formation of silver chloride, which 
precipitates, driving the reaction towards the product. Unfortunately, this was also not 
successful (table 2.7, entries 8 and 9).  
 
After these unsuccessful attempts and the observed deprotection under the employed 
reaction conditions, it was anticipated that a change in protecting group might be the key to 
achieving a successful synthesis of the benzimidazoles.  
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Synthesis of Benzimidazole Ether via N-Trityl-Protected 2-
Chlorobenzimidazole 
 
Our second choice of protecting group for this reaction was the trityl group. This group is 
stable under basic conditions and can be cleaved under mild acidic conditions. The trityl 
protection was carried out as described in the patent by Matsoukas et al. (scheme 2.19). [94] 
 
	  
Scheme 2.19: Trityl protection of 2-chlorobenzimidazole 21. [94] 
This reaction was carried out with a slight excess of trityl chloride. The product was purified 
by column chromatography, but proved to be highly sensitive towards acid, which led to 
decomposition of the product during the chromatography.  
Nevertheless, the etherification was attempted with the slightly impure starting material (table 
2.8).  
 
 
Entry Base Solvent Temperature Additive Outcome 
1 NaH DMF RT  <5% product 
2 Et3N DMF RT DMAP No product 
3 NaH THF 68 °C  No product 
4 NaH Neat 70 °C  No product 
5 NaH NMP 70 °C  Decomposition of SM 
6 NaH DMF 70 °C  ≈10% Product 
 
Table 2.8: Conditions for the synthesis of N-trityl protected benzimidazole ether 28. 
 
The optimisation was started with sodium hydride in DMF at room temperature. 
Encouragingly, a small amount of product was obtained (table 2.8 entry 1). To improve the 
yield a selection of different solvents was tried. Changing the base to triethylamine, and the 
addition of DMAP did not give any product (table 2.8, entry 2). Therefore, it was decided to 
continue with sodium hydride as the base. The reaction in THF did not yield any product and 
the starting material was recovered (table 2.8, entry 3). To eliminate any effects the solvent 
could have, the reaction was tried neat with benzyl alcohol as the nucleophile and solvent. 
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After removing the benzyl alcohol, no product could be detected (table 2.8, entry 4). In the 
following attempt NMP was employed as the solvent but these conditions led to the 
decomposition of the starting material (table 2.8, entry 5). The last reaction of this 
optimisation series was again run in DMF but at 70 °C. The product was formed but the yield 
was still very poor (table 2.8, entry 6).  
Looking at the structure of the N-trityl-2-chlorobenzimidazole 27 more closely, it is noticeable 
that the trityl group is sterically very demanding (figure 2.11).  
	  
Figure 2.11: 3-Dimensional structure of N-trityl-2-chlorobenzimidazole 27 generated by using Chem 3D®. 
 
The 3-dimensional structure shows that the three phenyl rings are organised like a propeller, 
with one of the phenyl rings very close to the envisaged reactive centre of the molecule. At 
elevated temperature the movements within the molecule should increase and allow the 
benzyl alcohol to attack at the position 2 of the benzimidazole 27. However, the yield did not 
greatly increase when the reaction was carried out at higher temperature. Another possible 
problem with the trityl group could be the electron donating properties of the three phenyl 
rings. This could increase the electron density at C-2 and result in a reduced reactivity 
towards nucleophiles.  
 
Even though some product could be obtained from this reaction, the conditions were still not 
good enough for the synthesis of a compound library. Therefore, the trityl protecting group 
was discarded as unsuitable.  
 
 
Synthesis of Benzimidazole via N-SEM-protected 2-Chlorobenzimidazole 
 
An extensive search in the literature suggested that a rather less commonly used protecting 
group could potentially be suitable for the present reaction: the trimethylsilylethoxymethyl 
(SEM) group. This protecting group is significantly smaller than the trityl group, inert to strong 
bases and nucleophiles and can be selectively removed with TBAF. Consequently, we 
decided to evaluate this form of N-protection (scheme 2.20). 
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Scheme 2.20: N-SEM-protection of 2-chlorobenzimidazole 21. 
 
The protection reaction was carried out by adapting a procedure described by Grice et al. [95] 
and gave the product in good yield.  
 
The N-SEM protected benzimidazole 29 was then reacted with benzyl alcohol under the 
same conditions as before, with sodium hydride in DMF (scheme 2.21). 
 
	  
Scheme 2.21: Synthesis of the two regioisomeric products 30 and 31 of N-SEM-protected benzimidazole 29. 
 
The reaction in DMF gave the desired benzimidazole benzyl ether in 41% yield at the first 
attempt. Interestingly, as evidenced by 1H-NMR spectroscopy, the N-SEM-protected 
benzimidazole ether is formed as a 1:1 mixture of two products. These two products derive 
from the tautomerism of the starting material and are the 6-methylbenzimidazole and 5-
methylbenzimidazole respectively. 
The deprotection was carried out utilising TBAF in THF, similarly to the conditions described 
by Bamberg et al. (scheme 2.22). [96] 
 
	  
Scheme 2.22: SEM-deprotection to the final benzimidazole ether 18. [96] 
 
Heating the reaction mixture with 5 equivalents of TBAF at 55 °C gave the benzimidazole 
ether 18 as a single product in 29% yield.  
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With workable reaction conditions for the etherification and deprotection in hand, the 
synthesis of the analogues was carried out, giving the N-protected benzimidazole ethers 30a-
f in 49-86% yield and the final benzimidazole ethers 18a-f between 10 and 54% overall yield 
(table 2.9).  
 
 
Substituent R H 2-Me 4-Me 2-Cl 3-Cl 4-Cl 3,4-Cl2 
Etherification 53% 77% 28% 49% 67% 83% 76% 
Deprotection 29% 33% 35% 87% 42% 45% 71% 
Overall 15% 25% 10% 43% 28% 37% 54% 
 
Table 2.9: Yields for the synthesis of the series of benzimidazole ethers 18a-f. 
 
Due to the low yield in the test deprotection reaction, the amount of TBAF was increased to 
ten equivalents and the reaction time prolonged to 48 hours, when preparing the analogues. 
The compounds synthesised were analogous to those prepared in the thioether series. This 
would enable us to directly compare the binding effects of the oxygen analogues versus the 
thioether analogues.  
 
2.1.7 Synthesis of 6-Aryl Substituted Benzimidazole Thioether 
 
The final series of benzimidazole analogues contains an aryl group at position 6. As before, 
the substitution on the aryl ring was to be varied according to the Topliss series. [63] 
 
The synthesis of the aryl substituted benzimidazoles 32 starts with the synthesis of 6-bromo 
2-mercaptobenzimidazole 9b. As discussed above, this can easily be synthesised from the 
corresponding diamine and carbon disulfide (scheme 2.23).  
 
	  
Scheme 2.23: Planned route for the synthesis of substituted 6-aryl benzimidazole thioethers 32. 
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After formation of the 2-mercaptobenzimidazole 9b, the next step is the conversion to the 
thioether 10b. The final and crucial step is the introduction of the substituted aryl ring via 
Suzuki-Miyaura coupling (scheme 2.23).  
This synthetic route has the advantage of a late-stage diversification. Therefore, the starting 
materials until the Suzuki coupling could be prepared on a large scale. 
 
There are, of course, numerous types of palladium cross couplings known. [97] The most 
suitable cross coupling for this system however, was considered to be the Suzuki-Miyaura 
coupling, which is a powerful method for the synthesis of biphenyls and is mechanistically 
well-understood (scheme 2.24).  
 
	  
Scheme 2.24: Catalytic cycle of the Suzuki-Miyaura coupling. [98] 
 
The catalytic cycle starts with the oxidative addition of the aryl bromide to the Pd(0). The cis 
Pd(II)-complex then isomerises to the trans isomer. Transmetallation with the boronic acid 
gives the Pd(II)-biphenyl complex that undergoes reductive elimination to give the biphenyl 
product and concomitantly regenerates Pd(0) to continue the catalytic cycle.  
 
In the above reported copper catalysed Ullmann-type coupling it was noted that the thioether 
12a appeared to cause deactivation of the copper catalyst. A similar deactivation could be 
expected for the palladium catalyst. Maxted [90] has reported on the ability of sulfur-containing 
compounds to poison transition metal catalysts and deactivate them. Among the poisoning 
compounds are sulfites, organic thiols and organic sulfides. All these compounds have at 
least one free electron pair that can form a dative bond to the metal catalyst (figure 2.12). 
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Figure 2.12: Examples of “catalyst toxic” and “non-toxic” sulfur-containing compounds. [90] 
 
In contrast, sulfur containing compounds which lack a free electron pair are not capable of 
binding to the catalyst and hence, cannot deactivate the metal catalyst. To prevent the 
deactivation, it was therefore decided to mask the thioether sulfur as a non-catalyst toxic 
sulfone (scheme 2.25).  
 
	  
Scheme 2.25: Oxidation of the benzimidazole thioether 10b to the corresponding sulfone 33. 
 
The oxidation was carried out with peracetic acid and gave the product in 58% yield.  
Following the pathway outlined above, the sulfone was to be subjected to the Suzuki-Miyaura 
coupling, followed by the reduction to the thioether to give the final product 32 (scheme 2.26).  
 
	  
Scheme 2.26: Planned route for the synthesis of 6-aryl benzimidazoles 32 via the sulfone 34. 
 
This procedure would have two advantages: on the one hand, the oxidation masks the sulfur 
and reduces its ability to deactivate the palladium catalyst during the Suzuki coupling and on 
the other hand, the respective sulfones are also a series of compounds that may have the 
ability to modulate the action of LRH-1.  
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2.1.7.1 Suzuki Coupling of Benzimidazole Sulfone 
 
The Suzuki reaction was carried out using a variety of different conditions (table 2.10). 
 
 
Entry Pd(PPh3)4 Base (2.0 eq.) PhB(OH)2 Solvent Outcome 
1 10 mol% NaHCO3 1.5 eq. THF No product 
2 10mol% Na2CO3 1.5 eq. Toluene < 2% 
3 10 mol% Na2CO3 1.5 eq. DME/H2O (10:1) No product 
4 10 mol% Na2CO3 1.5 eq. Tol/H2O (10:1) No product 
5 10 mol% K2CO3 1.5 eq. Tol/MeOH (10:1) No product 
6 10 mol% Na2CO3 1.5 eq. Tol/MeOH/H2O (10:1:1) No product 
7 20 mol%* K2CO3 2.0 eq. Dioxane/H2O (10:1) < 2% 
8 30 mol%* K2CO3 2.0 eq. DMF No product 
9 15 mol%* K2CO3 2.0 eq. DMF/MeOH/H2O No product 
*Pd(PPh3)4 formed in situ. 
Table 2.10: Suzuki coupling of the benzimidazole sulfone 33 with phenylboronic acid. 
 
The coupling reaction was first attempted in THF and in toluene (table 2.10, entries 1 and 2). 
The reaction in toluene gave trace amounts of the product (table 2.10, entry 2). Then a 
selection of different solvents and solvent mixtures were tried, but none of these conditions 
proved successful (table 2.10, entries 3-6). Then it was decided to increase the amount of 
phenylboronic acid and the catalyst loading level (table 2.10, entries 7-9). From these 
experiments only the reaction in a dioxane/water mixture gave traces of the desired product 
(table 2.10, entry 7).  
A possible reason for the failure of the reactions could be the decomposition of the catalyst. 
To address this possibility, in the last three reactions the Pd(PPh3)4 complex was formed in 
situ using Pd-acetate and triphenyl phosphine (table 2.10, entries 7-9).  
Another reason for the lack of success of the reaction could be the electronic properties of the 
benzimidazole 33. This electron rich aryl halide would undergo very slow oxidative addition. 
Due to the oxidation of the sulfur it is improbable that it is still able to deactivate the catalyst.  
 
After none of the conditions tried gave the desired product in a satisfactory yield, it was 
necessary to search for an alternative route for the synthesis of 6-aryl benzimidazole 
thioethers 32. 
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2.1.7.2 Alternative Route Towards 6-Aryl Benzimidazole Thioethers 
 
An alternative route for the synthesis of the desired aryl benzimidazoles 32 was considered to 
be via an “early” Suzuki coupling prior the formation of the 2-mercaptobenzimidazole.  
A comparison of the two retrosynthetic pathways is presented below (scheme 2.27): 
 
	  
Scheme 2.27: Comparison of the initial and revised routes for the synthesis of 6-aryl benzimidazoles 32. 
 
The starting material for both routes is 4-bromo-1,2-diaminobenzene 8b, but the order of 
events is reversed. The original approach started with the synthesis of the benzimidazole 
thioether 10b, which was envisaged to be cross-coupled to give the 6-aryl benzimidazole 32. 
The revised apporach begins with the Suzuki coupling to form the biaryl compound 36. After 
that, the benzimidazole 37 is formed, using similar reaction conditions to those already 
described.  
 
The new pathway was initiated with the N-Boc-protection of the 4-bromo-1,2-diaminobenzene 
8b, followed by the Suzuki coupling, using a procedure adapted from that described by 
Cheung et al. (table 2.11). [99]  
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Entry PhB(OH)2 Pd(dppf)Cl2 Na2CO3 Time 2-(2-ethoxy-
ethoxy)ethanol 
/H2O 
Yield 
1 2.0 eq. 20 mol% 8.0 eq. 11 h 1:0 < 2% 
2 2.0 eq. 10 mol% 8.0 eq. 11 h  3:1 20% 
3 2.0 eq. 20 mol% 8.0 eq. 36 h  1:1 77% 
4 2.0 eq. 20 mol% 8.0 eq. 36 h  1.5:1 85% 
 
Table 2.11: Optimisation of the Suzuki coupling with phenylboronic acid. 
 
The protection was carried out in a mixture of water and dichloromethane with a high excess 
of Boc-anhydride. After purification by column chromatography the pure product 38 was 
obtained in good yield. The N,N´-di-Boc-protected 4-bromo diamide 38 was then used for the 
Suzuki coupling, which was optimised with phenylboronic acid. It was found that the Suzuki 
coupling was most efficient in a solvent mixture of 2-(2-ethoxyethoxy)ethanol/water (1.5:1) 
and a 20 mol% catalyst loading level. 
With the key steps optimised the synthesis of analogues was carried out (table 2.12).  
 
 
R H 2-Me 4-Me 2-Cl 3-Cl 4-Cl 3,4-Cl2 4-OMe 
Yield 29% 55% 49% 19% 53% 46% 20% 16% 
 
Table 2.12: Yields for the Suzuki coupling. 
 
All the biaryls 39a-g could be obtained in yields ranging from 16 to 55% 
 
With the key cross-coupling achieved, the Boc-deprotection was carried out with TFA in 
dichloromethane (scheme 2.28).  
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Scheme 2.28: Deprotection to the biaryl diamine 39. 
 
The reaction was complete after 15 min. In order to remove traces of TFA the crude product 
was purified by column chromatography. Unfortunately, the purified product proved to be very 
unstable and decomposed immediately. This event was quite unexpected as the 
commercially available diamines can be stored at room temperature in air. A possible reason 
for the rapid decomposition could be the increased stability of the Wheland intermediate due 
to the greater delocalisation of the electrons in the biaryl system and the amine groups 
formed by protonation. 
It was found, however, that the TFA salt 40 of the diamine 36 was stable. In the light of this 
finding, it was decided to use the diamine crude, as obtained from the deprotection reaction in 
the subsequent formation of the 2-mercaptobenzimidazole 37. This reaction was carried out 
as described above, with one equivalent of base and gave only a poor yield of 16% (scheme 
2.29).  
 
	  
Scheme 2.29: Formation of the biaryl 2-meracpto benzimidazole 37. 
 
This very low yield can be explained by the fact that an insufficient amount of base to 
neutralise the TFA and deprotonate the diamine has been added. To increase the yield, the 
amount of base and carbon disulfide was increased to 10 equivalents and the temperature 
decreased to 50 °C to minimise the loss of the highly volatile carbon disulfide. With the 
improved reaction conditions in place, a significant increase in yield to up to 95% could be 
observed (scheme 2.29).   
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The final step of the synthetic sequence was the etherification of the thiol (table 2.13).  
 
 
R H 2-Me 4-Me 2-Cl 3-Cl 4-Cl 3,4-Cl2 4-OMe 
Overall Yield 11% 19% 20% 6% 4% 11% 4% 4% 
 
Table 2.13: Overall yields of the synthesis of the final 6-aryl benzimidazole thioethers 32a-g. 
 
The alkylations were carried out as previously described with sodium methoxide in DMF. The 
reactions proceeded smoothly and yielded the desired final benzimidazoles 32a-g in good to 
satisfactory yields.  
 
For the 3-chloro analogue 32d, a very small second signal in the benzyl region of the 1H-NMR 
spectrum could be detected. This indicated that a small amount of the N-alkylated 
benzimidazole thioether was formed. The two products could be separated by preparative 
TLC. The separated products were recrystallised and a single crystal X-ray structure 
determination carried out by Chris Frampton (Pharmophix Ltd, Cambridge) on the major 
product. This confirmed that the major product of the alkylations is the expected S-alkylated 
benzimidazole (figure 2.13).  
 
	  
Figure 2.13: Molecular structure of S-benzylated thioether 32d as determined by a single crystal X-ray experiment 
performed by Chris Frampton. 
 
The crystal structure shows that the alkylation took place predominantly at the sulfur as we 
hoped for, and not at the nitrogen. 
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2.2. Biological Testing of the Compound Library 
 
After the completion of the synthesis of this series of analogues, all of the compounds were 
tested for their binding properties to the LRH-1 ligand binding pocket. Eric Ortlund (Emory 
Hospital, Atlanta, Georgia, USA) kindly prepared and supplied us with an appropriate 
plasmid, which was used for the expression of LRH-1. 
 
Plasmids are circular double stranded DNA molecules, which are distinct from the 
chromosomal DNA of the cell. The length can range from one to one hundred thousand DNA 
base pairs. Plasmids for genetic or biological work are called vectors. These vectors are used 
for instance to express particular genes (scheme 2.30).   
 
	  
Scheme 2.30: Cartoon depicting the formation of a plasmid. [100] 
 
The plasmid contains genes responsible for antibiotic resistance. The DNA strand contains 
the gene of interest. Both the DNA and the plasmid are opened with restriction endonuclease 
(EcoRi) and mixed with DNA ligase to reform the two pieces as recombinant DNA.  
The plasmid used here encodes for the expression of a fusion protein consisting of the LRH-1 
LBD and a maltose binding protein (MBP), connected through a histidine chain. The function 
of the MBP is to increase the solubility of the protein and prevent unwanted aggregation.  
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2.2.1 Expression of LRH-1 
 
The fusion protein was expressed in E.coli bacterial cells (scheme 2.31).  
 
	  
Scheme 2.31: Cartoon showing the steps involved in the expression of proteins from E. coli (picture adapted from 
accessexelence.org [100]). 
 
The first step in the expression was to transfect the plasmid into the bacterial cells 
(transformation). The plasmid was added to a stock of bacterial cells in media and the cells 
were heat shocked (scheme 2.32).  
 
	  
Scheme 2.32: Principle of plasmid transfection via heat shock. 
 
The heat shock procedure involved heating a mixture of E.coli cells and the plasmid to 42 °C 
for 45 seconds and then placing the tube on ice to minimise the damage to the cells.  
The heating causes the cell walls to open slightly and allows the plasmid to enter the cell. 
After the heat-shock, the cells were incubated for 30 min at 37 °C and cloned. This stock of 
cells was then transferred to agar plates, in which the media was treated with antibiotics. 
Cells which contain the plasmid have immunity towards the antibiotics. Hence, only 
successfully transfected cells remain on the plate and are grown overnight. The following day 
a single colony was chosen and a culture grown. After 12 hours in 5 mL growth media, the 
cells were transferred into one litre of medium and grown for further 8 hours. This stock was 
then divided into 5 times 1 litre aliquots. These cultures were grown until an optical density of 
0.6 was achieved. The optical density was monitored by measuring the UV absorption at 600 
nm. This method can be used to estimate the concentration of a bacterial solution. When the 
target optical density was reached, the cells were induced with isopropyl β-D-1 
thiogalactopyranoside (IPTG) and incubated at 25 °C overnight (figure 2.14).  
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Figure 2.14: Structure of isopropyl β-D-1 thiogalactopyranoside (IPTG). 
 
IPTG is a sugar derivative that cannot be metabolised and enables the expression of the 
desired protein. 
After incubation for 24 hours the bacterial cells were centrifuged and the cells separated from 
the media solution. The supernatant was discarded and the cell pellet transferred into a 
smaller tube. The cell pellet was re-suspended in water and sonicated to destroy the bacterial 
cell walls and extract the protein. The suspension was treated with DNAse, an enzyme used 
to break up DNA and after centrifugation, the supernatant contained the crude protein.  
The protein was purified by FPLC. Due to the structure of the fusion protein, the histidine 
residues could be used to aid the purification process. Therefore, it was possible to use a Hi-
trap column, which contains nickel ions that bind to the His-tag of the protein. After the crude 
protein was loaded on the column, all impurities that did not have a histidine chain were 
washed away leaving only the protein on the column. Then, the protein was gradually eluted 
from the column by increasing the concentration of imidazole in the buffer. A SDS PAGE was 
run to determine the fractions that contained the protein and to determine the purity (figure 
2.15).  
 
	  
Figure 2.15: SDS PAGE of the expressed LRH-1 protein (1: Ladder, 2: flowthrough, 3-10 protein containing 
fractions). 
 
The protein containing fractions were combined and dialysed to remove residual imidazole. 
For that process the protein solution was transferred into a permeable tube, that allowed only 
small molecules to pass through. These tubes were placed in a buffer solution, which was 
changed every 8 hours.  
 
For the testing of the compounds, it was preferred to have only the LRH-1 LBD protein. At the 
outset it was not known whether the MBP would have an influence on the behaviour of the 
1    2    3      4    5    6      7      8     9   10 
MW 
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LRH-1 LBD in terms of ligand binding or co-activator binding in particular, because the MBP 
is bigger than the LRH-1 LBD itself. Ideally, the protein used for the testing would only be the 
LRH-1 LDB rather than the fusion protein. Therefore, the dialysis was combined with the 
cleavage of the MBP. 
This cleavage can be carried out with an enzyme derived form the tobacco etch virus (TEV). 
The enzyme recognises the specific sequence Glu-Asn-Leu-Tyr-Phe-Gln-(Gly/Ser) and 
cleaves the MBP fusion protein between the Gln and Gly/Ser residues, leaving the LRH-1 
LBD and the His tagged MBP.  This cleavage leaves the LRH-1 protein without a His-tag, 
which is required for some assays and therefore would limit the choice of potential assays.  
 
For the TEV-cleavage the protein solution was split into three batches and each was treated 
with increasing amounts of the TEV enzyme. After the cleavage/dialysis a SDS PAGE 
showed that only a small fraction of the protein was cleaved. The cleavage was repeated with 
small quantities of the protein but again, no cleavage was observed. Due to the prolonged 
time the protein was at 4 °C and the general instability of proteins this batch was discarded 
and the expression repeated.  
 
At the same time, Eric Ortlund provided us with a different plasmid, which only encodes for 
the LRH-1 LBD and a short His-tag. Expression of this protein under similar conditions as 
mentioned above was therefore attempted. The E. coli cells transfected with the plasmid grew 
well on the agar plate, but after inoculation of a single colony into LB broth, no further growth 
was observed. The procedure was repeated under close supervision of an experienced 
molecular biologist to detect any handling errors, but again, the cells did not grow. The great 
number of possible errors in the growth of bacterial cells makes the trouble shooting very 
challenging. Possible mistakes can be the wrong amount or type of antibiotics, bad condition 
of the cells, an alternative infection due to non-sterile handling or the wrong temperature and 
CO2 content during the incubation.  
Due to the failure in the TEV-cleavage and the unsuccessful attempts at expressing the short 
His-tag LRH-1 LBD protein it was decided to continue with the MBP fusion protein.  
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2.2.2 Testing of the Compound Library 
2.2.2.1 Review of Most Common Assays [101] 
 
There are many possible assays that can be used to evaluate the binding properties of small 
drug-like compounds to a protein. The most common types are ELISA assays, fluorescence 
polarisation assays, FRET assays and AlphaScreen® assays. 
 
 
Enzyme-Linked Immunosorbant Assay (ELISA) 	  
With the ELISA assay it is possible to measure the protein-protein interaction and effects of 
small molecule inhibitors (figure 2.16).  
	  
Figure 2.16: Cartoon showing the principle of the ELISA assay (picture from Iaszoology). [102] 
 
One of the proteins is attached to the surface of a 96 well plate and the second protein 
allowed to bind to the first protein. The second protein is then allowed to bind an antibody, 
which is attached to an enzyme and as a result a, readout is produced that is proportional to 
the amount of the second protein bound to the first. For the case an inhibitor is bound, an 
decease in readout can be observed. Alternatively, an activator would increase the readout. 
The detection of the second protein can occur in several ways, such as direct labelling of the 
protein with a signal generating enzyme or binding of an enzyme labelled antibody. 
Depending on the method chosen, the readouts can be UV absorbance, fluorescence or 
luminescence.  
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Fluorescence Polarisation Assay 
 
This assay enables the measurement of the association or dissociation between two 
molecules of which one has to be relatively small (figure 2.17).  
 
	  
Figure 2.17: Cartoon depicting the principle of a fluorescence polarisation assay (picture from Arkin et al.). [101] 
 
When a molecule labelled with a fluorophore is excited by polarised light it emits light with a 
degree of polarisation that is inversely proportional to the rate of molecular rotation. This 
molecular rotation is strongly dependent on the mass of the molecule. When a small molecule 
is fluorescently labelled and excited with polarised light, it will lose most of its polarisation due 
to rotation. However, when the small molecule is bound to a protein (bigger than 10 kDa), 
then the rotation is significantly reduced, which results in a higher intensity of polarised light 
being emitted. This differential can be quantified and forms the basis of this assay. 
 
 
Time Resolved Fluorescence/Förster Resonance Energy Transfer (TR-
FRET) 
 
FRET is a phenomenon of non-radiative energy transfer between two fluorophores. For FRET 
to occur, the emission spectrum of the donor fluorophore must overlap with the excitation 
spectrum of the acceptor fluorophore. Additionally, the donor and acceptor need to be in 
close proximity (10-20 nm). When the donor is excited, energy can be transferred to the 
acceptor via long range dipole-dipole interactions. In TR-FRET the donor has very long 
emission half-live. This delay of 50-150 µsec between excitation and measured acceptor 
emission allows most of the background fluorescence to decay before the acceptor emission 
is measured giving a better signal-to-niose ratio than the standard FRET (figure 2.18).  
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Figure 2.18: Cartoon depicting the principle of a TR-FRET assay (picture with kind permission taken from Phenex-
Pharma). [103] 
 
 
Amplified Luminescent Proximity Homogenous Assay (AlphaScreen®) 
 
The AlphaScreen® was originally developed as LOCI (luminescent oxygen channelling 
immunoassay) by Dade Behring Inc. and is now a product of PerkinElmer. Like the FRET 
assay, the AlphaScreen® is a proximity assay. The two molecules to be observed are bound 
to beads. The donor bead contains a photosensitiser, phthalocyanine, that converts ambient 
oxygen into singlet oxygen upon illumination at 680 nm. Therefore, excitation of the donor 
results in the formation of singlet oxygen, which diffuses to the acceptor bead. When the 
acceptor bead is within range, energy is transferred to the thioxene containing acceptor bead 
and light is produced. The emission is measured at 520-620 nm (figure 2.19).  
	  
Figure 2.19: Cartoon depicting the principle of a AlphaScreen® assay (Image used with kind permission of 
PerkinElmer © 2014 PerkinElmer). [104] 
 
The principle of the ELISA assay makes it unsuitable for the testing of the compounds 
prepared in this work. Additionally, several steps of washing make this assay impractical in a 
high throughput scenario. The FRET assay is also not suitable for the testing anticipated 
here, as it would require that one of the fluorophores is bound to the LRH-1 protein and the 
other to the co-activator peptide. Even though the former can be achieved by using the His-
tag, the fluorophore would be too far away for FRET to occur. To have the fluorophore in 
proximity to the AF-2 site, significant molecular modifications to the protein would be required, 
which would impart unknown effects to the binding properties of the co-factor and the 
potential ligands.  
 
The fluorescence polarisation assay could be used for the testing of the series of 
benzimidazoles. For this assay only one fluorophore is required that can be attached to a co-
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activator peptide. When the compound is an agonist it would enhance co-factor binding and 
the polarisation of the emitted light would be increased. Alternatively, if the compound is an 
antagonist, the co-activator binding would be reduced and hence, the polarisation would 
decrease. A limitation of the fluorescence polarisation assay is that the fluorophores quench 
over time. The AlphaScreen® is a FRET-type assay, where the distance of donor and 
acceptor beads can be longer than in a conventional FRET assay, enabling us to use the His-
tag to bind one of the fluorophore beads. The other bead can be attached to the peptide by a 
biotin linker. Due to previous experiments carried out by Dr Fiona Kyle on the AlphaScreen®, 
[105] it was decided to use this assay for the testing of this compound library.  
 
Taking previous experiments into account, a panel of 4 co-factors was selected for 
incorporation into the AlphaScreen® assay and testing of the synthesised compound library. 
These comprised PGC-1α and TIF2 as co-activators and DAX-1 and a phage display derived 
peptide published by Clyne et al. [23] as co-repressors. 
 
Unlike in other binding assays, the shape of the curves obtained from the AlphaScreen® are 
expected to follow a bell shape. This is because of the so-called hook effect (figure 2.20).  
 
	  
Figure 2.20: Explanation of the Hook effect (Image used with kind permission of PerkinElmer © 2014 PerkinElmer). 
[106] 
 
When the protein and peptide are titrated, the beads become progressively saturated by 
binding to their respective target and the alpha signal increases. At the hook point either the 
donor or the acceptor bead is fully saturated and the signal reaches its maximum. At 
concentrations above the hook point an excess of target molecules for the donor or acceptor 
bead exists, which inhibits their association and cause a decrease in alpha signal. As a 
consequence the working region of the output is in the region where the concentrations are 
below the hook region. 
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2.2.2.2 Assay Optimisation 
 
Before the testing was started the assay had to be optimised. To find an optimal ratio of 
protein to peptide, a titration was carried out with a 1:1 ratio of the LRH-1 protein to each of 
the selected peptides PGC-1α, Dax-1 TIF2 and the Clyne 4-16 peptide. As the LRH-1 protein 
binds its co-factor peptides in a 1:1 ratio, this ratio was used as a starting point for the 
optimisation (figure 2.21).  
 
 
 
Figure 2.21: Titration of LRH-1 and peptide in ratio 1:1. 
 
The titration was carried out in triplicate and the results of each titration are plotted in the 
graphs. The graphs only vaguely resemble the expected bell-shaped curve. This result could 
be due to a too high concentration of either peptide or protein. Therefore, the titration was 
repeated with a 10:1 ratio of protein and peptide (figure 2.22).  
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Figure 2.22: Titration of LRH-1 and peptide in ratio 10:1. 
 
The graphs obtained are now significantly smoother and with reduced error. Still, these 
results are not satisfactory, as they still do not exhibit the bell shape. Particularly, the curve 
for DAX-1 appears erroneous, as it exhibits only one high readout point. In all traces it can be 
seen that for the fifth lowest concentration point the alpha signal plummets to zero. This could 
have two possible reasons: First, it may be that the plate reader used has a problem reading 
that particular column of the plate or second, it could be a pipetting error, which caused one 
of the components to be present in insufficient quantity, so that the reading drops. To explore 
both possibilities the titration was repeated a third time using the same ratio of protein and 
peptide (figure 2.23). 
 
	   	  
	   	  
Figure 2.23: Repetition of the titration of LRH-1 and peptide in ratio 10:1. 
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A repetition of the titration gave the bell shaped curves confirming the chosen concentrations 
for protein and peptide and that the error seen in the graphs above was due to a pipetting 
error. Therefore, these titration curves were used for further considerations of the testing 
conditions.  
With this ratio set it is necessary to chose a concentration of the protein and peptide mixture. 
During the testing it is expected that antagonistic behaviour of the compound leads to a drop 
of the alpha signal. To detect this difference in alpha signal it was required to choose a 
concentration of protein and peptide high enough to see a reduction in alpha signal. In 
contrast, an agonist compound would increase the binding of protein and peptide and hence, 
lead to an increase in alpha signal. To observe this change, it was required to run the testing 
at a concentration low enough to detect this increase.  
 
To address both modes it was decided to run the assay against all peptides at one high and 
one low concentration (figure 2.24).  
 
 
	  
Figure 2.24: Determination of low and high concentration point for the assay. 
 
These concentrations were determined form the titration curves by choosing a point with low 
alpha signal and low concentration of protein and peptide to test for agonism and a point with 
high readout and concentration to detect antagonism. The high concentration point had to be 
before the hook effect takes place.  
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The concentrations for the compounds are summarised in the table below (table 2.14). 
 
Peptide Low conc 
peptide [µM] 
Low conc LRH-
1 [µM] 
High conc 
peptide [µM] 
High conc LRH-
1 [µM] 
PGC-1a 0.004 0.04 0.02 0.2 
DAX-1 0.003 0.03 0.03 0.3 
TIF2 0.02 0.2 0.06 0.6 
Clyne 4-16 0.003 0.03 0.01 0.1 
 
Table 2.14: Summary of peptide and protein concentrations. 
 
2.2.2.3 Assay Outline 
 
During the assay the concentration of protein and peptide were kept constant, while a titration 
of the compound was carried out. 
The assay was run on a 384 well plate with a standard format of the plate. Each plate was 
divided into 12 segments, where two segments contained one compound (figure 2.25).   
 
	  
Figure 2.25: Outline of 384-well assay plate and structures of the controls. 
 
On the left hand side of the plate was the low concentration and on the right hand side the 
high concentration of protein and peptide. In addition to the compounds, two known 
compounds were run to compare the tested compounds against them. For the testing for  
agonists, Whitby’s 5a compound [54] was used as standard. In the case of the testing for 
antagonists, the published Scripps compound was used (figure 2.26). [107] 
 
	   	  	   	  	   	  	  	   	  	  
	   	  
Compound A 
Compound B 
Compound A 
Compound C 
Compound D 
Compound B 
Compound C 
Compound D 
Compound E Compound E 
5a Control Scripps Control 
	   	  	   	  
Columns 1-12 protein and 
peptide at low concentration 
Columns 1-2, 4 and 6-12: 
compound titration from100 µM to 
5 nM, column 3: control (purple), 
column 5: background (yellow) 
Columns 13-24 protein and 
peptide at high concentration 
Columns 13-14, 16 and 18-24: 
compound titration from 100 µM to 
5 nM, column 15: control (purple), 
column 17: background (yellow) 
Rows A-C: compound A 
Rows D-F: compound B 
Row G: control compound 5a or 
Scripps compound 
Rows H-J compound C 
Rows K-M compound D 
Rows N-P compound E  
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Figure 2.26: Controls used in the AlphaScreen® assay: Whitby’s 5a compound and a Scripps compound. [54,107] 
 
At first a one-in-three serial dilution of the compounds in DMSO was carried out, starting from 
100 µM to 5 nM as the lowest concentration over 10 concentration points. An aliquot of these 
dilutions were transferred to the measuring plate. Then buffer, the LRH-1 protein and the 
respective peptide were added to the wells. After addition of the Ni-chelate acceptor beads 
the plate was incubated for 30 minutes before the streptavidin donor beads were added. The 
plate was again incubated and the alphasignal measured using a PherastarTM plate reader.  
 
To normalise the data, one column was dedicated for the measurement of the background, 
and another column to the measurement of the signal when no compound was added 
(control). The latter can be used as the baseline for the assay.  
 
2.2.3 Assay Results 	  
The results for the AlphaScreen® testing of all benzimidazoles against all 4 peptides are 
outlined below (figure 2.27). 
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Figure 2.27: Summary of the AlphaScreen® data for the testing of the compounds 10-33. 
 
The raw data was normalised using the background and the control using the formula below 
(equation 2.2). 100 (𝑟𝑒𝑎𝑑𝑜𝑢𝑡 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)(𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)  
Equation 2.2: Formula used for the normalisation of the raw assay data. 
 
Despite the fact that all compounds and controls were run under the same conditions, there is 
a significant variance in the results. This can be clearly seen in the graphs of the controls. 
The Whitby 5a compound [54] shows large error bars for the Clyne 4-16 peptide but appears 
consistent for the other peptides. On the other hand, the Scripps compound, which is a 
published LRH-1 antagonist [107] does not seem to have any effect on the binding of co-factor 
and protein. Ideally, compound 5a and the Scripps compound would reproducibly show clear 
agonism and antagonism respectively. As this is not the case, it is difficult to evaluate the 
data and no other control molecules were available. 
Interpreting the data here, it seems that the original lead compound (MeM-007) does indeed 
slightly increase the peptide binding for PGC-1α and TIF2, but has no effect on the Clyne 
peptide and DAX-1.  Two close derivatives of the lead compound, MeM-028D and MeM-028B 
also show an increase in alpha signal for PGC-1α for the high concentration experiment. At 
the same time MeM-028B decreases the binding of TIF2 at low concentration and Clyne 4-16 
at both concentrations. For compound MeM-013 the data appears contradictory: at low 
concentration the binding to DAX-1 increases, but it decreases for the high concentration. As 
the change in activity for both concentrations is very abrupt, it is more likely that this is due to 
an experimental error, rather than reflecting a true property of the compound. A steady 
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decline in activity can be found for MeM-026 at low concentrations for DAX-1. The compound 
MeM-174A causes a slight decrease in the binding of the Clyne peptide and an increase in 
the activity of DAX-1 at low concentration. At high concentration this compound greatly 
increases the binding of TIF2. Similar behaviour can be found for MeM-174B and MeM-
185Bn although not as strongly. A steady increase in DAX-1 binding is also observed for 
MeM-174C and MeM-180C at low concentrations. Interestingly, MeM-185Cl seems to cause 
a slight increase in binding for all four tested peptides in the high concentration experiment.  
 
Taking the results together, it appears that only a few of the compounds of the first series of 
analogues (different benzyl groups or commercial cores) have an effect on the binding of co-
factors. The most significant effects in binding could be observed among the ether analogues 
but none affected the PGC-1α binding, which was affected by the thioether series. Among the 
aryl substituted compounds none of the compounds was able to cause a significant change in 
the binding between protein and peptide. Comparing the equivalent ether and thioether 
analogues, shows that the properties of these two sets are quite different. While the thioether 
series has a stronger effect on PGC-1a and DAX, the ether series did not affect PGC-1α, but 
did effect TIF2, DAX and Clyne peptide. Also, the ether series contained more compounds 
that showed any activity.  
Due to the high levels of error and the fact that the controls did not perform consistently 
throughout the testing, any conclusions must be drawn with great care. The results of this 
testing could be used to select compounds for further testing, but the results need to be re-
validated before any firm conclusions can be drawn.  
 
Some of the compounds have negative values for their normalised data. It is unclear how to 
interpret these data. Negative values can occur when the background signal is higher than 
the compound or control signal, but this should not be the case at any time.  
 
There can be many factors that contribute to the inconsistency of the data of this assay. The 
most obvious point of error or mistake is during the pipetting. Pipetting errors would only 
affect one small part of the plate e.g. one row and should not affect the whole plate. Other 
handling related errors could also be mistakes while preparing the protein/peptide dilutions or 
in the incubation times. A prolonged incubation leads to a decrease in signal. Another factor 
that changes the signal strength is the duration of light exposure: The beads are sensitive to 
light, in particular the donor beads. Therefore, the light exposure was kept as short as 
possible.  
 
Other problems could arise from the configuration of the assay itself. The assay is designed 
to measure the fluorescence of the acceptor beads. It may be that be signal of a particular 
well is either contaminated with the bleeding through from adjacent wells or is not recorded 
properly by the plate reader. Other problems may arise from the fact that a fusion protein is 
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used for the testing. It is possible that the His-tag, used to attach the donor bead to the Ni-
chelate bead, is too far away for the energy transfer to be efficient and consistent enough. 
This would cause a permanently reduced signal. Furthermore, the MBP could influence the 
binding of the compound into the LBD.  
 
Some suggestions as to how to systematically address these questions are presented in the 
conclusions and future work sections of this thesis.  
 
The remainder of this chapter describes a separate project that was carried out in parallel to 
the aforementioned work. 
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2.3 Towards the synthesis of α-Helix Mimetic as LRH-1 Co-
Activator Binding Inhibitor 
 
The ability to control protein-protein interactions (PPI) is of great importance in modern drug 
discovery. [108–110] Until recently, protein-protein interactions were considered “undruggable”. 
[111] A potential way to target this type of interaction is with peptides. Unfortunately, there are 
many shortcomings associated to peptides as drugs, such as short duration of activity, lack of 
receptor subtype specificity and poor oral bioavailability. [112] Peptidomimetics are small 
protein-like compounds that mimic a natural peptide or protein and interact with the biological 
target. [113–115] They are designed to overcome the disadvantages of the peptide. Additionally, 
they can be designed to have improved potency or selectivity. Hamilton et al. [116] were the 
first to described completely non-peptidic synthetic molecules capable of mimicing the 
peptide’s α-helical structure. They developed a terphenyl based system able to mimic the i 
i+3 and i+7 positions of an α-helix (figure 2.28).  
 
	  
Figure 2.28: A: Schematic representation of an R-helical 12-mer peptide with i, i + 3, and i + 7 substituents, side 
view; B: top view; C: 3,2ʹ′,2"- trisubstituted terphenyl, top view; D: side view; E: X-ray crystal structure. [116] 
 
Several other designs followed targeting different PPIs. One example is the work of 
Katzenellenbogen et al. [12] who established a system to prevent the co-activator binding onto 
the AF-2 site of the estrogen receptor. Taking this idea forward, Andrew Bayly (Spivey Group 
2007-2011) [62] developed an α-helix mimetic designed to target the AF-2 site of LRH-1 and 
therefore prevent co-activator binding and transcriptional activity of the nuclear receptor. His 
α-helix mimetic is based on the atypical nuclear receptor small heterodimer partner (SHP), 
which is known to selectively repress LRH-1 activity (table 2.15). [23]  
 
i-4 i-3 i-2 i-1 i+1 i+2 i+3 i+4 i+5 i+6 i+7 i+8 i+9  
R P A I L Y A L L S S S L SHP NR Box 1 
V P S I L K K I L L E E P SHP NR Box 2 
 
Table 2.15: Residues of the SHP NR Box with the LXXLL motif (red). [23] 
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The residues of importance of the SHP-1 box are the i-1, i+1, i+2, i+3, i+4 and i+5 residues, 
which include the LXXLL motif required for co-activator binding. After selection of the 
appropriate scaffold [62] the final α-helix mimetic had the following structure (figure 2.29): 
 
	  
Figure 2.29: Left: Structure of Andrew Bayly’s proposed helix mimetic; Right: the overlap of the mimetic (gray) with 
SHP-1 box (green). [62] 
 
The displayed overlap with the SHP-1 box shows a good match in terms of 3-dimensional 
topology.  
 
2.3.1 Synthesis of α-Helix Mimetic 	  
The α-helix mimetic consists of an azabicyclo[2.2.2]octane scaffold, that can potentially be 
modified to have all required residues in place. The synthetic route Andrew Bayly developed 
commences with the synthesis of the dialkyl substituted maleimide which contains the i+4 and 
i+5 leucine residues (scheme 2.33). 
 
	  
i-1 (Ile) 
i+1 (Leu) i+2 (Tyr) 
i+4 (Leu) 
i+5 (Leu) 
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Scheme 2.33: Andrew Bayly’s synthesis of N-phenyl maleimide 47. [62] 
 
The starting material is the 2-hydroxyaniline 41, which in the first step was N-Boc-protected, 
before the hydroxy group was alkylated, putting the first leucine mimetic residue in place. 
Then, the aryl ring was alkylated via ortho-directed lithiation and quenching with the alkyl 
bromide. The C-C double bond was hydrogenated, using palladium on charcoal and gaseous 
hydrogen. After that, the N-Boc group was removed and the resulting aniline 46 was treated 
with maleic anhydride and a catalytic amount of sulfuric acid to give the final substituted N-
phenyl maleimide 47.  
 
In the next part of the synthesis the other part of the α-helix mimetic, which will undergo a 
Diels-Alder reaction with the maleimide 47 was prepared. This heterodiene 49 is required to 
participate in a hetero-Diels-Alder reaction to establish the key core azabicyclooctane unit of 
the mimetic, which requires further modification to access the final α-helix mimetic (scheme 
2.34). 
 
  Results and Discussion 	  
 75 
	  
Scheme 2.34: Proposed synthetic route of the final helix mimetic 54 incorporating early progress by Andrew Bayly. 
[62] 
 
This part of the synthesis was also initiated by Andrew Bayly and involved the formation of 
the dihydropyridine 49. The plan for my work was to combine this dihydropyridine with the 
previously synthesised substituted N-phenyl maleimide 47 via a hetero Diels-Alder reaction. 
The remaining steps are to install the i-1 moiety by Stille coupling. The N-Cbz group is then 
removed by hydrogenolysis and the free amine alkylated, constituting the i+1 residue mimetic. 
At the same time, the double bonds are hydrogenated. The maleimide 52 is then reductively 
opened and the phenyl group installed via Mitsunobu reaction to give the final α-helix mimetic 
54. Clearly, there are a number of regio- and stereochemical issues associated with these 
steps. It was planned to address them on a case-by-case basis as the synthetic studies 
progressed.  
 
2.3.2 Current Work on the Synthesis of α-Helix Mimetics 
2.3.2.1 Synthesis of N-Phenyl Maleimide 
 
The first task towards developing this chemistry was the synthesis of a substantial amount of 
the substituted maleimide 47 following the synthetic route outlined above, established by 
Andrew Bayly (scheme 2.32). [62] The synthesis was started with the N-Boc protection, 
followed by alkylation of the hydroxy group (scheme 2.35). 
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Scheme 2.35: N-Boc-protection and alkylation of 2-hydroxyaniline 41. 
 
The N-Boc protection and subsequent alkylation gave the product in good yields. The 
following step was the ortho-directed lithiation to introduce the second leucine mimetic group 
(table 2.16). 
 
 
Entry tBuLi Time (a) Temp (a)/(b) Time (b) Additive Yield 
1 2.4 eq. 20 min -65 °C/-15 °C 2 h - 45% 
2 2.4 eq. 1 h -65 °C/0 °C 1 h - 10% 
3 4.4 eq. 1 h -65 °C/-10 °C 1.5 h - 74% 
4 2.4 eq. 1 h -65 °C/-10 °C 1.5 h TBAI 56% 
 
Table 2.16: Optimisation of ortho-directed lithiation/alkylation of aniline 43 to give dialkylated aniline 44. 
 
The reaction was carried out as described by Andrew Bayly, but gave the product in just 45% 
yield (table 2.16, entry 1). Therefore, optimisation of the reaction conditions was undertaken. 
An increase in reaction temperature to 0 °C reduced the yield to 10% (table 2.16, entry 2). 
The addition of TBAI to enable an in situ Finkelstein reaction, only modestly increased the 
yield to 56% (table 2.16, entry 4). However, the use 4.4 equivalents of tert-BuLi resulted in a 
dramatic increase in yield to 74% (table 2.16, entry 3).  
 
After the alkylation, the double bond was reduced using hydrogen gas over 10% (w/w) 
palladium on carbon with concomitant deprotection of the aniline N-Boc group (scheme 
2.36).  
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Scheme 2.36: Synthesis of dialkyl aniline 46. 
 
The hydrogenation as well as the deprotection were carried out as described by Andrew 
Bayly [62] and gave the product in quantitative and 52% yield respectively, without any 
purification required. In the final step the substituted N-phenyl maleimide 47 was formed by 
condensation of the di-ortho substituted aniline 46 with maleic anhydride (scheme 2.37). 
 
	  
Scheme 2.37: Synthesis of alkylated N-phenyl maleimide 47. 
 
This reaction was carried out as a two-step process. First, the maleic anhydride and aniline 
46 were heated neat to 120 °C for one hour to obtain a glassy compound. This was then 
dissolved in a toluene/DMSO solvent mixture with a catalytic amount of sulfuric acid and 
heated to 135 °C for 18 hours to give the desired substituted N-phenyl maleimide 47 in 88% 
isolated yield. 
 
2.3.2.2 Synthesis of 1,6-Dihydropyridine 
 
The next part of the synthesis towards the α-helix mimetic is the Diels-Alder reaction of the 
substituted maleimide 47 and 1,6-dihydropyridine 49. The preparation of the heterodiene 
compound required 3-bromopyridine 55 to be converted to 3-tributylstannyl pyridine 48 
(scheme 2.38).  
	  
Scheme 2.38: Synthesis of 3-tributylstannyl pyridine 48. 
 
The reaction gave the desired product in 37% yield. Despite the poor yield it was decided not 
to further optimise the reaction conditions at this juncture.  
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The selective reduction of 3-tributyl stannly pyridine 48 was then attempted (table 2.17). 
 
 
Entry Reducing Agent CbzCl Warming up Time Outcome 
1 N-selectride (2.1 eq.) 1.2 eq. - No product 
2 N-selectride (2.1 eq.) 1.2 eq. - No product 
3 Li(tOBu)3AlH (2.1 eq.) 1.1 eq. 1 h Product formed, NMR not clean 
4 Li(tOBu)3AlH (2.1 eq.) 1.1 eq. 4 h Product looks very unclean 
5 Li(tOBu)3AlH (2.1 eq.) 1.1 eq. 6 h No product 
 
Table 2.17: Reduction conditions for the formation of 1,6-dihydropyridine 49. 
 
The first attempt of the reduction of the stannylated pyridine 48 was by using N-selectride. 
The CbzCl was added at -78 °C and the reaction mixture stirred at that temperature for one 
hour. Then, N-selectride was added and the reaction mixture stirred for another 3 hours at -78 
°C, before stirring it at room temperature for another 30 min. Quenching the reaction involved 
the addition of a basic solution of hydrogen peroxide. The quenched reaction mixture was 
stirred overnight. A 1H-NMR spectrum of the crude reaction mixture did not indicate the 
presence of product (table 2.17, entry 1). The reaction was therefore repeated using the 
same procedure but again, no product was obtained (table 2.17, entry 2). The reason for the 
failure of this procedure appeared to be that hydrogen peroxide caused destannylation of the 
formed dihydropyridine 49. Therefore, another reducing agent was evaluated.  
 
Sundberg et al. [117] reported the selective reduction of substituted pyridines to the 
corresponding 1,6-dihydropyridines by using Li(tBuO)3AlH. This method was applied to the 3-
stannyl pyridine 48 (table 2.17, entries 3-5). The reaction mixture was cooled to -78 °C, 
before CbzCl and Li(tBuO)3AlH were slowly added. Then, the reaction mixture was warmed to 
0 °C and stirred for another hour (table 2.17, entry 3). The reaction gave the product as a 
mixture of the 1,2- and 1,6-dihydropyridine and the 1H-NMR spectrum of the crude product 
mixture revealed many additional side products. To increase the amount of the 1,6- 
dihydropyridine 49 the warming up time was prolonged to 4 hours (table 2.17, entry 4). The 
1H-NMR spectrum of the crude reaction mixture still showed a mixture of the two possible 
products and many impurities. After extending the time to warm up the reaction mixture and 
stirring overnight at room temperature the product could not be detected possibly due to 
decomposition in situ (table 2.17, entry 5). 
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Attempted purification of the product by column chromatography led to destannylation of the 
product. Treating the silica gel with triethylamine prior to the column chromatography, 
unfortunately, did not change the outcome.  
 
As the stannylated dihydropyridine 49 is very unstable and was proving impossible to purify, 
another method for the synthesis of the 1,6-dihydropyridine was sought.  
 
Suginome et al. [118] have reported on a Rh-catalysed hydroboration for the synthesis of 1,2-
dihydropyridines with pinacolborane (Bpin). This reaction was tried on 3-picoline 56 as a 
model system (table 2.18).  
 
 
Entry Solvent Bpin  [RhCl(cod)]2 PCy3 Outcome 
1 Toluene 0.5 eq. 1 mol%  4 mol% No product 
2 Toluene 1.0 eq. 1 mol% 4 mol% No product 
3 Toluene 2.0 eq. 1 mol% 4 mol% Decomposition 
4 Toluene 1.5 eq. 5 mol% 20 mol% No product 
5 Toluene 1.5 eq. 10 mol% 40 mol% No product 
 
Table 2.18: Attempted hydroboration of 3-picoline 56 according to the method of Suginome. [118] 
 
In the first attempt, the reaction conditions employed were exactly as described by Suginome 
et al. [118] As it appeared that the amount of Bpin is very low, the reaction was also set up with 
greater amounts of Bpin. Interestingly, in the reaction with 2 equivalents of Bpin the 
decomposition of the starting material could be seen immediately after the addition of the 
Bpin (table 2.18, entry 3). As the catalyst load in the original procedure is also very low, two 
experiments were started using 5 and 10 mol% of the catalyst respectively. As before, no 
product was formed (table 2.18, entries 4 and 5).  
 
A way to circumvent the problems arising form the use of the tributylstannyl pyridine 48 is to 
use the already alkylated pyridine. In her Masters thesis, Fiona Lee (Spivey Group 2010-
2011) [119] synthesised the required pyridine derivative by lateral deprotonation of 3-picoline 
56 with LDA followed by alkylation  (scheme 2.39). [119]  
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Scheme 2.39: Synthesis of 3-(2-methyl butyl) pyridine 58. [119] 
 
She found that the only hydride source capable of reducing this alkylated pyridine 58 was 
sodium borohydride, which gave a mixture of the 1,2-, 1,4- and 1,6-dihydropyridines; the 
sterically more demanding N-selectride and Li(tBuO)3AlH, did not yield any product (scheme 
2.40). [119] 
 
	  
Scheme 2.40: Fiona Lee’s best conditions for the formation of 1,6-dihydropyridine 59. [119] 
 
Clearly, a new method had to be found for the synthesis of the desired alkylated 1,6- 
dihydropyridine 59. 
 
2.3.3 Alternative Pathway for the Synthesis of Alkylated 1,6-
Dihydropyridine 
 
Maranzano et al. [120] have reported on a facile synthesis of 1,6-dihydropyridines, which were 
then trapped in situ with a dienophile present in the reaction mixture. This method, in the 
context of how it could be applied to access our target 1,6-dihydropyridine, is shown below 
(scheme 2.41). 
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Scheme 2.41: Outline of proposed new pathway for the synthesis of α-helix mimetic scaffold 64. [120] 
 
The sequence starts with the formation of the benzyl pyridinium salt 60, which would then be 
reduced to the tetrahydropyridine 61 using sodium borohydride. This compound would then 
be treated with m-CPBA to give the N-oxide 62. Treatment with trifluoroacetic anhydride 
followed by sodium methoxide would then hopefully give p-methoxy tetrahydropyridine 63 as 
a precursor to the 1,6-dihydropyridine, which we would plan to directly trap via a hetero Diels-
Alder reaction to give the azabicyclooctane scaffold of the α-helix mimetic 64. Although this 
sequence is longer than the direct reduction of the pyridine and subsequent Diels-Alder 
reaction, each step here appears simple and was hoped to give the product in acceptable 
yield with complete selectively for the desired 1,6-dihydropyridine.  
The exploration of this sequence started with the benzylation of 3-(3-methylbutyl)pyridine 58 
(scheme 2.42). 
 
	  
Scheme 2.42: Synthesis of the N-benzyl tetraydropyridine 61. 
 
The benzylation reaction was carried out using benzyl bromide in toluene and gave the 
product in 81% yield. This salt was directly subjected to the reduction reaction with sodium 
borohydride as the reducing agent. After purification the product could be obtained in 53% 
yield.  
The next step in the sequence is the formation of the N-oxide (scheme 2.43). 
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Scheme 2.43: Formation of the 3-alkylated N-benzyl N-oxide 62. 
 
The reaction was carried out by modification of the method published by Gil et al. [121] Due to 
the high polarity of the N-oxide product 62, the purification consisted of a short column 
chromatography with basic alumina, that quenches any remaining m-CPBA. The solvent 
system was chosen as a gradient of methanol in dichloromethane. Using this method, all 
impurities were removed before the product was eluted off the alumina giving the product in 
42% yield. During the reaction, a considerable amount of a single byproduct was formed, 
which could not be identified.  
With the N-oxide 62 in hand, the next reaction was carried out which involved treatment with 
trifluoroacetic anhydride followed by sodium methoxide (scheme 2.44).  
 
	  
Scheme 2.44: Formation of p-methoxy tetrahydropyridine 63. 
 
After the formation of the TFA salt 65 all residues of trifluoroacetic anhydride or TFA were 
removed under reduced pressure and by co-evaporation with toluene. Next, the TFA salt was 
treated with sodium methoxide to give the p-methoxy tetrahydropyridine 63. Due to the high 
instability of the product, it was used crude in the following Diels-Alder reaction (scheme 
2.45).  
 
	  
Scheme 2.45: Diels-Alder reaction towards the α-helix mimetic scaffold precoursor 64. 
 
By heating the p-methoxy tetrahydropyridine 63 to reflux, it should be converted to the 1,6-
dihydropyridine 66 as the only product, which should immediately react further with the 
N N O
a
(a): m-CPBA, CH2Cl2, RT, 16 h (42%).
61 62
N O
OMe
NN CF3CO2
a b
(a): TFAA, CH2Cl2, 0 ºC, 1 h; (b): MaOMe, CH2Cl2/MeOH, RT, 1.5 h (14%).
62 65 63
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substituted N-phenyl maleimide 47 to give the desired Diels-Alder adduct. The selectivity for 
the 1,6-dihydropyridine 66 and the corresponding Diels-Alder adduct can be explained by the 
proposed mechanism of this transformation (scheme 2.46).  
 
	  
Scheme 2.46: Proposed mechanism of 1,6-dihydropyridine 66 formation. [120] 
 
The nitrogen lone pair donates its electrons towards the methoxy group, which departs and 
acts as a base to effect the elimination reaction that gives the 1,6-dihydropyridine 66. 
 
Maranzano et al. [120] claim that any subsequent Diels-Alder reaction is completely endo 
selective. Unfortunately, the amount of the Diels-Alder product obtained was not sufficient to 
verify that this was also the case for our reaction.  
 
From this point onwards the route outlined by Andrew Bayly towards the final α-helix would 
comprise three further steps (scheme 2.47). 
 
	  
Scheme 2.47: Proposed remaining steps towards the synthesis of the α-helix mimetic 54. [62] 
 
Unfortunately, time constraints prevented exploration of these steps, but the next step would 
be the hydrogenolysis/hydrogenation to remove the N-benzyl group and reduce the double 
bond followed by N-alkylation. Then, reductive opening of the maleimide ring and subsequent 
Mitsunobu reaction should give the final α-helix mimetic 54. The prospects for achieving this 
OMe
N
H
N
OMe
OMe
N
MeOH
63 66
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hopefully in the near future are evaluated in the conclusions and future work sections of this 
thesis. 
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3. Conclusions 
3.1 Synthesis and Testing of Potential Benzimidazole-based 
LRH-1 Antagonists 
 
The first aim of this project was to find a new antagonist or inverse agonist of LRH-1 as a lead 
towards a potential breast cancer treatment. Starting from a lead found by Andrew Bayly, [62] 
three series of analogues have been synthesised and tested for their binding to the LRH-1 
LBD. The first series comprised benzimidazole thioether analogues with different benzyl 
substitution patters. The synthesis work went smoothly and the products could be obtained in 
acceptable yields.  
For the second series, the substitution pattern was kept the same, but the sulfur atom was 
exchanged for an oxygen atom. The synthesis proved difficult and a novel route for the 
synthesis of this series had to be found, which finally led to the synthesis of the desired 
benzimidazole ether analogues. 
In the third series a substituted aryl group was introduced into the benzimidazole structure. By 
developing a new route towards these analogues the synthesis of this series could be 
successfully accomplished.  
After the completion of the synthesis the prepared analogues were tested for their binding 
properties to the LRH-1 LBD. The assay used was an AlphaScreen® proximity assay. To 
address the testing for both agonists and antagonists the assay was run at two different 
concentrations. The testing results show a significant variance in the readout which makes it 
impossible do draw firm conclusions. Nevertheless, a few compounds could be identified 
which appeared to display weak agonistic properties. These compounds need to be 
submitted for further evaluation to confirm their status as interesting new leads.  
 
3.2 Synthesis of a α-Helix Mimetic as Potential Co-Activator 
Binding Inhibitor 	  
The second aim of the research presented in this thesis was the synthesis of an α-helix 
mimetic as a potential co-activator binding inhibitor for LRH-1.  
Andrew Bayly (Spivey group 2007-2011) had already outlined a route for a synthesis of the α-
helix mimetic. [62] 
The first task of this project was therefore to synthesise a large quantity of the substituted N-
phenyl maleimide 47 following the route established by Andew Bayly. [62] The synthesis went 
smoothly and the maleimide 47 could be obtained in good yield. 
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The second task was the synthesis of a 3-stannylated 1,6-dihydropyridine 49, which was then 
to be combined with the substituted N-phenyl maleimide 47, to give the scaffold of the α-helix 
mimetic. This synthesis proved difficult and a new route for the preparation of the desired 1,6-
dihydropyridine based on the synthesis of a 1,6-dihydropyridine by Maranzano et al. [120] was 
established. Although this route does not provide access to the target α-helix mimetic, it gives 
a firm foundation for future work to hopefully achieve this synthetic goal in the near future 
(scheme 3.1).  
 
	  
Scheme 3.1: Summary of progress so far towards the synthesis of α-helix mimetic 54. 
 
In conclusion, during this work two different approaches towards modulating the activity of 
LRH-1 have been targeted. In the first approach, the synthesis of a conventional antagonist, 
which was designed to bind to the ligand binding pocket was attempted and some promising 
compounds were identified. In the second approach, an α-helix mimetic designed to bind to 
the AF-2 binding site and prevent co-activator binding was investigated. Although the 
synthetic route was not completed, progress was made towards that end. 
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4. Future Work 
4.1 Further Development of Benzimidazole-based LRH-1 
Modulators 
 
After the completion of the synthesis of the series of benzimidazole analogues and their 
evaluation as potential agonists or antagonists, it appears that compounds MeM-028B, MeM-
028D and MeM-185Cl increase the binding of co-activator PGC-1α to LRH-1. These 
compounds should therefore be subjected to further testing to confirm their binding activity to 
LRH-1. As the results from the testing are inconclusive, it is necessary to further improve the 
assay conditions to obtain reproducible and reliable data. The controls used for the testing 
seem unsuitable, as the results for these compounds could not be reproduced consistently 
throughout the experiments. Whitby’s compound 5a is a LRH-1 agonist [54] and was used as a 
control during the testing. The assay results obtained for compound 5a do not reflect this 
ability. Similarly, the Scripps compound, [107] a known LRH-1 antagonist, appears to have no 
effect on the binding of LRH-1 to the co-factor peptides used in our assay. Therefore, part of 
the ongoing assay optimisation has to be to find more suitable controls. With the optimised 
conditions in place, the mentioned compounds MeM-028B, MeM-028D and MeM-185Cl can 
be tested again to verify the data. Additionally, a complimentary assay based on activity 
rather than binding should be established to exclude false hits. 
 
To find a compound with antagonistic rather than agonistic properties another series could be 
synthesised with substituents protruding towards the helix 12 (purple) of the LRH-1 LBD 
(figure 4.1).  
 
	  
Figure 4.1: Left: image of the crystal structure of Whitbys compound 5a bound into the entrance of the ligand 
binding pocket of the LBD of LRH-1 (PDB: 3PLZ). Right: overlay of the structures of Whitby’s compound 5l and 
AB_WC057. [54,55,62] 
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Assuming that compound AB_WC057 binds in an analogus fashion to that revealed in the 
crystal structure of Whitby’s compound 5a bound to the LBD of LRH-1, in order for a 
substituent to point towards helix 12 (purple), it will need to be situated at the benzyl ring of 
the benzyl thioether. To test this possibility several alkyl substituted benzyl thioethers with 
different chain topologies will need to be prepared (scheme 4.1).  
 
	  
Scheme 4.1: Proposed synthesis of alkyl-substituted benzimidazole thioethers 67. 
 
Additionally, it would be interesting to evaluate a naphthyl group and other fused aromatic 
ring systems in place of the benzyl ring (scheme 4.2).  
 
	  
Scheme 4.2: Proposed synthesis of naphthyl benzimidazole 68. 
 
These syntheses could be carried out as described previously: it should be possible to 
alkylate the 2-mercapto function of benzimidazole 11 under basic conditions using substituted 
benzyl halides for example 2-(bromomethyl)naphthalene in combination with sodium 
methoxide in DMF. These lipophilic and bulky groups would be anticipated to point towards 
helix 12, once bound to LRH-1 and could displace it, resulting in an inability to allow co-
activator binding.  
 
As the ether series generally appeared to perform better in the binding assay than the 
thioether series, it will be interesting to change the ether linkage to an amine linkage. 
Synthetically, the same route as for the ether analogues could probably be employed 
(scheme 4.3). 
 
	  
Scheme 4.3: Proposed synthesis of amino benzimidazoles 70. 
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Starting from the SEM-protected 2-chlorobenzimidazole 29, the secondary amine could 
probably be formed using benzyl amine. The resulting benzimidazole benzyl amine 69 should 
be deprotected with TBAF in THF.  
These proposed compounds should then be tested for their binding using the AlphaScreen®, 
to obtain an indication of their binding to the LRH-1 LBD and the most promising derivatives 
also be tested in an activity assay. Clearly however, the aforementioned optimisation of the 
AlphaScreen® assay needs to be completed before this can be accomplished.  
 
4.2 Synthesis of the α-Helix Mimetic 
 
Notwithstanding the results obtained in the abovementioned work towards benzimidazole 
based LRH-1 antagonists, a potentially complimentary approach to prevent the transcriptional 
activity of LRH-1 is by targeting the AF-2 site. This was addressed by the synthesis work 
carried out towards the α-helix mimetic 54.  
However, further optimisation of the key Diels-Alder reaction is required. Prior to this, it will be 
necessary to optimise the reaction conditions for the preparation of the 1,6-dihydropyridine 66 
and in particular the formation of the p-methoxy tetrahydropyridine 63, which currently gives 
the product in poor yield (scheme 4.4). 
 
	  
Scheme 4.4: Formation of p-methoxy tetrahydropyridine 63. 
 
After the optimisation of the Diels-Alder reaction, the next step will be the deprotection of the 
N-benzyl group and hydrogenation of the double bond. These two transformations will 
hopefully be carried out in one step using standard hydrogenolysis conditions (scheme 4.5).  
 
N O
OMe
N
a
(a): i: TFAA, CH2Cl2, 0 ºC, 1 h; ii: NaOMe, CH2Cl2/MeOH, RT, 1.5 h (14%).
62 63
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Scheme 4.5: Proposed synthesis of the final α-helix mimetic 54. 
 
These reactions are followed by the alkylation of the just deprotected nitrogen, which can be 
anticipated to successfully be carried out with 1-bromo-3-methyl propane. After the alkylation, 
the former maleimide ring is to be subjected to a reductive ring opening using sodium 
borohydride at elevated temperature. The resulting primary alcohol needs to be converted to 
the aryl ether, which mimics the i+2 tyrosine residue (figure 2.26). There are several 
possibilities to carry out this reaction. The most straight-forward method will involve a 
Mitsunobu reaction with a phenol. A fallback route will be to convert the hydroxy group to a 
better leaving group such as tosylate or mesylate and carry out a nucleophilic substitution 
reaction. 
 
Once the synthetic route for the α-helix mimetic has been established, a series of analogues 
with varying substituents will be prepared and tested for their efficacy to prevent co-activator 
binding.  
 
It is envisioned that this testing should be possible using the same AlphaScreen® method as 
used for the benzimidazole derivatives mentioned above, once optimised. Development 
beyond this will strongly depend on the results of these studies, but will undoubtedly reflect 
the fact that α-helix mimetics hold the prospect of being deployed for the disruption of 
numerous protein-protein interactions of crucial importance in a plethora of therapeutically 
important signal transduction cascades. In this context it is important to note that the majority 
of protein-protein interactions are mediated by α-helices. [122] 
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5. Experimental 
 
General Directions 
All reactions were performed under anhydrous conditions, in oven-dried or flame-dried 
glassware and under a nitrogen atmosphere. Anhydrous Solvents: MeCN, toluene, Et2O, 
CH2Cl2 and THF were used directly after passage through Al2O3 columns in a Grubb dry- 
solvent system (Innovative Technology Inc.). Solvents were degassed using a freeze-pump-
thaw cycle. Reagents: were purchased from commercial suppliers and handled according to 
COSHH regulations. Chromatography: column chromatography was performed on silica gel  
(Merck Kieselgel 60 F254 230-400 mesh) or basic alumina following the method of W. C. Still. 
[123] Thin Layer Chromatography (TLC) was carried out on Merck aluminium-backed plates 
pre- coated with silica (0.2 mm, 60 F254). The plates were visualised either by quenching of 
ultraviolet fluorescence (λmax = 254 nm) or by charring with KMnO4, phosphomolybdic acid, 
vanillin or ninhydrin TLC dip. Melting points: were determined on a Reichardt hot stage 
apparatus. Infra red spectra: were recorded neat on Perkin-Elmer Paragon 1000 Fourier 
transform spectrometer. Only selected absorbances (νmax) are reported. 1H-NMR spectra: 
were recorded at 400 MHz on a Bruker AV 400 spectrometer. Chemical shifts (δH) are given 
in parts per million (ppm) and are referenced to the residual solvent peak of CDCl3, DMSO-d6 
or MeOD-d4. Coupling constants (J) are reported in Hz and to the nearest 2 significant 
figures. 13C-NMR spectra: were recorded at 100 MHz on a Bruker 400 AV spectrometer. 
Chemical shifts (δC) are given in ppm and referenced to the residual solvent peaks of CDCl3, 
DMSO-d6 or MeOD-d4. Mass spectra: low resolution mass spectra (m/z) and high resolution 
mass spectra were recorded on either a VG platform II or VG AutoSpec spectrometers, using 
electron ionization (EI) or chemical ionization (CI). High Resolution Mass Spectrometry 
measurements are valid to ± 5ppm. 
Note on Regional Assignments 
Throughout this thesis benzimidazoles having a substituent in the “benzo” ring are designated 
as being 6-substituted, when in fact they are a ~1:1 mixture of 5-and 6-substituted isomers 
(for the N-substituted case) or a single undetermined isomer (for the N-H case) 
 
General Procedure A [84] 
The diamine was dissolved in a 10:1 mixture of EtOH and H2O. NaOH was added and the 
reaction stirred for 5 min. CS2 was added and the reaction heated to 70 °C for 3.5 h. After that 
time activated charcoal was added and the reaction mixture heated to reflux for another 15 
min. The reaction mixture was cooled to RT and filtered. The filtrate was acidified with acetic 
acid (50%) and the precipitate was filtered and washed with H2O to give the pure product.  
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2-Mercapto-6-methylbenzimidazole 11 [84] 
 
The reaction was carried out as described in the general procedure A, with 3,4-
diaminotoluene (0.51 g, 4.15 mmol, 1.0 eq.), CS2 (0.25 mL, 4.09 mmol, 1.0 eq.), and NaOH 
(0.18 g, 4.37 mmol, 1.0 eq.) in H2O (3 mL) and EtOH (30 mL) to give the 2-
mercaptobenzimidazole 11 as a gray powder (389 mg, 58%). Rf :0.1 (1% MeOH/CH2Cl2); mp: 
193-200 ºC; ν/cm-1 (neat) 3122, 2580, 1574, 1495, 1329, 798, 718, 665; δH (DMSO-d6, 400 
MHz) 2.32 (3H, s, CH3), 6.83-6.98 (2H, m, H-5 and H-7), 7.01 (1H, dd, J 7.9 and 3.3 Hz, H-4), 
12.45 (2H, br s, SH and NH); δC (DMSO-d6, 100 MHz) 20.9, 109.4, 110.1, 123.2, 130.3, 
131.6, 132.5, 167.8; MS (ES+) m/z 165 (M+H+, 34%), M+CH3COOH+, 27%); HRMS (ES+) 
165.0486 calculated for C8H9N2S+ (M+H+) found 165.0476, Δ= -6.1 ppm. 	  
2-Mercaptobenzimidazole 4 [84] 
 
The synthesis was carried out using the general procedure A, with phenylenediamine (2.00 g, 
18.49 mmol, 1.0 eq.), CS2 (1.10 mL 18.49 mmol, 1.0 eq.) NaOH (0.78 g, 19.50 mmol, 1.05 
eq.) in H2O (3 mL) and EtOH (30 mL) to give the 2-mercaptobenzimidazole 4 as a light brown 
powder (1.42 g, 9.45 mmol, 51%). Rf: 0.1 (1% MeOH/CH2Cl2); mp: 200-205 ºC; ν/cm-1 (neat) 
3110, 2572, 1667, 1510, 1464, 1356, 1177, 740, 702, 658; δH (DMSO-d6, 400 MHz) 7.17-7.07 
(4H, m, Ar-H), 12.53 (2H, s, NH, SH); δC (DMSO-d6, 100 MHz) 109.5, 122.3, 132.2, 168.1; 
MS (ES+) m/z 151 (M+H+, 35%), 300 (M+M+, 14%); HRMS (ES+) 151.0330 calculated for 
C7H7N2S+ (M+H+) found 151.0341, Δ= +7.3 ppm. 
 
6-tert-Butyl-2-mercaptobenzimidazole 9a 
 
The synthesis was carried out as described in the general procedure A using 4-(tert-butyl)-
1,2-diaminobenzene (1.00 g, 6.09 mmol, 1.0 eq.), CS2 (1.00 ml, 16.92 mmol, 2.8 eq.) and 
NaOH (0.25 g, 6.25 mmol, 1.0 eq.) in H2O (1.5 mL) and EtOH (15 mL) to give the substituted 
2-mercaptobenzimidazole 9a as a light brown powder (1.13 g, 5.48 mmol, 89%). Rf: 0.2 (1% 
MeOH/CH2Cl2); mp: 216-219 ºC; ν/cm-1 (neat) 3076, 2958, 1488, 1324, 1243, 1191, 856, 808, 
753, 710; δH (DMSO-d6, 400 MHz) 1.27 (9H, s, C(CH3)3), 7.10-7.03 (2H, m, H-5 and H-7), 
7.18 (1H, dd, J 8.4, 1.7 Hz, H-4), 12.42 (2H, br s, SH and NH); δC (DMSO-d6, 100 MHz) 31.5, 
34.5, 105.9, 109.0, 119.8, 130.1, 132.3, 145.3, 167.9; MS (ES+) m/z 207(M+H+, 100%); 
HRMS (ES+) 207.0956 calculated for C11H15N2S+ (M+H+) found 207.0957, Δ= +0.5 ppm. 
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6-Bromo-2-mercaptobenzimidazole 9b 
 
The synthesis was carried out as described in the general procedure A using 4-bromo-1,2-
benzenediamine (2.00 g, 10.7 mmol, 1.0 eq.) CS2 (0.64 mL, 10.7 mmol, 1.0 eq.) and NaOH 
(0.50 g, 12.5 mmol, 1.1 eq.) in H2O (3 mL) and EtOH (30 mL) to give the 6-bromo-
2mercaptobenzimidazole 9b as a brown powder (1.05 g, 4.58 mmol, 43%). Rf: 0.2 (1% 
MeOH/CH2Cl2); mp: 205-210 ºC; ν/cm-1 (neat) 3109, 1577, 1521, 1477, 1373, 1055, 912, 845, 
796; δH (DMSO-d6, 400 MHz) 7.08 (1H, d, J 8.9 Hz, H-5), 7.32-7.22 (2H, m, H-4, H-7); δC 
(DMSO-d6, 100 MHz) 111.0, 111.9, 114.3, 124.9, 131.7, 133.8, 169.1; MS (ES+) m/z 228/230 
(M+H+, 100%), 246 (M+NH4+, 50%); HRMS (ES+) 228.9435 calculated for C7H6N2S79Br+ 
(M+H+) found 228.9437, Δ= +0.9 ppm 
 
General Procedure B [84] 
The 2-mercaptobenzimidazole was dissolved in dry DMF. A solution of NaOMe in MeOH was 
added. The reaction mixture was stirred at RT for 30 min. Then the desired benzyl bromide 
was added to the reaction mixture, which was stirred at RT for another 16 h. After that time 
H2O was added and the mixture extracted with CH2Cl2. The organic layer was dried over 
Na2SO4 and the solvent removed in vacuo. The crude product was purified by column 
chromatography to afford the desired product. 
 
2-{[(2-Methylphenyl)methyl]sulfanyl}-1H-benzimidazole 10 
 
The reaction was carried out as described in the general procedure B, using 2-
mercaptobenzimidazole 4 (800 mg, 5.32 mmol, 1.0 eq.), NaOMe (0.34 g, 6.38 mmol, 1.2 eq. 
in 2 mL MeOH), and 2-methylbenzyl bromide (0.71 mL, 5.32 mmol, 1.0 eq.) in DMF (6 mL). 
The crude product was purified by flash column chromatography (CH2Cl2) to give the 
benzimidazole thioether 9 as white crystals (0.72 g, 2.83 mmol, 53%). Rf: 0.7 (10% 
MeOH/CH2Cl2); mp: 148-150 ºC; ν/cm-1 (neat) 3045, 2961, 2869, 2803, 1436, 1400, 1350, 
1269, 1229, 982, 740; δH (CDCl3, 400 MHz) 2.48, (3H, s, CH3), 4.66, (2H, PhCH2), 7.19 (1H, 
td, J 7.0, 2.2 Hz, Ar-H), 7.29-7.23 (2H, m, Ar-H), 7.30-7.32 (2H, m, Ar-H), 7.47-7.35, m, Ar-H), 
7.81 (1H, br s, Ar-H), 10.00 (1H, s, NH); δC (CDCl3, 100 MHz) 19.3, 35.7, 122.6, 126.4, 128.2, 
130.2, 130.7, 134.30, 137.2, 150.1; MS (ES+) m/z 255 (M+H+, 100%); HRSM (ES+) 255.0956 
calculated for C15H14N2S+ (M+H+) found 255.0955, Δ= -0.4 ppm. 
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6-tert-Butyl-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 10a 
	  
The reaction was carried out as described in the general procedure B, with 2-
mercaptobenzimidazole 9a (600 mg, 2.91 mmol, 1.0 eq.), NaOMe (188 mg, 3.49 mmol, 1.2 
eq. in 2 mL MeOH), 2-methylbenzyl bromide (427 µL, 3.20 mmol, 1.1 eq.) in DMF (3.3 mL). 
After purification by column chromatography (CH2CH2) the benzimidazole thioether 10a was 
obtained as a white crystalline solid (600 mg, 1.93 mmol, 66%) of the Rf: 0.4 (2% 
MeOH/CH2Cl2); mp: 108-111 °C; ν/cm-1 (neat) 3031, 2957, 2801, 1629, 1390, 1280, 1233, 
986, 811, 731, 652; δH (CDCl3, 400 MHz) 1.46 (9H, s, C(CH3)3), 2.48 (3H, s, CH3), 4.65 (2H, 
s, PhCH2), 7.20 (1H, td, J 6.9 and 2.4 Hz, Ar-H), 7.25-7.30 (2H, m, Ar-H), 7.34-7.43 (2H, m. 
Ar-H), 7.60 (1H, br s, Ar-H), 9.68 (1H, br s, NH); δC (CDCl3, 100 MHz) 19.3, 31.9, 34.9, 35.8, 
120.5, 126.4, 128.2, 130.2, 130.7, 134.4, 137.2, 146.1, 149.7; MS (ES+) m/z 311 (M+H+, 
100%); HRMS (ES) 311.1582 calculated for C19H23N2S+ (M+H+) found 311.1568, Δ= -4.5 
ppm. 	  
6-Bromo-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 10b 
 
The synthesis was conducted in accordance with the general procedure B, utilising 6-bromo-
2-mercaptobenzimidazole 9b (800 g, 3.49 mmol, 1.0 eq.), NaOMe (249 mg, 4.54 mmol, 1.3 
eq. in 1.60 mL MeOH) and 2-methylbenzyl bromide (0.51 mL, 3.84 mmol, 1.1 eq.) in DMF (4 
mL). After purification by column chromatography (CH2Cl2) the pure benzimidazole thioether 
10b was obtained as a white solid. (0.34 g, 1.03 mmol, 30%); Rf: 0.3 (CH2Cl2); mp: 165-166 
°C; ν/cm-1 (neat) 3021, 2927, 2813, 2675, 1387, 1331, 1268, 1225, 1048, 984, 909, 800, 730; 
δH (CDCl3, 400 MHz) 2.42 (3H, s, CH3), 4.57 (2H, s, PhCH2), 7.14 (1H, td, J 7.1 and 2.3 Hz, 
Ar-H), 7.17-7.26 (2H, m, Ar-H), 7.28-7.45 (3H, m, Ar-H), 7.68 (1H, br s, Ar-H); δC (CDCl3, 100 
MHz) 19.4, 35.7, 115.7, 125.7, 126.5, 128.4, 130.2, 130.8, 134.1, 137.2, 151.3; MS (ES+) m/z 
333/335 (M+H+, 90%); HRMS (ES) 333.0061 calculated for C15H14N2S79Br+ (M+H+) found 
333.0071, Δ= +3.0 ppm. 	  
6-Methyl-2-{[phenylmethyl]sulfanyl}-1H-benzimidazole 12 
	  
The compounds was synthesised as described in the general procedure B, using 2-mercapto-
6-methylbenzimidazole 11 (150 mg, 0.91 mmol, 1.0 eq.), NaOMe (66 mg, 1.18 mmol, 1.3 eq. 
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in 0.5 mL MeOH), benzyl bromide (0.13 mL, 1.00 mmol, 1.1 eq.) in DMF (1.5 mL). Purification 
by column chromatography (CH2Cl2) afforded the benzimidazole thioether 12 as white 
crystals (99.1 mg, 0.39 mmol, 43%). Rf: 0.1 (CH2Cl2); mp: 138-143 ºC; ν/cm-1 (neat) 3029, 
2924, 2860, 2797, 2624, 1494, 1438, 1394, 1338, 1275, 1228, 987, 802, 700; δH (CDCl3, 400 
MHz) 2.45 (3H, s, CH3), 4.51 (2H, s, PhCH2), 7.04 (1H, dd, J 8.4 and 1.5 Hz, H-7), 7.32-7.21 
(4H, m, Ar-H), 7.38-7.32 (2H, m, Ar-H), 7.42 (1H, d, H-4); δC (CDCl3, 100 MHz) 21.8, 37.6, 
123.9, 127.8, 128.8, 129.1, 132.5, 136.9, 149.2; MS (ES+) m/z 255 (M+H+, 100%), HRMS 
(ES+) 255.0956 calculated for C15H15N2S+ (M+H+) found 255.0947, Δ= -3.5 ppm. 
 
6-Methyl-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 12a 
 
The reaction was carried out as described in the general procedure B, with 2-mercapto-6-
methylbenzimidazole 11 (600 mg, 3.65 mmol, 1.0 eq.), NaOMe (0.26 g, 4.8 mmol, 1.3 eq. in 2 
mL MeOH) and the 2-methylbenzyl bromide (0.49 mL, 3.65 mmol, 1.0 eq.) in DMF (6 mL). 
The crude product was purified by column chromatography (10:1 PE/EtOAc) to give the 
benzimidazole thioether 12a as a white solid (86.6 mg, 0.32 mmol, 53%). Rf: 0.2 (PE/EtOAc 
10:3); mp: 117-123 ºC; ν/cm-1 (neat) 3027, 2921, 2863, 2794, 2618, 1392, 1275, 987, 801, 
729; δH (CDCl3, 400 MHz) 2.40 (3H, s, CH3), 2.48 (3H, s, CH3), 4.56 (2H, s, PhCH2), 7.06 
(1H, dd, J 8.3 and 1.6 Hz, Ar-H), 7.11 (1H, td, J 7.0, 2.3 Hz, Ar-H), 7.23-7.15 (2H, m, Ar-H), 
7.28-7.31 (2H, m, Ar-H), 7.45 (1H, br s, Ar-H); δC (CDCl3, 100 MHz) 19.3, 21.8, 35.9, 123.9, 
126.4, 128.2, 130.1, 130.7, 132.4, 134.5, 137.1, 149.4; MS (ES+) m/z 269 (M+H+, 100%); 
HRSM (ES+) 269.1112 calculated for C16H17N2S+ (M+H+) found 269.1110, Δ= -0.7 ppm. 
 
6-Methyl-2-{[(4-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 12b 
 
The synthesis was carried out as described in the general procedure B, using 2-
mercaptobenzimidazole 11 (100 mg, 0.609 mmol, 1 eq.), NaOMe (40.0 mg, 0.73 mmol, 1.2 
eq.) and α-bromo-p-xylene (135.0 mg, 0.73 mmol, 1.2 eq.) in DMF (2 mL) and MeOH (0.3 
mL). Purification by column chromatography afforded the pure benzimidazole thioether 12b 
as a white crystalline solid (64.4 mg, 0.24 mmol, 39%). Rf: 0.4 (2% MeOH/CH2Cl2); mp: 146-
150 °C; ν/cm-1 (neat) 3022, 2922, 2856, 1513, 1394, 1339, 1275, 1229, 980, 801, 729; δH 
(CDCl3, 400 MHz) 2.33 (3H, s, CH3), 2.47 (3H, s, CH3), 4.52 (2H, s, PhCH2), 7.07 (1H, d, J 
8.3 Hz, Ar-H), 7.11 (2H, d, J 7.8 Hz, Ar-H), 7.24-7.28 (2H, m, Ar-H), 7.32 (1H, br s, Ar-H), 
7.44 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 100 MHz) 21.3, 21.8, 37.5, 124.1, 128.9, 129.6, 
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132.6, 133.8, 137.6, 149.2; MS (ES+) m/z 269 (M+H+, 100%); HRMS (ES+) 269.1112 
calculated for C16H17N2S+ (M+H+) found 289.1114, Δ= +0.7 ppm. 
 
6-Methyl-2-{[(2-chlorophenyl)methyl]sulfanyl}-1H-benzimidazole 12c 
 
The synthesis was conducted according the general procedure B, using 2-
mercaptobenzimidazole 11 (100 mg, 0.61 mmol, 1.0 eq.), NaOMe (40 mg, 0.76 mmol, 1.3 eq. 
in 0.3 mL MeOH), 2-chlorobenzyl bromide (106 µL, 0.73 mmol, 1.2 eq.), in DMF (2 mL). The 
crude product was purified by column chromatography to afford the benzimidazole thioether 
12c as a white solid (49.2 mg, 0.17 mmol, 28%). Rf: 0.5 (2% MeOH/CH2Cl2); mp: 108-111 °C; 
ν/cm-1 (neat) 3056, 2921, 2792, 2629, 1443, 1392, 1337, 1276, 1229, 1055, 987, 803, 758, 
734, 670; δH (CDCl3, 400 MHz) 2.44 (3H, s, CH3), 4.59 (2H, s, PhCH2), 7.03 (1, d, J 8.5 Hz, 
Ar-H), 7.07 (1H, td, J, 7.46 and 1.4 Hz, Ar-H), 7.13 (1H, td, J 7.7 and 1.8 Hz, Ar-H), 7.29-7.31 
(2H, m, Ar-H), 7.36 (1H, dd, J 7.6 and 1.8 Hz, Ar-H), 7.42 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 
100 MHz) 21.8, 35.4, 124.3, 127.2, 129.3, 129.8, 131.2, 132.8, 134.9, 143.6; MS (ES+) m/z 
289/291 (M+H+, 100%); HRMS (ES+) 289.0566 calculated for C15H14N2S35Cl+ (M+H+) found 
289.0574, Δ= +2.8 ppm. 
 
6-Methyl-2-{[(3-chlorophenyl)methyl]sulfanyl}-1H-benzimidazole 12d 
 
The synthesis was conducted according the general procedure B, using 2-
mercaptobenzimidazole 11 (100 mg, 0.61 mmol, 1.0 eq.), NaOMe (40 mg, 0.77 mmol, 1.3 eq. 
in 0.3 mL MeOH), 3-chlorobenzyl bromide (106 µL, 0.73 mmol, 1.2 eq.), in DMF (2 mL). The 
crude product was purified by column chromatography to afford the benzimidazole thioether 
12d as a white solid (73.9 mg, 0.26 mmol, 42%). Rf: 0.5 (2% MeOH/CH2Cl2); mp: 132-136 °C; 
ν/cm-1 (neat) 3053, 2924, 2858, 1597, 1576, 1432, 1391, 1336, 1272, 1226, 804, 732, 690; δH 
(CDCl3, 400 MHz) 2.44 (3H, s, CH3), 4.48 (2H, s, PhCH2), 7.05 (1H, dd, J 8.1 and 1.5, Ar-H), 
7.11-7.25 (3H, m, Ar-H), 7.29 (1H, t, J 1.8 Hz, Ar-H), 7.42 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 
100 MHz) 21.8, 36.9, 124.2, 127.2, 127.9, 129.1, 130.0, 132.8, 134.5, 139.0, 148.5; MS (ES+) 
m/z 289/291 (M+H+, 100%); HRMS (ES+) 289.0566 calculated for C15H14N2S35Cl+ (M+H+) 
found 289.0571, Δ= +1.7 ppm. 
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6-Methyl-2-{[(4-chlorophenyl)methyl]sulfanyl}-1H-benzimidazole 12e 
 
The synthesis was conducted according the general procedure B, using 2-
mercaptobenzimidazole 11 (100 mg, 0.61 mmol, 1.0 eq.), NaOMe (41 mg, 0.77 mmol, 1.3 eq. 
in 0.3 mL MeOH), 4-chlorobenzyl bromide (106 µL, 0.73 mmol, 1.2 eq.), in DMF (2 mL). The 
crude product was purified by column chromatography to afford the benzimidazole thioether 
12e as a white solid (47.5 mg, 0.16 mmol, 27%). Rf: 0.4 (2% MeOH/CH2Cl2) mp: 168-172 °C; 
ν/cm-1 (neat) 2786, 2719, 2606, 1490, 1394, 1277, 1226, 1088, 1013, 991, 829, 805, 722, 
676; δH (CDCl3, 400 MHz) 2.44 (3H, s, CH3), 4.49 (2H, s, PhCH2), 7.00-7.13 (1H, m, Ar-H), 
7.21 (2H, d, J 8.5 Hz, Ar-H), 7.26-7.30 (3H, m, Ar-H), 7.42 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 
100 MHz) 21.8, 36.9, 124.5, 128.9, 130.4, 133.1, 133.7, 135.5, 148.4; MS (ES+) m/z 289/291 
(M+H+, 100%); HRMS (ES+) 289.0566 calculated for C15H14N2S35Cl+ (M+H+) found 289.0577, 
Δ= +3.8 ppm. 
 
6-Methyl-2-{[(3,4-dichlorophenyl)methyl]sulfanyl}-1H-benzimidazole 12f 
	  
The synthesis was conducted according the general procedure B, using 2-
mercaptobenzimidazole 11 (100 mg, 0.61 mmol, 1.0 eq.), NaOMe (41 mg, 0.77 mmol, 1.3 eq. 
in 0.3 mL MeOH), 3,4-dichlorobenzyl bromide (106 µL, 0.73 mmol, 1.2 eq.), in DMF (2 mL). 
The crude product was purified by column chromatography to afford the benzimidazole 
thioether 12f as a white solid (147.63 mg, 0.46 mmol, 75%). Rf:0.5 (2% MeOH/CH2Cl2); mp: 
101-104 °C; ν/cm-1 (neat) 2923, 2859, 2794, 1470, 1394, 1338, 1274, 1132, 1031, 986, 904, 
802, 726; δH (CDCl3, 400 MHz) 2.44 (3H, s, CH3), 4.44 (2H, s, PhCH2), 7.05 (1H, dd, J 8.2 
and 1.5 Hz, Ar-H), 7.15 (1H, dd, J 8.2 and 2.1 Hz, Ar-H), 7.22-7.32 (2H, m, Ar-H), 7.37-7.48 
(2H, m Ar-H); δC (CDCl3, 100 MHz) 21.8, 36.2, 124.3, 128.4, 130.7, 130.9, 131.9, 132.7, 
132.9, 137.4, 148.1; MS (ES+) m/z 323/325/327 (M+H+, 100%); HRMS (ES+) 232.0177 
calculated for C15H13N2S35Cl2+ (M+H+) found 232.0181, Δ= +1.2 ppm. 	  
N-Phenyl benzimidazole 13 
 
The reaction was carried out following a modified procedure by Buchwald et al. [88] 
Benzimidazole 12a (50 mg, 0.19 mmol, 1.0 eq.) was dissolved in DMF (0.4 mL) in a 
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microwave tube. Iodobenzene (42 µL, 0.38 mmol, 2.0 eq.), phenathroline (67 mg, 0.38 mmol, 
2.0 eq.), CuI (36 mg, 0.29 mmol, 1.0 eq.) and Cs2CO3 (121 mg, 0.38 mmol, 2.0 eq.) were 
added, the lid was closed and the gas was exchanged to nitrogen. The vial was heated to 110 
°C for 16 h. After that, the reaction mixture was cooled to RT and water added. The mixture 
was extracted with CH2Cl2. The crude product was purified by column chromatography to 
afford the N-phenyl benzimidazole 13 as a yellow solid (17 mg, 0.05 mmol, 25%). Rf: 0.5 (2% 
MeOH/CH2Cl2); mp: 186-191 °C; ν/cm-1 (neat) 2921, 1596, 1498, 1433, 1363, 1293, 1217, 
798, 760, 732, 696; δH (CDCl3, 400 MHz) 2.38 (3H, s, CH3, 2.49 (3H, s, CH3), 4.62 (2H, d, J 
4.8 Hz, PhCH2), 7.02 (1H, s br, Ar-H), 7.11 (2H, ddd, J 10.0, 5.3 and 2.0 Hz, Ar-H), 7.13-7.16 
(1H, m, Ar-H), 7.30-7.39 (3H, m, Ar-H), 7.48-7.54 (3H, m, Ar-H), 7.58 (1H, s, Ar-H); δD 
(CDCl3, 100 MHz) 19.3, 21.7, 35.5, 109.2, 109.6, 110.1, 118.2, 124.0, 126.4, 127.1, 128.2, 
129.0, 129.9, 130.4, 130.7, 137.4; MS (ES+) m/z 345 (M+H+, 100%); HRMS (ES+) 345.1425 
calculated for C22H21N2S+ (M+H+) found 345.140, Δ= 1.4 ppm. 
 
2-Hydroxy-6-methylbenzimidazole 17 
 
The reaction was carried out in analogy to a procedure by Dannhardt et al. [91] 3,4-
Diaminotoluene (200 mg, 1.64 mmol, 1.0 eq.) was dissolved in THF (5 mL) the reaction 
mixture was cooled to 0 °C prior the addition of carbonyldiimidazole (384 mg, 2.37 mmol, 1.4 
eq.). The reaction was stirred at RT for 16 h. The precipitated product was filtered and 
washed with THF to afford the pure 2-hydroxybenzimidazole 17 as a white solid (128 mg, 
0.86 mmol, 53%). Rf: 0.2 (4% MeOH/CH2Cl2); mp: 213-217 °C; ν/cm-1 (neat) 2999, 1722, 
1672, 1637, 1612, 1506, 1477, 1374, 1279, 1210, 1026, 885, 848, 786, 766, 748; δH (DMSO-
d6, 400 MHz) 2.26 (3H, s, CH3), 6.72 (2H, d, J 7.7 Hz, Ar-H), 6.78 (1H, d, J 7.8 Hz, Ar-H), 
10.45 (1H, s, NH), 10.48 (1H, s, OH); δC (DMSO-d6, 100 MHz) 21.1, 108.2, 109.0, 120.9, 
127.4, 129.4, 129.8, 155.4; No mass spectrum could be obtained. 
 
2-Chloro-6-methylbenzimidazole 21 
 
The reaction was carried out in analogy to the procedure described by Blythin et al. [92] 2-
Hydroxy-6-methylbenzimidazole 17 (1.05 g, 7.10 mmol, 1.0 eq.) was added to phosphorous 
oxychloride (5.00 mL, 53.6 mmol, 7.6 eq.) the neat reaction mixture was heated to 100 °C for 
4.5 h. The reaction mixture was carefully poured onto ice and the remaining phosphorous 
oxychloride neutralised with NaOH solution. The pH was adjusted to 9 when a white 
precipitate formed. The precipitate was filtered and washed with CH2Cl2 to get the product. 
Purification by column chromatography (dry loaded, 4% MeOH/CH2Cl2) afforded the 2-
chlorobenzimidazole 21 as a white solid (38 mg, 2.27 mmol, 32%) Rf: 0.2 (4% MeOH/CH2Cl2); 
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ν/cm-1 (neat) 2872, 2806, 2179, 2028, 1960, 1441, 1344, 1296, 1229, 988, 800; δH (DMSO-d6, 
400 MHz) 2.39 (3H, s, CH3), 7.03 (1H, dd, J 8.5, 1.6 Hz, Ar-H), 7.20-7.60 (2H, m, Ar-H), 
137.07 (1H, s br, OH); (DMSO-d6, 100 MHz) 21.2, 123.8, 131.8, 137.9; m/z 167/169 (M+H, 
100%); HRMS (ES+) 167.0376 calculated for C8H8N235Cl+ (M+H+), found 167.0369, Δ= -4.2 
ppm. 
 
N-Boc-2-chloro-6-methylbenzimidazole 22  
 
2-Chloro-6-methylbenzimidazole 21 (10 mg, 0.06 mmol, 1.0 eq.) was dissolved in dry MeCN 
(0.5 mL). DMAP (0.7 mg, 0.006 mmol, 0.1 eq.) and Et3N (10 µL, 0.075 mmol, 1.25 eq.) were 
added to the reaction mixture, which was stirred at RT for 17 h. Purification by column 
chromatography afforded the N-boc protected 2-chlorobenzimidazole 22 as a greenish 
powder (10 mg, 0.04 mmol, 60%); Rf: 0.2; mp: 67-72 °C; ν/cm-1 (neat) 2979, 1744, 1496, 
1480, 1369, 1341, 1318, 1296, 1269, 1202, 1147, 1133, 1123, 1076, 1030, 847, 804, 763; δH 
(CDCl3, 400 MHz) 1.71 (18H, 2 s, 2×C(CH3)3), 2.45 (3H, s, CH3), 2.48 (3H, s, CH3), 7.13-7.19 
(2H, m, Ar-H), 7.44 (1H, s br, Ar-H), 7.53 (1H, d, J 8.2 Hz, Ar-H), 7.74-7.78 (2H, m, Ar-H); δC 
(CDCl3, 100 MHz) 21.5, 22.1, 28.2, 86.6, 86.7, 114.4, 115.0, 119.1, 119.6, 126.1, 126.5, 
134.7, 135.4, 141.3, 147.5; No mass spectrum could be obtained. 
 
N-Trityl-2-chloro-6-methylbenzimidazole 27 
 
The reaction was carried out as described in the patent by Matsoukas et al. [94] 2-Chloro-6-
methyl benzimidazole 21 (20 mg, 0.12 mmol, 1.0 eq.) and trityl chloride (50 mg, 0.18 mmol, 
1.5 eq.) were dissolved in CH2Cl2 (0.5 mL). Et3N (42 µL, 0.3 mmol, 2.5 eq.) was added and 
the reaction mixture was stirred at ambient temperature for 16 h. The crude product was 
attempted to purify by column chromatography (7:3 CH2Cl2/Hex) but the product 
decomposes. Attempts to recrystallise the product failed. Therefore the product is only 
verified by 1H-NMR and mass spectroscopy and used crude. The product 27 was obtained as 
a yellow solid (42 mg, 0.10 mmol, 83%). Rf: 0.2; δH (CDCl3, 400 MHz) 2.14 (3H, s, CH3), 7.18-
7.26 (1H, m, Ar-H), 7.18-7.26 (37H, m, Ar-H and trityl chloride), 7.48 (1H, d, J 2.0 Hz, Ar-H), 
7.57 (1H, d, J 8.2 Hz, Ar-H); m/z 409/411 (M+H, 22%). 
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2-Chloro-6-methyl-1-{[2-{trimethylsilyl)ethoxy]methyl}-benzimidazole 29 
 
The reaction was carried out following a modified procedure by Grice et al. [95] 2-Chloro-6-
methyl benzimidazole 21 (1.5 g, 9.00 mmol, 1.0 eq.) was dissolved in DMF (30.00 mL). NaH 
(47 mg, 11.7 mmol, 1.3 eq.) was added slowly and the reaction mixture stirred for 30 min. 
Then, SEM-Cl (1.91 mL, 10.80 mmol, 1.2 eq.) was added and the reaction stirred at RT for 
another 16 h. The crude product was purified by column chromatography to afford the pure N-
SEM-protected 2-chlorobenzimidazole 29 as a yellow oil (1.50 g, 5.58 mmol, 62%). Rf: 0.4 
(2% Acetone/CH2Cl2); ν/cm-1 (neat) 2958, 1718, 1470, 1356, 1330, 1263, 1248, 1081, 939, 
917, 833, 805, 693; δH (CDCl3, 400 MHz) -0.05 (18H, 2 s, 2×SiC(CH3)3), 0.74-1.10 (4H, m, 
SiCH2), 2.47 (6H, d, J 6.3 Hz, 2×CH3), 3.38-3.79 (4H, m, 2×OCH2), 5.51 (2H, s, NCH2), 7.11 
(2H, td, J 8.3 and 1.5 Hz, Ar-H), 7.23 (1H, s br, Ar-H), 7.32 (1H, d, J 8.3 Hz, Ar-H), 7.45-7.48 
(1H, m, Ar-H), 7.56 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 100 MHz) -1.4, 17.8, 21.6, 21.9, 66.7, 
73.0, 73.2, 109.8, 110.1, 119.1, 119.4, 124.8, 125.1, 133.0, 133.2, 133.9, 135.3, 139.9, 140.4, 
142.1; m/z 297/299 (M+H, 100%); HRMS (ES+) 297.1190 calculated for C14H21N2OSi35Cl+ 
(M+H+), found 297.1182, Δ= -2.7 ppm. 
 
General Procedure C 
In an oven-dried round-bottom flask benzyl alcohol was dissolved in dry DMF. NaH was 
added slowly and the reaction mixture stirred for 30 min. A solution of the N-SEM-protected 2-
chlorobenzimidazole in DMF was added to the reaction mixture, which was stirred at RT for 
48 h. Then, the reaction mixture was quenched with H2O and extracted with CH2Cl2. The 
combined organic layer was dried over Na2SO4 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography to afford the pure 
product.  
 
2-(Benzyloxy)-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-benzimidazole 30  
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (300 mg, 1.02 mmol, 1.0 eq.), benzyl alcohol (188 mg, 1.32 mmol, 
1.3 eq.), NaH (83 mg, 2.09 mmol, 1.8 eq.) in DMF (10 mL). Column chromatography of the 
crude product (2% acetone/CH2Cl2) gave the pure benzimidazole ether 30 as a colourless, oil 
(196 mg, 0.53 mmol, 53%) Rf: 0.6 (2% acetone/CH2Cl2); ν/cm-1 (neat) 3178, 2952, 1703, 
1632, 1543, 1502, 1473, 1355, 1286, 1248, 1080, 858, 835, 798, 696; δH (CDCl3, 400 MHz) -
0.06 (9H, s, Si(CH3)3), -0.07 (9H, s, Si(CH3)3), 0.86-0.93 (4H, m, alkyl), 2.46 (3H, s, CH3), 
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3.49-3.57 (4H, m, alkyl), 5.37 (4H, s, PhCH2), 5.60 (4H, d, J 2.1 Hz, OCH2), 7.02 (2H, dd, J 
12.5 and 8.1 Hz, Ar-H), 7.14 (1H, s br, Ar-H), 7.21 (2H, d, J 8.1 Hz, Ar-H), 7.34-7.45 (7H, m, 
Ar-H), 7.48 (4H, d, J 7.7 Hz, Ar-H); δC (CDCl3, 100 MHz) -1.4, 17.8, 21.7, 66.3, 71.1, 71.2, 
108.7, 109.4, 117.4, 118.1, 122.6, 123.4, 128.20, 128.7, 131.4, 131.6, 131.8, 133.7, 135.7, 
137.9, 140.3, 156.9, 157.2; MS (ES+) m/z 369 (M+H, 100%); HRMS (ES+) 369.1998 
calculated for C21H29N2O2Si+ (M+H+), found 369.1988, Δ= -2.7 ppm. 
 
6-Methyl-2-[(2-methylphenyl)methoxy]-1-{[2-trimethylsilyl)ethoxy]methyl}-
benzimidazole 30a 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (301 mg, 1.01, 1.0 eq.), 2-methylbenzyl alcohol (161 mg, 1.32 mmol, 
1.3 eq.), NaH (78 mg, 1.96 mmol, 1.9 eq.) in DMF (10 mL). Column chromatography of the 
crude product (2% acetone/ CH2Cl2) gave the pure benzimidazole ether 30a as a colourless 
oil (298 mg, 0.78 mmol, 77%). Rf: 0.5 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2955, 2922, 2892, 
1629, 1597, 1540, 1462, 1433, 1360, 1280, 1248, 1079, 988, 833, 745, 690; δH (CDCl3, 400 
MHz) -0.07 (9H, s, Si(CH3)3), -0.08 (9H, s, Si(CH3)3), 0.80-0.93 (4H, m, alkyl chain), 2.43 (6H, 
s, CH3), 2.46 (6H, s, CH3), 3.44-3.58 (4H, m, alkyl), 5.36 (4H, s, PhCH2), 5.60 (4H, s, OCH2), 
7.03 (2H, m, Ar-H), 7.14 (0.5H, s, br, Ar-H), 7.23 (5H, dd, J 15.6 and 7.4 Hz, Ar-H), 7.32-7.27 
(2H, m, Ar-H), 7.40 (1H, s br, Ar-H), 7.46 (3H, dd, J 7.7 and 4.5 Hz, Ar-H); δC (CDCl3, 100 
MHz) -1.4, 17.9, 19.2, 21.7, 21.8, 66.3, 70.4, 71.2, 71.3, 108.7, 109.5, 117.4, 118.3, 122.6, 
123.4, 126.2, 128.9, 129.3, 129.4, 130.6, 131.4, 131.6, 131.8, 133.7, 133.8, 137.2, 138.0, 
140.4, 156.9, 157.2; MS (ES+) m/z 383 (M+H, 100%); HRMS (ES+) 383.2155 calculated for 
C22H31N2O2Si+ (M+H+), found 383.2137, Δ= -4.7 ppm. 
 
6-Methyl-2-[(4-methylphenyl)methoxy]-1-{[2-trimethylsilyl)ethoxy]methyl}-
benzimidazole 30b 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (300 mg, 1.01, 1.0 eq.), 4-methylbenzyl alcohol (162 mg, 1.32 mmol, 
1.3 eq.), NaH (62 mg, 1.56 mmol, 1.6 eq.) in DMF (10 mL). Column chromatography of the 
crude product (2% acetone/ CH2Cl2) gave the pure benzimidazole ether 30b as a colourless 
(119 mg, 0.31 mmol, 28%). Rf: 0.5 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2951, 1718, 1631, 
1597, 1540, 1463, 1436, 1360, 1281, 1247, 1078, 989, 833, 805, 751, 688; δH (CDCl3, 400 
MHz) -0.05 (18H, 2 s, 2×Si(CH3)3), 0.84-0.97 (4H, m, alkyl), 2.38 (6H, s, CH3), 2.47 (6H, s, 
CH3), 3.47-3.58 (4H, m, alkyl), 5.35 (4H, d, J 1.5 Hz, PhCH2), 5.57 (4H, d, J 1.7 Hz, OCH2), 
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6.98-7.09 (2H, m, Ar-H). 7.15 (1H, s br, Ar-H), 7.21 (5H, dd, J 8.0 and 3.9 Hz, Ar-H), 7.40 
(5H, d, J 7.8 Hz, Ar-H), 7.49 (1H, d, J 8.1 Hz, Ar-H); δC (CDCl3, 100 MHz) -1.5, 17.7, 21.3, 
21.6, 21.7, 66.1, 70.9, 71.1, 71.8, 108.6, 109.4, 117.3, 118.0, 122.5, 123.3, 128.4, 129.3, 
131.2, 131.5, 131.7, 132.6, 133.7, 137.9, 138.4, 140.3, 156.9, 157.2; MS (ES+) m/z 383 
(M+H, 92%); HRMS (ES+) 383.2160 calculated for C22H31N2O2Si+ (M+H+), found 383.2137, 
Δ= 1.3 ppm. 
 
2-[(2-Chlorophenyl)methoxy]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-
benzimidazole 30c 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (301 mg, 1.01, 1.0 eq.), 2-chlorobenzyl alcohol (188 mg, 1.32 mmol, 
1.3 eq.), NaH (70 mg, 1.75 mmol, 1.8 eq.) in DMF (10 ml). Column chromatography of the 
crude product (2% acetone/ CH2Cl2) gave the pure benzimidazole ether 30c as a pale yellow 
oil (201 mg, 0.49 mmol, 49%). Rf 0.6 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2953, 1634, 1595, 
1540, 1466, 1438, 1361, 1361, 1079, 1058, 941, 856, 833, 752, 680; δH (CDCl3, 400 MHz) 
0.08 (18H, 2 s, 2×Si(CH3)3), 0.73-0.95 (4H, m, alkyl), 2.45 (6H, d, J 2.2 Hz, CH3), 3.46-3.59 
(4H, m, alkyl), 5.38 (4H, s, PhCH2), 5.69 (4H, s, OCH2), 6.98-7.06 (1H, m, Ar-H), 7.13-7.16 
(1H, m, Ar-H), 7.21 (4H, d, J 8.1 Hz, Ar-H), 7.30 (4H, d J 0.7 Hz, Ar-H), 7.39 (1H, s br, Ar-H), 
7.41-7.48 (3H, m, Ar-H), 7.57 (1H, dd, J 7.3 and 1.9 Hz, Ar-H);  δC (CDCl3, 100 MHz) -1.4, 
17.9, 21.8, 66.4, 69.3, 71.4, 108.8, 109.5, 117.5, 118.2, 122.7, 123.4, 127.1, 129.8, 130.0, 
130.3, 131.5, 131.6, 131.9, 133.5, 133.8, 134.1, 137.9, 140.4, 156.7, 157.0; MS (ES+) m/z 
403/405 (M+H, 100%); HRMS (ES+) 403.1609 calculated for C21H28N2O2Si35Cl+ (M+H+), found 
403.1599, Δ= -2.5 ppm. 
 
2-[(3-Chlorophenyl)methoxy]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-
benzimidazole 30d 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (303 mg, 1.02, 1.0 eq.), 3-chlorobenzyl alcohol (188 mg, 1.32 mmol, 
1.3 eq.), NaH (83 mg, 2.09 mmol, 1.8 eq.) in DMF (10 mL). Column chromatography of the 
crude product (1% acetone/ CH2Cl2) gave the pure benzimidazole ether 30d as a pale yellow 
oil (273 mg, 0.68 mmol, 67%). Rf: 0.6 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2958, 1635, 1595, 
1541, 1467, 1425, 1361,1281, 1248, 1080, 1009, 858, 835, 783, 704, 682; δH (CDCl3, 400 
MHz) -0.07, (9H, s, Si(CH3)3), -0.08, (9H, s, Si(CH3)3), 0.78-0.95 (4H, m, alkyl), 2.45 (6H, d, J 
2.7 Hz, CH3), 3.42-3.61 (4H, m, alkyl), 5.37 (4H, s, PhCH2), 5.56 (4H, d, J 2.2 Hz, OCH2), 
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7.02 (2H, t, J 9.6 Hz, Ar-H), 7.14 (1H, s, Ar-H), 7.20 (1H, d, J 8.1 Hz, Ar-H), 7.31-7.39 (7H, m, 
Ar-H), 7.41-7.51 (3H, m, Ar-H); δC (CDCl3, 100 MHz) -1.3, 17.8, 21.8, 66.4, 70.9, 71.3, 108.8, 
109.5, 117.5, 118.2, 122.8, 123.5, 126.2, 128.2, 128.8, 130.1, 131.6, 131.9, 133.8, 134.7, 
137.7, 137.8, 140.2, 156.6, 156.9; MS (ES+) m/z 403/405 (M+H, 88%); HRMS (ES+) 403.1609 
calculated for C21H28N2O2Si35Cl+ (M+H+), found 403.1593, Δ= -4.0 ppm. 
 
2-[(4-Chlorophenyl)methoxy]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-
benzimidazole 30e 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (303 mg, 1.02, 1.0 eq.), 4-chlorobenzyl alcohol (188 mg, 1.32 mmol, 
1.3 eq.), NaH (88 mg, 2.20 mmol, 1.8 eq.) in DMF (10 mL). Column chromatography of the 
crude product (2% acetone/ CH2Cl2) gave the pure product 30e as a colourless oil (340 mg, 
0.84 mmol, 83%). Rf: 0.3 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2952, 1718, 1631, 1596, 1540, 
1463, 1441, 1360, 1280, 1248, 1080, 937, 834, 804, 756, 691; δH (CDCl3, 400 MHz) -0.08 
(9H, s, Si(CH3)3), -0.09 (9H, s, Si(CH3)3), 0.79-0.91 (4H, m, alkyl), 2.45, (6H, s, CH3), 3.46-
3.56 (4H, m, alkyl), 5.35 (4H, s, PhCH2), 5.55 (4H, s, OCH2), 6.98-7.05 (2H, m, Ar-H), 7.13 
(1H, s br, Ar-H), 7.19 (1H, d, J 8.1 Hz, Ar-H), 7.33-7.46 (10H, m, Ar-H); δC (CDCl3, 100 MHz) -
1.4, 17.9, 21.8, 66.4, 71.0, 108.7, 109.5, 117.5, 118.2, 122.7, 123.5, 128.9, 129.7, 131.6, 
131.9, 133.8, 134.2, 134.6, 137.9, 140.2, 156.9; MS (ES+) m/z 403/405 (M+H, 100%); HRMS 
(ES+) 403.1609 calculated for C21H28N2O2SiCl35+ (M+H+), found 403.1598, Δ= -2.7 ppm. 
 
2-[(3,4-Dichlorophenyl)methoxy]-6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-
benzimidazole 30f 
 
The reaction was carried out as described in general procedure C, using N-SEM-protected 2-
chlorobenzimidazole 29 (303 mg, 1.02, 1.0 eq.), 2-chlorobenzyl alcohol (188 mg, 1.32 mmol, 
1.3 eq.), NaH (83 mg, 2.09 mmol, 1.8 eq.) in DMF (10 mL). Column chromatography of the 
crude product (2% acetone/CH2Cl2) gave the pure benzimidazole ether 30f as a yellow oil 
(338 mg, 0.77 mmol, 76%). Rf: 0.3 (2% acetone/CH2Cl2); ν/cm-1 (neat) 2952, 1633, 1597, 
1540, 1469, 1396, 1356, 1341, 1280, 1248, 1078, 1029, 833, 754, 690; δH (CDCl3, 400 MHz) 
-0.07, (9H, s, Si(CH3)3), -0.08, (9H, s, Si(CH3)3), 0.83-0.94 (4H, m, alkyl), 2.45 (6H, d, J 2.9 
Hz, CH3), 3.46-3.57 (4H, m, alkyl), 5.36 (4H, s, PhCH2), 5.53 (4H, d, J 2.2 Hz, OCH2), 7.02 
(2H, t, J 8.8 Hz, Ar-H), 7.13 (1H, s, br, Ar-H), 7.20 (1H, d, J 8.1 Hz, Ar-H), 7.29-7.38 (3H, m, 
Ar-H), 7.45 (3H, dd, J 11.6 and 8.2 Hz, Ar-H), 7.58 (2H, s br, Ar-H); δC (CDCl3, 100 MHz) -1.4, 
17.9, 21.8, 66.5, 70.2, 71.3, 108.8, 109.5, 117.6, 118.2, 122.9, 123.6, 127.5, 130.1, 130.8, 
  Experimental 	  
 104 
131.7, 132.1, 132.8, 132.9, 133.9, 135.9, 137.8, 140.1, 156.5, 156.8; MS (ES+) m/z 
437/439/441 (M+H, 100%); HRMS (ES+) 437.1219 calculated for C21H27N2O2SiCl352+ (M+H+), 
found 437.1216, Δ= -0.7 ppm. 
 
General Procedure D [96] 
The SEM-protected benzimidazole was added to a 1M solution of TBAF in THF. The reaction 
mixture was heated to 55 °C for 18 h. Then, the reaction mixture was cooled to RT and H2O 
was added. The mixture was extracted with Et2O. The combined organic layer was dried over 
Na2SO4 and the solvent removed under reduced pressure. The product was purified by 
column chromatography to give the pure product. 
 
2-(Benzyloxy)-6-methyl-1H-benzimidazole 18 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole benzyl ether 30 (196 mg, 0.53 mmol, 1.0 eq.) and TBAF (1 M in THF, 5.30 mL, 
5.3 mmol, 10.0 eq.). Purification by column chromatography afforded the deprotected 
benzimidazole 18 as a white solid (36 mg, 0.15 mmol, 29%). Rf: 0.5 (2% acetone/CH2Cl2); 
mp: 149-155 °C; ν/cm-1 (neat) 3032, 2922, 1634, 1532, 1449, 1429, 1345, 1277, 1213, 1049, 
1028, 969, 918, 865, 834, 792, 756, 713, 696; δH (CDCl3, 400 MHz) 2.43 (3H, s, CH3), 5.54 
(2H, s, PhCH2), 6.98 (1H, d, J 8.0 Hz, Ar-H), 7.19, (1H, s br, Ar-H), 7.24-7.33 (1H, m, Ar-H), 
7.37 (3H, d, J 5.6 Hz, Ar-H), 7.43 (2H, s, Ar-H); δC (CDCl3, 100 MHz) 21.8, 71.8, 122.9, 128.5, 
128.4, 128.7, 131.5, 135.6, 157.6; MS (ES+) m/z 239 (M+H, 100%); HRMS (ES+) 239.1184 
calculated for C15H15N2O+ (M+H+), found 239.1184, Δ= 0.0 ppm. 
 
6-Methyl-2-[(2-methylphenyl)methoxy]-1H-benzimidazole 18a 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30a (286 mg, 0.75 mmol, 1.0 eq.) and TBAF (1M in THF, 7.50 mL, 7.50 
mmol, 10.0 eq.). After column chromatography (2% acetone/CH2Cl2) the pure deprotected 
benzimidazole 18a was obtained as a white solid (65 mg, 0.26 mmol, 33%). Rf: 0.5 (2% 
acetone/CH2Cl2); mp: 127-132 °C; ν/cm-1 (neat) 3043, 2932, 1696, 1635, 1551, 1454, 1350, 
1275, 1315, 1062, 1029, 969, 937, 800, 736, 703; δH (CDCl3, 400 MHz) 2.36 (3H, s, CH3), 
2.43 (3H, s, CH3), 5.54 (2H, s, PhCH2); 6.94-7.02 (1H, m Ar-H), 7.04 (0.5H, s, Ar-H), 7.11 
(0.5H, d, J 8.0 Hz, Ar-H), 7.17-7.24 (2H, m, Ar-H), 7.25-7.32 (1H, m, Ar-H), 7.36-7.50 (2H, m, 
Ar-H), 8.75 (1H, s, NH); δC (CDCl3, 100 MHz) 19.0, 21.8, 70.3, 109.2, 109.9, 117.4, 118.0, 
122.7, 123.0, 126.2, 129.1, 129.6, 130.6, 131.5, 132.3, 133.6, 137.4, 138.9, 141.3, 157.7, 
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158.1; MS (ES+) m/z 253 (M+H, 100%); HRMS (ES+) 253.1341 calculated for C16H17N2O+ 
(M+H+), found 369.1340, Δ= -0.4 ppm. 
 
6-Methyl-2-[(4-methylphenyl)methoxy]-1H-benzimidazole 18b 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30b (110 mg, 0.29 mmol, 1.0 eq.) and TBAF (1 M in THF, 2.40 mL, 2.4 
mmol, 8.3 eq.). Purification by column chromatography (2% acetone/CH2Cl2) afforded the 
pure deprotected benzimidazole 18b as a while solid (29 mg, 0.11 mmol, 35%). Rf: 0.4 (2% 
acetone/CH2Cl2); mp: 155-160 °C; ν/cm-1 (neat) 3032, 2919, 1634, 1552, 1453, 1349, 1313, 
1273, 1218, 1063, 972, 938, 846, 802, 714; δH (CDCl3, 400 MHz) 2.35 (3H, s, CH3), 2.42 (3H, 
s, CH3); 5.49 (2H, s, PhCH2), 6.94-7.01 (1H, m, Ar-H), 7.15 (3H, d, J 7.8 Hz, Ar-H), 7.27-7.43 
(3H, m, Ar-H), 9.44 (1H, s br, NH); δC (CDCl3, 100 MHz) 21.4, 21.7, 71.8, 122.8, 128.6, 129.4, 
131.3, 132.5, 138.5, 158.0; MS (ES+) m/z 253 (M+H, 100%); HRMS (ES+) 253.1341 
calculated for C16H17N2O+ (M+H+), found 253.1348, Δ= 2.8 ppm. 
 
2-[(2-Chlorophenyl)methoxy-6-methyl-1H-benzimidazole 18c 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30c (190 mg, 0.47 mmol, 1.0 eq.) and TBAF (1 M in THF, 2.40 mL, 2.4 
mmol, 5.1 eq.). After purification by column chromatography the deprotected benzimidazole 
18c was obtained as a white solid (116 mg, 0.43 mmol, 87%). Rf: 0.5 (2% acetone/CH2Cl2); 
mp: 110-120 °C; ν/cm-1 (neat) 3062, 2927, 1638, 1550, 1444, 1351, 1315, 1273, 1217, 1029, 
941, 800, 748, 681; δH (CDCl3, 400 MHz) 2.42 (3H, s, CH3), 5.64 (2H, s, PhCH2), 6.92-702 
(1H, m, Ar-H), 7.13-7.25 (3H, m, Ar-H), 7.27-7.39 (2H, m, Ar-H), 7.43 (1H, dt, J 7.6 and 1.6 
Hz, Ar-H); δC (CDCl3, 100 MHz) 21.7, 69.1, 122.9, 126.9, 129.7, 129.9, 130.1, 131.4, 133.3, 
133.9, 157.8; MS (ES+) m/z 273/275 (M+H, 100%); HRMS (ES+) 273.0795 calculated for 
C15H14N2OCl35+ (M+H+), found 273.0800, Δ= 1.8 ppm. 
 
2-[(3-Chlorophenyl)methoxy-6-methyl-1H-benzimidazole 18d 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30d (263 mg, 0.65 mmol, 1.0 eq.) and TBAF (1 M in THF, 6.50 mL, 6.5 
mmol, 10.0 eq.). Purification by column chromatography gave the deprotected benzimidazole 
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18d as a white solid (74 mg, 0.27 mmol, 42%). Rf: 0.5 (2% acetone/CH2Cl2); mp: 109-118 °C; 
ν/cm-1 (neat) 3048, 2923, 1635, 1551, 1456, 1428, 1349, 1272, 1215. 1068, 981, 866, 787, 
737, 682; δH (CDCl3, 400 MHz) 2.45 (3H, s, CH3), 5.51 (2H, s, PhCH2), 6.99-7.05 (1H, m, Ar-
H), 7.19-7.26 (3H, m, Ar-H), 7.28-7.34 (2H, m, Ar-H), 7.38 (1H, t, J 1.8 Hz, Ar-H), 10.02 (1H, 
s, br, NH); δC (CDCl3, 100 MHz) 21.7, 70.7, 122.9, 126.1, 128.1, 128.7, 129.9, 131.6, 134.5, 
137.5, 157.7; MS (ES+) m/z 273/275 (M+H, 100%); HRMS (ES+) 273.0795 calculated for 
C15H14N2OCl35+ (M+H+), found 273.0790, Δ= -1.8 ppm. 
 
2-[(4-Chlorophenyl)methoxy-6-methyl-1H-benzimidazole 18e 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30e (327 mg, 0.81 mmol, 1.0 eq.) and TBAF (1 M in THF, 8.10 mL, 8.1 
mmol, 10 eq.). Purification by column chromatography gave the deprotected benzimidazole 
18e as a white solid (105 mg, 0.38 mmol, 45%). Rf: 0.5 (2% acetone/CH2Cl2); mp: 163-167 
°C; ν/cm-1 (neat) 3049, 2923, 1634, 1551, 1492, 1454, 1407, 1347, 1313, 1271, 1217, 1091, 
1065, 1016, 977, 939, 840, 802, 737; δH (CDCl3, 400 MHz) 2.45 (3H, s, CH3), 5.48 (2H, s, 
PhCH2), 6.96-7.06 (1H, m, Ar-H), 7.06-7.61 (6H, m, Ar-H), 10.25 (1H, s br, NH); δC (CDCl3, 
100 MHz) 21.72 (s), 70.88 (s), 122.93 (s), 128.84 (s), 129.63 (s), 131.53 (s), 133.89 (s), 
134.53 (s), 157.85 (s); MS (ES+) m/z 273 (M+H, 100%); HRMS (ES+) 273.0795 calculated for 
C15H14N2OCl+ (M+H+), found 273.0786, Δ= -3.3 ppm. 
 
2-[(3,4-Dichlorophenyl)methoxy-6-methyl-1H-benzimidazole 18f 
 
The synthesis was carried out according to the general procedure D, using N-SEM-protected 
benzimidazole ether 30f (326 mg, 0.74 mmol, 1.0 eq.) and TBAF (1 M in THF, 7.40 mL, 7.40 
mmol, 5.1 eq.).  After purification by column chromatography the product 18f was obtained as 
a white solid (168 mg, 0.55 mmol, 71%). Rf: 0.5 (2% acetone/CH2Cl2); mp: 53-65 °C; ν/cm-1 
(neat) 3061, 2927, 1632, 1553, 1463, 1399, 1350, 1278, 1261, 1217, 1130, 1067, 1028, 974, 
819, 797, 747, 688; δH (CDCl3, 400 MHz) 2.46 (3H, s, CH3), 5.46 (2H, PhCH2), 7.01-7.06 (1H, 
m, Ar-H), 7.09 (1H, dd, J 8.2 and 2.0 Hz, Ar-H), 7.24 (1H, s, Ar-H), 7.29-7.38 (2H, m, Ar-H), 
7.39 (1H, d, J 1.9 Hz, Ar-H); δC (CDCl3, 100 MHz) 21.7, 70.1, 123.1, 127.1, 129.7, 130.6, 
131.7, 132.7, 135.5, 157.7; MS (ES+) m/z 307/309/311 (M+H, 100%); HRMS (ES+) 307.0405 
calculated for C15H13N2OCl352+ (M+H+), found 307.0424, Δ= 6.2 ppm. 
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tert-Butyl N-(5-bromo-2-{[(tertbutoxy)carbonyl]amino}phenyl)carbamate 38 [99] 
 
The synthesis was carried out as described by Cheung et al. [99] 6-Bromo diaminophenyl 8b 
(50 mg, 0.27 mmol, 1.0 eq.) and Boc-anhydride (295 mg, 1.35 mmol, 5 eq.) were dissolved in 
CH2Cl2 (0.75 mL). An aqueous solution of NaOH (27 mg, 0.67 mmol, 2.5 eq. in 0.35 mL H2O) 
was added to the reaction mixture, which was vigorously stirred at RT for 16 h. The fractions 
were separated and the aqueous layer was extracted with CH2Cl2. The combined organic 
layer was dried over Na2SO4 and the solvent removed under reduced pressure. Purification 
by column chromatography afforded the pure Boc-protected diamine 38 as a white solid (73 
mg, 0.19 mmol, 69%). Rf: 0.1 (7:3 CH2Cl2/Hex), mp: 160-170 °C; ν/cm-1 (neat) 3273, 2978, 
1695, 1595, 1537, 1508, 1481, 1392, 1304, 1278, 1254, 1158, 1085, 1053, 859, 769; δH 
(CDCl3, 400 MHz) 1.53 (18H, s, 2×C(CH3)3), 6.73 (2H, d, J 70.2 Hz Ar-H), 7.19 (1H, dd, J 8.6 
and 2.2 Hz, Ar-H), 7.28-7.40 (1H, m, Ar-H), 7.73 (1H, s br, Ar-H); m/z 411 (M+Na, 25%); 
HRMS (ES+) 409.0739 calculated for C16H23N2O4BrNa+ (M+Na+), found 409.0738, Δ= -0.2 
ppm. The spectrum is in agreement to the published spectral data. [99] 
 
General Procedure E [99] 
This general procedure describes a method which is in analogy to the described procedure by 
Cheung et al. [99] Boc-protected 4-bromo-1,2-benzenediamine was dissolved in degassed 2-
(2-ethoxyethoxy)ethanol. Then Pd(dppf)Cl2 and boronic acid were added. The atmosphere 
was exchanged to nitrogen and an aqueous solution of NaHCO3 was added to the reaction 
mixture, which was heated to 90 °C for 48 h. After that time the reaction was cooled to RT 
and H2O was added. The aqueous layer was extracted with CH2Cl2. The combined organic 
layer was dried over Na2SO4 and the solvent removed in vacuo. The product was purified by 
column chromatography. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-phenylphenyl)carbamate 39 
 
The synthesis was performed as outlined in the general procedure E in two vials, each with 4-
Br di-Boc diamine 38 (300 mg, 0.67 mmol, 1.0 eq.), phenylboronic acid (192 mg, 1.33 mmol, 
2.0 eq.), Pd(dppf)Cl2 (126 mg, 0.12 mmol, 0.2 eq.), NaHCO3 (656 mg, 5.26 mmol, 8.0 eq. in 
5.5 mL H2O) in 2-(2-ethoxyethoxy)ethanol (8 mL). The crude product was purified by column 
chromatography (CH2Cl2/Hex 6:4) to give the biaryl 39 as a pale yellow solid (171 mg, 0.45 
mmol, 29%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 58-65 °C; ν/cm-1 (neat) 3310, 2978, 1701, 1594, 
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1494, 1414, 1392, 1239, 1154, 1048, 1023, 863, 758, 735, 696; δH (CDCl3, 400 MHz) 1.57 
(18H, s, 2×C(CH3)3), 6.80 (2H, s, br, NH), 7.32-7.41 (2H, m, Ar-H), 7.42-7.49 (2H, m, Ar-H), 
7.55-7.63 (2H, m, Ar-H), 7.76 (1H, s br, Ar-H); δc (CDCl3, 100 MHz) 28.4, 81.1, 127.2, 127.4, 
128.8, 140.4, 153.9; MS (ES+) m/z 407 (M+Na, 55%); HRMS (ES+) 407.1947 calculated for 
C22H28N2O4Na+ (M+Na+), found 407.1938, Δ= -2.2 ppm. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(2-methylphenyl)phenyl)carbamate 39a 
 
The synthesis was carried out according to the general procedure E in two separate vials, 
each using 4-Br di-Boc diamine 38 (300 mg, 0.77 mmol, 1.0 eq.), 2-Methylphenylboronic acid 
(210 mg, 1.54 mmol, 2.0 eq.), Pd(dppf)Cl2 (125 mg, 0.15 mmol, 0.2 eq.), NaHCO3 (653 mg, 
6.16 mmol, 8.0 eq. in 5.5 mL H2O) in 2-(2-ethoxyethoxy)ethanol (8 mL). The crude product 
was purified by column chromatography (CH2Cl2/Hex 7:3) to give the biaryl 39a as a pale 
yellow solid (339 mg, 0.85 mmol, 55%). Rf: 0.2 (4:6 Hex/CH2Cl2); mp: 55-59 °C; ν/cm-1 (neat) 
3305, 2978, 1702, 1455, 1484, 1367, 1247, 1154, 1049, 1023, 757, 735; δH (CDCl3, 400 
MHz) 1.51 (9H, s, C(CH3)3), 1.54 (9H, s, C(CH3)3), 2.28 (3H, s, CH3), 6.77 (1H, br s, Ar-H), 
7.09 (1H, dd, J 8.2 and 1.9 Hz, Ar-H), 7.18-7.22 (2H, m, Ar-H), 7.22-7.25 (2H, m, Ar-H), 7.45 
(1H, br s, NH), 7.52 (1H, br s, NH); δC (CDCl3, 100 MHz) 20.7, 28.4, 81.1, 125.9, 126.4, 
127.4, 129.9, 130.4, 135.5, 141.1, 153.9; MS (ES+) m/z 421 (M+Na+, 100%), 199 (M-2×boc+, 
32%); HRMS (ES+) 421.2103 calculated for C23H30N2O4Na+ (M+Na+) found 421.2092, Δ= -2.6 
ppm. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(4-methylphenyl)phenyl)carbamate 39b 
 
 
The reaction was conducted according to the general procedure E in two vials, each with 4-Br 
di-Boc diamine 38 (300 mg, 0.77 mmol, 1.0 eq.), 4-methylphenylboronic acid (211 mg, 1.54 
mmol, 2.0 eq.), Pd(dppf)Cl2 (125 mg, 0.15 mmol, 0.2 eq.), NaHCO3 (653 mg, 6.16 mmol, 8.0 
eq. in 5.5 mL H2O) in 2-(2-ethoxyethoxy)ethanol (8 mL). The crude product was purified by 
column chromatography (CH2Cl2/Hex 7:3) to give the biaryl 39b as a pale yellow solid (301 
mg, 0.76 mmol, 49%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 61-66 °C; ν/cm-1 (neat) 3307, 2977, 
2931, 1696, 1506, 1366, 1240, 1155, 1050, 1024, 808, 770, 736; δH (CDCl3, 400 MHz) 1.53 
(18H, s, 2×C(CH3)3), 2.38 (2H, s, CH3), 6.76, (2H, br s, Ar-H), 7.22 (2H, d, J 7.9, Ar-H), 7.33 
(1H, dd, J 8.4 and 2.1, Ar-H), 7.42-7.48 (2H, m, Ar-H), 7.53 (1H, br s, Ar-H), 7.70 (1H, br s, 
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Ar-H); δc (CDCl3, 100 MHz) 21.2, 28.4, 81.1, 126.9, 129.6, 137.3, 153.9; MS (ES+) m/z 421 
(M+Na+, 90%), 199 (M-2×boc+, 43%); HRMS (ES+) 421.2103 calculated for C23H30N2O4Na+ 
(M+Na+) found 421.2107, Δ= 0.9 ppm. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(2-chlorophenyl)phenyl)carbamate 39c 
 
The reaction was carried out as described in the general procedure E in two identical 
batches, each with 4-Br di-Boc diamine 38 (251 mg, 0.65 mmol, 1.0 eq.), 2-
chlorophenylboronic acid (204 mg, 1.30 mmol, 2.0 eq.), Pd(dppf)Cl2 (100 mg, 0.13 mmol, 0.2 
eq.), NaHCO3 (557 mg, 5.3 mmol, 8.2 eq. in 4.8 mL H2O) in 2-(2-ethoxyethoxy)ethanol (7.5 
mL). The crude product was purified by column chromatography (CH2Cl2/Hex 7:3) to give the 
biaryl 39c as a pale yellow solid (103.4 mg, 0.25 mmol, 19%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 
65-70 °C; ν/cm-1 (neat) 3308, 2978, 1701, 1525, 1478, 1367, 1241, 1153, 1050, 1023, 756, 
736; δH (CDCl3, 400 MHz) 1.53 (18H, s, 2×C(CH3)3), 6.77 (2H, br s, Ar-H), 7.29-7.38 (2H, m, 
Ar-H), 7.38-7.44 (2H, m, Ar-H), 7.52-7.59 (2H, m, Ar-H), 7.73 (1H, br s, Ar-H); δc (CDCl3, 100 
MHz) 28.4, 81.1, 127.2, 127.4, 128.8, 140.4, 153.9; MS (ES+) m/z 441/443 (M+Na+, 100%), 
199 (M-2×boc+, 43%); HRMS (ES+) 441.1557 calculated for C22H27N2O4Cl35Na+ (M+Na+) 
found 441.1538, Δ= -4.3 ppm. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(3-chlorophenyl)phenyl)carbamate 39d 
 
The synthesis was conducted as outlined in general procedure E in two vials, both with 4-Br 
di-Boc diamine 38 (300 mg, 0.77 mmol, 1.0 eq.), 3-chlorolphenylboronic acid (234 mg, 1.54 
mmol, 2.0 eq.), Pd(dppf)Cl2 (125 mg, 0.15 mmol, 0.2 eq.), sodium bicarbonate (655 mg, 6.17 
mmol, 8.0 eq. in 5.5 mL H2O) in 2-(2-ethoxyethoxy)ethanol (8 mL). The crude product was 
purified by column chromatography (CH2Cl2/Hex 7:3) to give the product 39d as a pale yellow 
solid (283 mg, 0.68 mmol, 53%). Rf: 0.1 (4:6 Hex/CH2Cl2) mp: 60-63 °C; ν/cm-1 (neat) 3304, 
2978, 2933, 1698, 1527, 1478, 1391, 1366, 1241, 1151, 1047, 1024, 778, 693; δH (CDCl3, 
400 MHz) 1.53 (18H, s, 2×C(CH3)3), 6.76 (2H, br s, Ar-H), 7.29-7.34 (2H, m, Ar-H), 7.41-7.45 
(1H, m, Ar-H), 7.48-7.55 (2H, m, Ar-H), 7.60-7.65 (1H, m, Ar-H), 7.69-7.74 (1H, m Ar-H); δC 
(CDCl3, 100 MHz) 28.4, 77.4, 81.2, 125.4, 127.2, 127.4, 127.5, 134.7, 142.2, 153.9; MS (ES+) 
m/z 441 (M+Na+, 19%); HRMS (ES+) 441.1557 calculated for C22H27N2O4Cl35Na+ (M+Na+), 
found 441.1550, Δ= -1.6 ppm.  
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tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(4-chlorophenyl)phenyl)carbamate 39e 
 
The reaction was carried out as described in general procedure E in two vials, both with 4-Br 
di-Boc diamine 38 (250 mg, 0.65 mmol, 1.0 eq.), 2-methylphenylboronic acid (201 mg, 1.29 
mmol, 2.0 eq.), Pd(dppf)Cl2 (100 mg, 0.13 mmol, 0.2 eq.), NaHCO3 (553 mg, 5.22 mmol, 8.0 
eq. in 4.8 mL H2O) in 2-(2-ethoxyethoxy)ethanol (7.5 mL). The crude product was purified by 
column chromatography (CH2Cl2/Hex 7:3) to give the biaryl 39e as a yellow solid (250.5 mg, 
0.59 mmol, 46%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 66-75 °C; ν/cm-1 (neat) 3307, 2978, 1701, 
1486, 1367, 1239, 1153, 1092, 1051, 1023, 1012, 812, 735; δH (CDCl3, 400 MHz) 1.53, (18H, 
s, 2×C(CH3)3), 6.75 (2H, br s, Ar-H), 7.30 (1H, dd, J 8.4 and 2.1 Hz, Ar-H), 7.35-7.39 (2H, m, 
Ar-H), 7.47-7.48 (2H, m, Ar-H), 7.55 (1H, d, J 8.5 Hz, Ar-H), 7.71 (1H, br s, Ar-H); δc (CDCl3, 
100 MHz) 28.4, 77.4, 81.2, 127.4, 127.6, 128.4, 128.9, 133.5, 138.8, 153.9; MS (ES+) m/z 
441/443 (M+Na+, 32%); HRMS (ES+) 441.1557 calculated for C22H27N2O4Cl35Na+ (M+Na+), 
found 441.1564, Δ= 1.6 ppm. 
 
tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(3,4-dichlorophenyl)phenyl)carbamate 
39f 
 
The synthesis was performed as described in the general procedure E in two separated vials, 
both with 4-Br di-Boc diamine 38 (250 mg, 0.66 mmol, 1.0 eq.), 3,4-dichloroboronic acid (300 
mg, 1.55 mmol, 2.0 eq.), Pd(dppf)Cl2 (127 mg, 0.13 mmol, 0.2 eq.), NaHCO3 (560 mg, 5.28 
mmol, 8.1 eq. in 4.8 mL H2O) in 2-(2-ethoxyethoxy)ethanol (7.5 mL). The crude product was 
purified by column chromatography (CH2Cl2/Hex 6:4) to give the biaryl 39f as an orange solid 
(142 mg, 0.31 mmol, 20%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 64-70 °C; ν/cm-1 (neat) 3305, 2979, 
1699, 1593, 1474, 1367, 1241, 1152, 1050, 1025, 871, 813, 736; δH (CDCl3, 400 MHz) 1.53 
(18H, s, 2×C(CH3)3), 6.77 (2H, s br, Ar-H), 7.28, (1H, dd, J 8.5 and 2.3 Hz, Ar-H), 7.35-7.40 
(1H, m, Ar-H), 7.46 (1H, d, J 8.3 Hz, Ar-H), 7.46 (1H, d, J 8.3 Hz, Ar-H), 7.62 (1H, d, J 2.1 Hz, 
Ar-H); δc (CDCl3, 100 MHz) 28.3, 126.3, 128.7, 128.9, 129.9, 129.9, 130.7, 132.8, 140.3, 
153.8; No Mass spectrum could be obtained from that compound. 
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tert-Butyl N-(2-{[(tert-butoxy)carbonyl]amino}-5-(4-methoxyphenyl)phenyl)carbamate 
39g 
 
The reaction was carried out according to general procedure E in two vials, both with 4-Br di-
Boc diamine 38 (257 mg, 0.67 mmol, 1.0 eq.), 4-methoxyphenylboronic acid (202 mg, 1.33 
mmol, 2.0 eq.), Pd(dppf)Cl2 (102 mg, 0.12 mmol, 0.2 eq.), NaHCO3 (557 mg, 5.26 mmol, 8.0 
eq. in 4.80 mL H2O) in 2-(2-ethoxyethoxy)ethanol (7.50 mL). The crude product was purified 
by column chromatography (CH2Cl2/Hex 6:4) to give the biaryl 39g as a yellow solid (85 mg, 
0.21 mmol, 16%). Rf: 0.1 (4:6 Hex/CH2Cl2); mp: 58-63 °C; ν/cm-1 (neat) 3314, 2976, 1709, 
1508, 1367, 1244, 1162, 1042, 820; δH (CDCl3, 400 MHz) 1.53 (18H, s, 2×C(CH3)3), 3.84 (3H, 
s, OCH3), 6.75 (2H, s br, NH), 6.92-6.98 (2H, m, Ar-H), 7.30 (1H, dd, J 8.8 and 1.8 Hz, Ar-H), 
7.44-7.57 (2H, m, Ar-H), 7.69 (1H, s, Ar-H); δc (CDCl3, 100 MHz) 28.4, 55.5, 77.4, 81.0, 
114.3, 128.2, 132.9, 154.0, 159.3; MS (ES+) m/z 437 (M+Na, 52%); HRMS (ES+) 437.2052 
calculated for C23H30N2O5Na+ (M+Na+), found 437.2041, Δ= -2.5 ppm. 
 
General Procedure F 
The Boc-protected biaryl compound was dissolved in CH2Cl2. An excess of TFA was added 
and the reaction mixture stirred for 15 min. and the solvent and remaining TFA was removed 
under reduced pressure. The TFA salt was directly used for the next reaction. The TFA salt 
was dissolved in a 10:1 mixture EtOH and H2O. Then 10 eq. of NaOH were added. The 
reaction mixture was stirred for 10 minutes before 10 eq. of carbon disulfide were added. The 
reaction mixture was heated to 50 °C for 4 h. After that time the reaction mixture was cooled 
to RT and the solvent and remaining carbon disulfide was removen in vacuo. The crude 
product was purified by flash column chromatography.  
 
6-Phenyl-1H-2-mercaptobenzimidazole 37  
 
The synthesis was carried out according to general procedure F, using N-N’-di-Boc protected 
biaryl 39 (152 mg, 0.39 mmol, 1.0 eq.), TFA (0.5 mL, high excess), CS2 (0.6 mL 9.88 mmol, 
24.9 eq.), NaOH (161 mg, 4.03 mmol, 10.3 eq. in 1 mL H2O) in EtOH (2 mL). Purification by 
column chromatography gave the 2-mercaptobenzimidazole 37 as a light brown solid (91 mg, 
0.4 mmol, 100%) Rf: 0.4 (EtOAc/Hex, 4:6); mp: >240 °C; ν/cm-1 (neat) 3065, 2339, 1598, 
1465, 1301, 1184, 856, 807, 754, 659; δH (MeOD-d4, 400 MHz) 7.27 (1H, dd, J 8.2 and 0.8 
Hz, Ar-H), 7.37 (1H, tt, J 7.4 and 1.3, Ar-H), 7.41-7.43 (2H, m, Ar-H), 7.44-7.45 (2H, m, Ar-H), 
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7.55-7.62 (2H, m, Ar-H); δc (MeOD-d4, 100 MHz) 107.8, 109.7, 121.7, 126.8, 128.5, 131.8, 
133.1, 136.7, 140.9, 150.5, 168.4; No mass spectrum could be obtained. 
 
6-(2-Methylphenyl)-1H-2-mercaptobenzimidazole 37a 
 
The reaction was carried out as described in the general procedure F, using N,N’-di-Boc 
protected 2-metyl biaryl 39a (338.7 mg, 0.85 mmol, 1. 0 eq.), TFA (0.5 mL high excess) in 
CH2Cl2 (2.00 mL), CS2 (0.77 mL, 12.75 mmol, 15.0 eq.), NaOH (340 mg, 8.5 mmol, 10.0 eq.) 
in EtOH (4 mL), H2O (2 mL). The crude product was purified by column chromatography (dry 
loaded, gradient EtOAc/Hex 4:6 to 8:2) to give the 2-mercaptobenzimidazole 37a as a pale 
yellow solid (146 mg, 0.61 mmol, 71%). Rf: 0.5 (EtOAc/Hex, 4:6); mp: >240 °C; ν/cm-1 (neat) 
3164, 3075, 3010, 2951, 2308, 1600, 1525, 1495, 1471, 1322, 1183, 983, 924, 857, 813, 753, 
725; δH (DMSO-d6, 400 MHz) 2.21 (3H, s, CH3), 7.02 (1H, d, J 1.5 Hz, Ar-H), 7.07 (1H, dd, J 
8.1 and 1.6 Hz, Ar-H), 7.16-7.22 (2H, m, Ar-H), 7.22-7.30 (3H, m, Ar-H), 12.57 (2H, s br, NH 
and SH); δc (DMSO-d6, 100 MHz) 20.2, 109.1, 109.7, 123.5, 125.9, 127.2, 129.7, 130.3, 
131.3, 132.4, 134.8, 135.6, 141.2, 168.5; MS (CI+) m/z 240 (M, 18%); HRMS (CI+) 240.0721 
calculated for C14H12N2S+ (M), found 240.0729, Δ= 3.3 ppm.  
 
6-(4-Methylphenyl)-1H-2-mercaptobenzimidazole 37b 
 
The synthesis was carried out as described in the general procedure F, using N-N’-di-Boc 
protected 4-methyl biaryl 39b (301.7 mg, 0.75 mmol, 1.0 eq.), TFA (2.00 mL, high excess) in 
CH2Cl2 (2.00 mL), CS2 (1.0 mL, 16.52 mmol, 21.7 eq.), NaOH (300 mg, 7.60 mmol, 10.1 eq.), 
EtOH (2 mL), H2O (1 mL). Purification by column chromatography (dry loaded, gradient 
(EtOAc/Hex 4:6 to 8:2) afforded the 2-mercaptobenzimidazole 37b as a white solid (137 mg, 
0.72 mmol, 95%) Rf: 0.4 (EtOAc/Hex, 4:6); mp: >240 °C; ν/cm-1 (neat) 3047, 2958, 2857, 
2578, 2303, 1617, 1481, 1465, 1301, 1187, 791, 706, 620; δH (MeOD-d4, 400 MHz) 2.36 (3H, 
s, CH3), 7.24 (3H, ddd, J 8.2, 4.1 and 0.8 Hz, Ar-H), 7.38 (1H, m, Ar-H), 7.41 (1H, dd, J 8.2 
and 1.7 Hz, Ar-H), 7.45-7.49 (2H, m, Ar-H); δc (MeOD-d4, 100 MHz) 19.7, 107.5, 109.6, 
121.8, 126.5, 129.1, 131.6, 133.0, 136.6, 136.7, 137.9, 168.2; MS (CI+) m/z 241 (M+H+, 35%); 
HRMS (CI+) 241.0779 calculated for C14H13N2S+ (M+H+), found 241.0791, Δ= -3.3 ppm. 
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6-(2-Chlorophenyl)-1H-2-mercaptobenzimidazole 37c 
 
The reaction was carried out as described in the general procedure F, using N-N’-di-Boc 
protected 2-chloro biaryl 39c (50 mg, 0.12 mmol, 1.0 eq.), TFA (1.00 mL, high excess) in 
CH2Cl2 (2.00 mL), CS2 (0.11 mL, 1.8 mmol, 15 eq.), NaOH (50 mg, 1.2 mmol, 10 eq.) in EtOH 
(2 mL) and H2O (1 mL). Column chromatography (dry loaded, EtOAc/Hex, 4:6 to 8:2) of the 
crude product afforded the pure 2-mercaptobenzimidazole 37c as a pale yellow solid (33 mg, 
0.51 mmol, 104%). Rf: 0.5 (4:6 EtOAc/Hex); mp: >240 °C; ν/cm-1 (neat) 3068, 2317, 1598, 
1441, 1185, 858, 808, 754, 696, 632; δH (MeOD-d4, 400 MHz) 7.27 (1H, dd, J 8.2 and 0.8 Hz, 
Ar-H), 7.30-7.36 (1H, m, Ar-H), 7.39-7.46 (3H, m, Ar-H), 7.54-7.62 (2H, m, Ar-H); δc (MeOD-
d4, 100 MHz) 107.8, 109.7, 121.9, 126.7, 126.8, 128.5, 131.8, 133.1, 136.7, 140.9, 153.7, 
168.4; No mass spectrum could be obtained from this compound. 
 
6-(3-Chlorophenyl)-1H-2-mercaptobenzimidazole 37d 
 
The reaction was carried out as described in the general procedure F, using N-N’-di-Boc 
protected 3-chloro biaryl 39d (283 mg, 0.68, 1.0 eq.), TFA (2.00 mL, large excess) in CH2Cl2 
(3.00 mL), CS2 (0.7 mL 11.61 mmol, 17.1 eq.) NaOH (300 mg, 7.5 mmol, 11.0 eq.) in EtOH 
(4.00 mL) and H2O (2.00 mL). The crude product was purified by column chromatography 
(dry loaded, gradient EtOAc/Hex 4:6 to 8:2) to give the pure 2-mercaptobenzimidazole 37d as 
a white solid (149 mg, 0.57 mmol, 84%). Rf: 0.4 (EtOAc/Hex, 4:6); mp: >240 °C; ν/cm-1 (neat) 
3063, 2325, 1594, 1498, 1465, 1186, 770, 686, 635; δH (DMSO-d6, 400 MHz) 7.22 (1H, d, J 
8.3 Hz, Ar-H), 7.34-7.42 (2H, m, Ar-H), 7.43-7.46 (2H, m, Ar-H), 7.60 (1H, dt, J 7.8 and 1.4 
Hz, Ar-H), 7.68 (1H, t, J 1.9 Hz, Ar-H), 12.67 (2H, s, NH and SH); δc (DMSO-d6, 100 MHz) 
107.6, 109.9, 121.7, 125.5, 126.4, 126.9, 130.8, 132.3, 133.1, 133.7, 142.5, 168.9; MS (ES+) 
m/z 261/263 (M+H+, 100%); HRMS (ES+) 261.0253 calculated for C13H10N2SCl35+ (M+H+), 
found 261.0255, Δ= 0.8 ppm. 
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6-(3,4-Dichlorophenyl)-1H-2-mercaptobenzimidazole 37f 
 
The synthesis was conducted in accordance with the general procedure F, using N-N’-di-Boc 
protected 3,4-dichloro biaryl 39f (132 mg, 0.29 mmol, 1.0 eq.), TFA (0.50 mL, high excess) in 
CH2Cl2 (2.00 mL), CS2 (0.5 mL, 8.40 mmol, 28.9 eq.), NaOH (120 mg, 3.00 mmol, 10.3 eq.) in 
EtOH (4.00 mL) and H2O (2.00 mL). Purification by column chromatography (dry loaded, 
gradient (EtOAc/Hex, 4:6 to 8:2) afforded the pure 2-mercaptobenzimidazole 37f as a light 
yellow solid (84 mg, 0.28 mmol, 98%). Rf: 0.4 (EtOAc/Hex, 4:6); mp: >240 °C; ν/cm-1 (neat) 
3099, 2578, 1465, 1188, 1135, 797, 749, 620; (DMSO-d6, 400 MHz) 7.21 (1H, d, J 8.3 Hz, Ar-
H), 7.36-7.41 (1H, m, Ar-H), 7.46 (1H, dd, J 8.2 and 1.7 Hz, Ar-H), 7.63 (1H, dd, J 8.4 and 2.0 
Hz, Ar-H), 7.68 (1H, d, J 8.3 Hz, Ar-H), 7.90 (1H, d, J 2.1 Hz, Ar-H), 12.68 (1H, s, NH), 12.73 
(1H, s, br, SH); δc (DMSO-d6, 100 MHz) 108.1, 110.3, 122.1, 127.4, 128.9, 130.2, 131.4, 
132.1, 132.9, 133.5, 141.4, 168.5; No mass spectrum could be obtained. 
 
6-(4-Methoxyphenyl)-1H-2-mercaptobenzimidazole 37g 
 
The reaction was carried out as described in the general procedure F, using N-N’-di-Boc 
protected 4-methoxy biaryl 39g (75 mg, 0.49 mmol, 1.0 eq.), TFA (1.50 mL, high excess), in 
CH2Cl2 (2.00 mL), CS2 (0.23 mL, 4.9 mmol, 10 eq.), NaOH (196 mg, 4.9 mmol, 10 eq. in 1.50 
mL H2O) in EtOH (4.00 mL). Column chromatography of the crude product afforded the pure 
2-mercaptobenzimidazole 37g as a pale yellow solid (133 mg, 0.51 mmol, 104%). Rf: 0.5 (4:6 
EtOAc/Hex); mp: 215-220 °C; ν/cm-1 (neat) 3534, 3110, 2835, 1608, 1530, 1486, 1285, 1249, 
1205, 1176, 1035, 1018, 833, 805; (MeOD-d4, 400 MHz) 3.83 (3H, s, OCH3), 6.95-7.01 (2H, 
m, Ar-H), 7.24 (1H, dd, J 8.3 and 0.8 Hz, Ar-H), 7.36 (1H,dd, J, 1.7 and 0.7 Hz, Ar-H), 7.39 
(1H, dd, J 1.7 and 0.7 Hz, Ar-H), 7.47-7.56 (2H, m, Ar-H); δc (MeOD-d4, 100 MHz) 55.8, 
108.7, 111.0, 115.3, 123.0, 129.1, 132.8, 134.5, 137.8, 160.7; No Mass spectrum could be 
obtained for this compound. 
 
General Procedure G [84] 
The 2-mercapto-6-aryl benzimidazole was dissolved in DMF. NaOMe was added and the 
solution stirred for 30 min. Then 2-methylbenzyl bromide was added and the reaction mixture 
stirred for 16 h. After that, H2O was added and the mixture extracted with CH2Cl2. The 
combined organic layer was dried over Na2SO4 and reduced in vacuo. The crude product was 
purified by column chromatography.  
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2-{[(2-Methylphenyl)methyl]sulfanyl}-6-phenyl-1H-benzimidazole 32 
 
The reaction was performed as outlined in the general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37 (81 mg, 0.35 mmol, 1.0 eq.), NaOMe (25 mg, 0.47 mol, 1.3 eq.) 
and 2-methylbenzyl bromide (63 µL, 0.47 mmol, 1.3 eq.) in DMF (2 mL). After purification via 
column chromatography (CH2Cl2) the pure benzimidazole thioether 32 was obtained as a 
white solid (44 mg, 0.13 mmol, 37%). Rf: 0.2 (CH2Cl2); mp: 197-208 °C; ν/cm-1 (neat) 3379, 
3045, 2941, 2859, 2757, 1599, 1444, 1389, 1282, 1227, 982, 732, 697; δH (CDCl3, 400 MHz) 
2.43 (3H, s, CH3), 4.60 (2H, s, PhCH2), 7.13 (1H, td, J 6.6 and 3.0 Hz, Ar-H), 7.17-7.23 (2H, 
m, Ar-H), 7.34 (2H, dd, J 8.9 and 7.2 Hz, Ar-H), 7.41-7.53 (3H, m, Ar-H), 7.56-7.67 (3H, m, 
Ar-H), 7.71 (1H, s br, Ar-H); δC (CDCl3, 100 MHz) 19.4, 35.8, 122.5, 126.5, 127.1, 127.5, 
128.3, 128.9, 130.2; MS (ES+) m/z 331 (M+H, 100%); HRMS (ES+) 331.1269 calculated for 
C21H19N2S+ (M+H+), found 331.1285, Δ= 4.8 ppm. 
 
6-(2-Methylphenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32a 
 
The synthesis was carried out according to general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37a (134 mg, 0.55 mmol, 1.0 eq.), NaOMe (39 mg, 0.72 mmol, 1.3 
eq.), 2-methylbenzyl bromide (96 µL, 0.72 mmol, 1.3 eq.) in DMF (4 mL). The crude product 
was purified by column chromatography to give the benzimidazole thioether 32a as a yellow 
solid (92 mg, 0.27 mmol, 49%). Rf: 0.3 (CH2Cl2); mp: 183-186 °C; ν/cm-1 (neat) 3025, 2929, 
2625, 1632, 1447, 1393, 1327, 1266, 1229, 988, 816, 756, 730; δH (CDCl3, 400 MHz) 2.27, 
(3H, s, CH3), 2.36 (3H, s, CH3), 4.59 (2H, PhCH2), 7.08 (1H, td, J 7.2 and 1.9 Hz, Ar-H), 7.12-
7.15 (1H, m, Ar-H), 7.17 (2H, td, J 8.4 and 1.6 Hz, Ar-H), 7.23-7.33 (5H, m, Ar-H), 7.49 (1H, 
d, J 1.6 Hz, Ar-H), 7.57 (1H, d, J 8.2 Hz, Ar-H); δC (CDCl3, 100 MHz) 19.3, 20.7, 35.8, 124.3, 
125.8, 126.4, 127.2, 128.2, 130.1, 130.3, 130.4, 130.7, 134.1, 135.7, 136.8, 137.2, 142.27 (s), 
150.6; MS (ES+) m/z 345 (M+H, 100%); HRMS (ES+) 345.1425 calculated for C22H21N2S+ 
(M+H+), found 345.1443, Δ= 5.2 ppm. 
 
6-(4-Methylphenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32b 
 
The synthesis was performed using the general procedure G, with 6-aryl-2-
mercaptobenzimidazole 37b (162 mg, 0.67 mmol, 1.0 eq.) NaOMe (47 mg, 0.88 mmol, 1.3 
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eq.) and 2-methylbenzyl bromide (120 µL, 0.88 mmol, 1.3 eq.) in DMF (5 mL). The product 
was purified by column chromatography (CH2Cl2) to give the benzimidazole thioether 32b as 
a yellow glassy solid (99 mg, 0.29 mmol, 43%). Rf: 0.3 (CH2Cl2); mp: 208-212 °C; ν/cm-1 
(neat) 3069, 2301, 1601, 1469, 1306, 1187, 861, 810; δH (CDCl3, 400 MHz) 2.40 (3H, s, CH3), 
2.41 (3H, s, CH3), 4.59 (2H, s, PhCH2), 7.11 (1H, td, J 6.9 and 2.6 Hz, Ar-H), 7.16-7.23 (2H, 
m, Ar-H), 7.25 (2H, d, J 7.6 Hz, Ar-H), 7.31 (1H, d, J 7.31 Hz, Ar-H), 7.46 (1H, dd, J 8.4 and 
1.7 Hz, Ar-H), 7.51 (1H, d, J 8.1 Hz, Ar-H), 7.57 (1H, s br, Ar-H); δC (CDCl3, 100 MHz) 19.4, 
21.2, 35.8, 122.3, 126.5, 127.3, 128.3, 129.6, 130.2, 130.8, 134.4, 136.3, 136.8, 137.2, 138.9, 
150.4; MS (ES+) m/z 345 (M+H, 100%); HRMS (ES+) 345.1425 calculated for C22H21N2S+ 
(M+H+), found 345.1436, Δ= 3.2 ppm. 
 
6-(2-Chlorophenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32c 
 
The reaction was conducted as describes in the general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37c (26.6 mg, 0.10 mmol, 1.0 eq.), NaOMe (7.01 mg, 0.13 mmol, 13 
eq.), 2-methybenzyl bromide (17 µL, 0.13 mmol, 1.3 eq.) in DMF (0.5 mL). The crude product 
was purified by column chromatography (CH2Cl2) affording the benzimidazole thioether 32c 
as a white solid (11 mg, 0.03 mmol, 32%). Rf: 0.2 (CH2Cl2); mp: 177-179 °C; ν/cm-1 (neat) 
3026, 1603, 1523, 1431, 1386, 1270, 1229, 982, 820, 753, 373, 697, 668, 639; δH (CDCl3, 
400 MHz) 2.41, (3H, s, CH3), 4.60 (2H, s, PhCH2), 7.11 (1H, td, J 6.9 and 2.5 Hz, Ar-H), 7.16-
7.22 (2H, m, Ar-H), 7.31 (1H, d, J 8.73 Hz, Ar-H), 7.33-7.37 (1H, m, Ar-H), 7.41-7.51 (2H, m, 
Ar-H), 7.57-7.62 (2H, m, Ar-H), 7.62 (1H, d, J 1.5 Hz, Ar-H), 7.73 (1H, s br, Ar-H); δC (CDCl3, 
100 MHz) 19.3, 35.7, 122.5, 126.4, 126.9, 127.4, 128.2, 128.8, 130.1, 134.1, 136.4, 137.1, 
141.5, 150.4; MS (ES+) m/z 331 (M-Cl, 100%), 365 (M+H+, 3%); HRMS (ES+) 365.0879 
calculated for C21H18N2SCl+ (M+H+), found 365.0875, Δ= -1.1 ppm. 
 
6-(3-Chlorophenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32d 
 
The synthesis was carried out in accordance to the general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37d (139 mg, 0.53 mmol, 1.0 eq.), NaOMe (37 mg, 0.69 mmol, 1.3 
eq.), 2-methylbenzyl bromide (92 µL, 0.69 mmol, 1.3 eq.) in DMF (4 mL). After the purification 
by column chromatography (CH2Cl2) the benzimidazole thioether 32d was obtained as a pale 
yellow glassy solid (19 mg, 0.05 mmol, 10%). Rf: 0.2 (CH2Cl2); mp: 50-56 °C; ν/cm-1 (neat) 
2923, 2851, 2802, 2624, 1592, 1563, 1427, 1383, 1336, 1279, 1097, 1079, 1029, 983, 886, 
816, 777, 730, 693, 642; δH (CDCl3, 400 MHz) 2.43 (3H, s, CH3), 4.62 (2H, s, PhCH2), 7.09-
7.16 (1H, m, Ar-H), 7.17-7.22 (1H, m, Ar-H), 7.30-7.44 (3H, m, Ar-H), 7.38-7.57 (3H, m, Ar-H), 
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7.48-7.70 (2H, m, Ar-H), 7.80 (1H, s, Ar-H); MS (ES+) m/z 365/367 (M+H+, 100%); HRMS 
(ES+) 365.0879 calculated for C21H18N2SCl35+ (M+H+), found 365.0895, Δ= 4.4 ppm. 
 
6-(4-Chlorophenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32e 
 
The reaction was carried out as described in the general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37e (44 mg, 0.17 mmol, 1.0 eq.), NaOMe (13 mg, 0.24 mmol, 1.4 
eq.), 2-methylbenzyl bromide (29 µL, 0.22 mmol, 1.3 eq.), in DMF (2 mL) After purification by 
column chromatography (CH2Cl2) the benzimidazole thioether 32e was obtained as a white 
solid (16 mg, 0.04 mmol, 24%). Rf: 0.4 (CH2Cl2); mp: 186-192 °C; δH (CDCl3, 400 MHz) 2.43 
(3H, s, CH3), 5.55 (2H, s, PhCH2), 6.50 (1H, d, J 7.8 Hz, Ar-H), 7.06 (1H, t, J 7.5 Hz, Ar-H), 
7.19-7.31 (3H, m, Ar-H), 7.40 (4H, q, J 9.8, Ar-H), 7.53-7.64 (1H, m, Ar-H), 7.98 (1H, d, J 8.6 
Hz, Ar-H); δH (CDCl3, 400 MHz) 19.3, 46.6, 109.3, 122.2, 123.8, 125.2, 126.8, 128.2, 128.9, 
129.1, 130.8, 132.8, 133.8, 134.8, 136.5, 138.3, 139.5, 140.9; MS (ES+) m/z 365/367 (M+H, 
21%); HRMS (ES+) 365.0879 calculated for C21H18N2SCl35+ (M+H+), found 365.0866, Δ= -3.6 
ppm. 
 
6-(3,4-Dichlorophenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32f 
 
The reaction was carried out as described in general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37f (70 mg, 0.24 mmol, 1.0 eq.), NaOMe (16.6 mg, 0.31 mmol, 1.3 
eq.), 2-methylbenzyl bromide (41 µL, 0.31 mmol, 1.3 eq.) in DMF (2 mL). Purification by 
column chromatography gave the benzimidazole thioether 32f as a yellow solid (21 mg, 0.05 
mmol, 22%). Rf: 0.5 (CH2Cl2); mp: 67-73 °C; ν/cm-1 (neat) 3387, 3019, 2921, 2853, 2803, 
2619,1628, 1591, 1554, 1433, 1333, 1280, 1225, 1133, 1093, 1028, 985, 807, 732; δH 
(CDCl3, 400 MHz) 2.40 (3H, s, CH3), 4.60 (2H, s, PhCH2), 7.12 (1H, dt, J 9.2 and 4.6 Hz, Ar-
H), 7.15-7.23 (2H, m, Ar-H), 7.31 (1H, dt, J 7.4 and 2.2 Hz, Ar-H), 7.40 (2H, td, J 8.8 and 1.9 
Hz, Ar-H), 7.50 (2H, dd, J 15.0 and 8.4 Hz, Ar-H), 7.55-7.61 (1H, m, Ar-H), 7.67 (1H, dd, J 6.3 
and 2.2 Hz); δC (CDCl3, 100 MHz) 19.4, 35.7, 122.0, 126.5, 126.7, 128.4, 128.7, 129.2, 130.8, 
132.9, 133.7, 134.1, 137.2, 141.8, 151.4; MS (ES+) m/z 399/401/404 (M+H, 100%); HRMS 
(ES+) 399.0490 calculated for C21H17N2SCl352+ (M+H+), found 399.0501, Δ= 2.8 ppm. 
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6-(4-Methoxyphenyl)-2-{[(2-methylphenyl)methyl]sulfanyl}-1H-benzimidazole 32g 
 
The synthesis was conducted according to the general procedure G, using 6-aryl-2-
mercaptobenzimidazole 37g (133 mg, 0.51 mmol, 1.0 eq.), NaOMe (36 mg, 0.66 mmol, 1.3 
eq.), 2-methylbenzyl bromide (9 µL, 0.66 mmol, 1.3 eq.) in DMF (4.3 mL). Purification by 
column chromatography (2% MeOH/CH2Cl2) afforded the pure benzimidazole thioether 32g 
as a pale yellow solid (40 mg, 0.11 mmol, 22%). Rf: 0.2 (CH2Cl2); mp: 190-194 °C; ν/cm-1 
(neat) 2935, 1733, 1608, 1527, 1437, 1387, 1227, 1178, 1034, 981, 833, 809, 735; δH (CDCl3, 
400 MHz) 2.46 (3H, s, CH3), 3.88 (3H, s, OCH3), 4.62 (2H, s, PhCH2), 7.01 (2H, d, J 8.7 Hz, 
Ar-H), 7.11-7.18 (1H, m, Ar-H), 7.22 (2H, dd, J 4.0 and 1.7 Hz, Ar-H), 7.31-7.37 (1H, m, Ar-
H), 7.45 (1H, dd, J 8.4 and 1.7 Hz, Ar-H), 7.57 (2H, d, J 8.7 Hz, Ar-H), 7.67 (1H, s br, Ar-H); 
δC (CDCl3, 100 MHz) 19.0, 29.7, 55.3, 114.2, 114.3, 126.4, 128.4, 130.1, 130.6, 137.3, 137.5, 
150.1, 159.1; MS (ES+) m/z 361 (M+H, 100%); HRMS (ES+) 361.1375 calculated for 
C22H21N2OS+ (M+H+), found 361.1376, Δ= 0.3 ppm. 
 
6-Bromo-2-{[(2-methylphenyl)methyl]sulfonly}-1H-benzimidazole 33  
 
6-Bromo benzimidazole benyl ether 10b (279 mg, 0.84 mmol, 1.0 eq.) was dissolved in 
CH2Cl2. Peracetic acid (0.6 mL, high excess) was added to the reaction mixture, which was 
heated to 40 °C for 2 h. After that time the solvent and remaining acid was removed under 
reduced pressure. The cure product was purified by column chromatography (dry loaded, 1% 
MeOH/CH2Cl2) to give the product 33 as a white solid (115 mg, 0.32 mmol, 38%). Rf: 0.6 (1% 
MeOH/CH2Cl2) mp: 175-181 °C; ν/cm-1 (neat) 2929, 2461, 2352, 2198, 2146, 2034, 2003, 
1331, 1132, 915, 812, 785, 748; δH (CDCl3, 400 MHz) 2.33 (3H, s, CH3), 4.83 (2H, s, PhCH2), 
6.84-7.06 (2H, m, Ar-H), 7.17 (2H, dd, J 6.1 and 1.8 Hz, Ar-H), 7.51 (1H, dd, J 8.7 and 1.9 Hz, 
Ar-H), 7.59 (1H, d, J 8.7 Hz, Ar-H), 7.83 (1H, d, J 1.8 Hz, Ar-H); m/z 366 (M+H, 100%); 
HRMS (ES+) 364.9959 calculated for C15H14N2O2SBr+ (M+H+), found 364.9946, Δ= -3.6 ppm. 
 
N-Boc-2-hydroxyaniline 42 [62] 
 
2-Hydroxyaniline 41 (500 mg, 4.58 mmol, 1.0 eq.) was dissolved in THF (10 mL). Then, 
Boc2O (1.99 g, 9.16 mmol, 2.0 eq.) was added to the reaction mixture, which was stirred at 
RT for 16 h. The crude product was recrystallised from Et2O and hexane to give the product 
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42 as pale brown crystals (929.5 mg, 4.44 mmol, 97%). The spectrum is in agreement with 
the already obtained data. [62] δH (CDCl3, 400 MHz) 1.53 (9H, s, C(CH3)3), 6.69 (1H, s br, NH), 
6.85 (1H, ddd, J 7.9, 7.2 and 1.6 Hz, Ar-H), 6.96 (1H, dd, J 8.1, 1.6 Hz, Ar-H), 7.03 (1H, ddd, 
J 8.7, 7.3 and 1.6 Hz, Ar-H), 7.10 (1H, dd, J 7.8, 1.6 Hz, Ar-H), 8.15 (1H, s br, OH); m/z 209 
(M+Na, 25%). 
 
tert-Butyl N-[2-(2-methylpropoxy)phenyl]carbamate 43 [62] 
 
The reaction was carried out as described by Andrew Bayly. N-Boc 2-Hydroxyaniline 42 (500 
mg, 2.39 mmol, 1.0 eq.) was dissolved in dry DMF  (12.4 mL). 1-Bromo-2-methyl propane 
(0.39 mL, 3.59 mmol, 1.5 eq.) and Cs2CO3 (1.25 g, 3.82 mmol, 1.6 eq.) were added and the 
reaction mixture heated to 60 °C for 6 h. After that time the reaction mixture was cooled down 
to RT and H2O was added. The phases were separated and the aqueous layer extracted with 
EtOAc. The combined organic layer was dried over Na2SO4 and the solvent removed in 
vacuo. Purification by column chromatography (Hex/EtOAc, 6:1) gave the product 43 as a 
yellow oil (367.8 mg, 1.38 mmol, 58%). The spectral data correspond to the data reported by 
Andrew Bayly. [62] δH (CDCl3, 400 MHz) 1.06 (6H, d, J 6.7 Hz, CH(CH3)2), 1.55 (9H, s, 
C(CH3)3), 2.15 (1H, dq, J 6.8 and 6.7 Hz, CH2CH), 3.78 (2H, d, J 6.6 Hz, Ar-OCH2), 6.79-6.88 
(1H, m, Ar-H), 6.91-6.99 (2H, m, Ar-H), 7.08 (1H, s br, N-H), 8.08 (1H, s br, Ar-H); m/z 265 
(M, 100%).  
 
tert-Butyl N-[2-(2-methylprop-2-en-1-yl)-6-(2-methylpropoxy)phenyl] carbamate 44 [62] 
 
The reaction was carried out in analogy to the procedure described by Andrew Bayly. tert-
Butyl N-[2-(2-methylpropoxy)phenyl]carbamate 43 (500 mg, 1.88 mmol, 1.0 eq.) was 
dissolved in dry THF (4 mL). The reaction mixture was cooled to -78 °C before tBuLi (1.6 M, 
5.17 mL, 8.27 mmol, 4.4 eq.) was added slowly. The reaction mixture was warmed up to -10 
°C and stirred for 1.5 h. Then, 3-bromo-2-methyl propene (0.42 mL, 4.14 mmol, 2.2 eq.) was 
added and the reaction mixture stirred at -10 °C for another 1.5 h. The reaction was 
quenched by adding saturated NH4Cl solution. The phases were separated and the aqueous 
phase extracted with EtOAc. The combined organic layer was dried over Na2SO4 and 
removed under reduced pressure. Purification by column chromatography afforded the pure 
product 44 as a pale yellow oil (446 mg, 1.39 mmol, 74%). The spectra are in agreement with 
the data reported by Andrew Bayly. [62] δH (CDCl3, 400 MHz) 1.02 (6H, d, J 6.7 Hz, CH(CH3)2), 
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1.47 (9H, s, C(CH3)3), 1.64 (3H, s, C(=C)CH3), 2.09 (1H, dq, J 6.8, 6.6 Hz, CH2CH), 3.39 (2H, 
s, Ar-CH2), 3.72 (2H, d, J 6.5 Hz, OCH2), 4.49-4.94 (1H, m, C=CH2), 5.93 (1H, s br, NH), 6.75 
(1H, dd, J 8.1, 1.3 Hz, Ar-H), 6.80 (1H, dd, J 7.9, 1.3 Hz, Ar-H), 7.11 (1H, t, J 7.9 Hz, Ar-H); 
m/z 320 (M+H, 10%).  	  
tert-Butyl N-[2-(methylpropoxy)-6-(2-methylpropyl)phenyl] carbamate 45 [62] 
 
The reaction was carried out as described in the PhD thesis by Andrew Bayly. In a two-neck 
flask tert-butyl N-[2-(2-methylprop-2-en-1-yl)-6-(2-methylpropoxy)phenyl] carbamate 44 (1.61 
g, 5.01 mmol, 1.0 eq.) was dissolved in MeOH (4 mL). Pd/C (10 mol%, 182 mg, 0.1 eq.) was 
added to the reaction mixture. The flask was evacuated and carefully filled with hydrogen. 
This was repeated and a balloon with hydrogen was left connected to the flask. The reaction 
mixture was stirred for 4 h at RT. After that time the solution was filtered through CeliteTM and 
washed with CH2Cl2. The solvent was removed to give the pure product as colourless 45 
crystals (1.57 g, 4.91 mmol, 98%). The spectra correspond to the reported data by Andrew 
Bayly. [62] δH (CDCl3, 400 MHz) 0.88 (6H, d, J 6.5 Hz, Ar-CH2CH(CH3)2), 1.02 (6H, d, J 6.7 Hz, 
OCH2(CH3)2), 1.47 (9H, s, C(CH3)3), 1.89 (1H, dq, J 6.8, 6.7 Hz, CH2CH) 2.08 (1H, dq, J 6.6, 
6.7 Hz, OCH2CH), 2.51 (2H, d, J 7.2 Hz, Ar-CH2), 3.45 (3H, s, CH3), 3.71 (2H, d, J 6.5 Hz, 
OCH2), 5.86 (1H, s br, NH), 6.71 (1H, dd, J 8.3, 1.3 Hz, Ar-H), 6.76 (1H, dd, J 7.8 and 1.3 Hz, 
Ar-H), 7.10 (1H, t, J 7.9 Hz, Ar-H); m/z 222 (M-Boc+, 100%). 
 
2-(2-Methylpropoxy)-6-(2-methylpropyl)aniline 46 [62] 
 
The reaction was carried out as described by Andrew Bayly. tert-Butyl N-[2-(methylpropoxy)-
6-(2-methylpropyl)phenyl] carbamate 45 (431 mg, 1.34 mmol, 1.0 eq.) was dissolved in 
CH2Cl2 (5 mL). TFA (7.00 mL, high excess) was added and the reaction mixture was stirred 
for 15 minutes at RT. The excess of TFA and solvent was removed under reduced pressure. 
The pure product 46 was obtained as a brown oil (156 mg, 0.70 mmol, 52%) without further 
purification needed. The spectra obtained are in correspondence to the reported data by 
Andrew Bayly. [62] δH (CDCl3, 400 MHz) 0.98 (2H, d, J 6.6 Hz, Ar-CH2CH(CH3)2), 1.07 (6H, d, 
J 6.7 Hz, OCH2CH(CH3)2), 1.98 (1H, dq, J 6.8, 6.7 Hz, Ar-CH2CH), 2.15 ( 1H, dq, J 6.8, 6.6 
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Hz, OCH2CH), 2.42 (2H, d, J 7.2 Hz, Ar-CH2), 3.78 (2H, d, J 6.5 Hz, OCH2), 6.55-6.83 (3H, m, 
Ar-H); m/z 222 (M+H+, 100%). 
 
N-[2-(2-Methylpropoxy)-6-(2-methylpropyl)phenyl] maleimide 47 [62] 
 
The reaction was carried out as described in the PhD thesis by Ardrew Bayly. 2-(2-
Methylpropoxy)-6-(2-methylpropyl)anline 46 (313 mg, 1.4 mmol, 1.0 eq.) and maleic 
anhydride (137 mg, 1.4 mmol, 1.0 eq.) were heated neat to 120 °C for 1 h. Then, the glassy 
product was dissolved in toluene (0.4 mL) and DMSO (0.1 mL) and H2SO4 (8 µL, 0.14 mmol, 
0.1 eq.) was added. The reaction mixture was heated to 135 °C for 20 h. The crude product 
was purified by column chromatography to afford the product 47 as a yellow solid (371 mg, 
123 mmol, 88%). The spectra were in agreement to the reported data by Andrew Bayly. [62] δH 
(CDCl3, 400 MHz) 0.85 (6H, d, J 6.6 Hz, Ar-CH2CH(CH3)2), 0.89 (6H, d, J 6.7 Hz, 
OCH2CH(CH3)2), 1.76 (1H, dq, J 13.6 and 6.8 Hz, Ar-CH2CH), 1.94 (1H, dq, J 13.6 and 6.6 
Hz, OCH2CH), 2.33 (2H, d, J 7.3 Hz, Ar-CH2), 3.67 (2H, d, J 6.2 Hz, OCH2), 6.79 (1H, dd, J 
8.3 and 1.2 Hz, Ar-H), 6.83-6.90 (3H, m, CH=CH, Ar-H), 7.27 (1H, t, J 8.02 Hz, Ar-H); m/z 
302 (M+H+, 5%). 	  
3-(2-Methylbutyl)-N-benzylpyridinium bromide 60 
 
Benzyl bromide (0.45 mL, 3.7 mmol, 1.1 eq.) was dissolved in toluene, and added drop wise 
to a solution of 3-alkyl pyridine 58 (500 mg, 3.35 mmol, 1.0 eq.) in acetone (0.4 mL). The 
reaction mixture was stirred at RT for 16 h. The remaining solvent and benzyl bromide were 
removed in vacuo to afford the pure product 60 as a white solid (867 mg, 2.7 mmol, 81%). Rf: 
0.0 (2% MeOH/ CH2Cl2); mp: 209-212 °C; ν/cm-1 (neat) 2961, 2932, 1630, 1497, 1448, 1455, 
1381, 1359, 1196, 1144, 740, 707, 691; δH (CDCl3, 400 MHz) 0.75 (3H, d, J 6.6 Hz, CH2CH3), 
0.81 (3H, t, J 7.4 Hz, CH2CH3CH2), 1.05-1.18 (1H, m, CH2CH3), 1.20-1.33 (1H, m, CH2CH3), 
1.61-1.82 (1H, m, CH2CHCH2), 2.57 (1H, dd, J 13.8 and 8.2 Hz, Ar-CH2), 2.80 (1H, dd, J 13.8 
and 6.1 Hz, Ar-CH2), 6.26 (2H, s, PhCH2), 7.10-7.50 (3H, m, Ar-H), 7.69 (2H, ddd, J 5.4, 2.8 
and 1.6 Hz, Ar-H), 7.92 (1H, dd, J 8.0 and 5.9, Ar-H), 8.09 (1H, dt, J 8.0 and 1.3 Hz, Ar-H), 
9.49 (2H, dt, J 7.2 and 1.7 Hz, Ar-H); δC (CDCl3, 100 MHz) 11.3, 18.5, 28.8, 35.9, 39.7, 63.6, 
127.8, 129.53, 129.6, 129.8, 133.4, 142.5, 143.1, 144.6, 145.4; The mass spectrum could not 
be obtained. 
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3-(2-Methylbutyl)-N-benzyl tetrahydropyridine 61 
 
The reaction was carried out as described by Maranzano et al. [120] The benzyl pyridinium salt 
60 (857 mg, 2.67 mmol, 1.0 eq.) was dissolved in dry MeOH (16 mL). The reaction mixture 
was cooled to 0 °C and NaBH4 (404 mg, 10.68 mmol, 4.0 eq.) was added in small portions. 
The reaction mixture was heated to 65 °C for 16 h. after that time, the reaction mixture was 
cooled to RT and the solvent was removed under reduced pressure. The remaining solid was 
re-dissolved in CH2Cl2 and H2O was added. The phases were separated and the aqueous 
layer was extracted with CH2Cl2. The combined organic layer was dried over Na2SO4 and the 
solvent was removed in vacuo. Purification by column chromatography afforded the pure 
product 61 as a colourless oil (344 mg, 1.14 mmol, 53%). Rf: 0.5 (6% MeOH/CH2Cl2); ν/cm-1 
(neat) 2958, 2913, 1660, 1494, 1453, 1377, 1359, 969, 737, 698; δH (CDCl3, 400 MHz) 0.84 
(3H, d, J 6.8 Hz, CH3), 0.87 (3H, t, J 7.37 Hz, CH3), 0.91-0.97 (1H, m, CH2CH3), 1.02-1.19 
(1H, m, CH2CH3), 1.29-1.40 (1H, m, Ar-CH2), 1.40-1.50 (1H, m, Ar-CH2), 1.72 (1H, dd J 13.33 
and 8.60, CH2CHCH2), 1.95 (1H, dd, J 13.24 and 4.50, CH2CHCH2), 2.15 (2H, s, H-5), 2.43-
2.62 (2H, m, H-6), 2.85 (2H, d, J 2.4 Hz, H-2), 3.59 (2H, s, PhCH2), 5.44 (1H, s, H-4), 7.23-
7.29 (1H, m, Ar-H), 7.41 (4H, m, Ar-H), δC (CDCl3, 100 MHz) 11.6, 19.2, 26.1, 29.5, 32.6, 
43.5, 49.8, 56.1, 62.9, 120.3, 127.1, 128.3, 135.3, 138.6; m/z 244 (M+H, 100%); HRMS (ES+) 
244.2065 calculated for C17H26N+ (M+H+), found 244.2065, Δ= 0.0 ppm. 
 
3-(2-Methylbutyl)-N-benzyl-N-oxide tetrahydropyridine 62 
 
The reaction was carried out following a procedure by Maranzano et al. [121] The 3-alkyl 
tetrahydropyridine 61 (264 mg, 1.08 mmol, 1.0 eq.) and m-CPBA (205 mg, 1.18 mmol, 1.1 
eq.) were dissolved in CH2Cl2 (5 mL). The reaction mixture was stirred at RT for 16 h. The 
crude product was concentrated and filtered through a short column of basic silica using a 
concentration gradient starting from 2% MeOH/CH2Cl2 to 10% MeOH/CH2Cl2 to give the 
product 62 as a yellow oil (117 mg, 0.45 mmol, 42%). Rf: 0.2 (6% MeOH/CH2Cl2); ν/cm-1 
(neat) 3262, 2959, 2921, 1659, 1454, 1378, 1033, 916, 728, 700; δH (CDCl3, 400 MHz) 0.75-
0.87 (6H, 2xCH3), 0.99-1.18 (CH2CHCH2), 1.24-1.48 (3H, m, alkyl), 1.75 (1H, dd, J 14.2 and 
8.2 Hz, Ar-CH2), 1.97 (1H, dd, J 14.3, 6.59 Hz, ArCH2), 2.23-2.44 (1H, m, H-6), 2.53-2.69 (1H, 
m, H-5), 3.14-3.43 (1H, m, H-2), 3.94 (1H, d, J 40.4 Hz, H-2), 4.28-4.54 (2H, m, PhCH2), 5.55 
(1H, dd, J 3.3 and 1.7 Hz, H-4), 7.32-7.45 (3H, m, Ar-H), 7.52-7.58 (2H, m, Ar-H); δC (CDCl3, 
100 MHz) 11.4, 18.9, 19.1, 23.4, 29.2, 29.5, 32.2, 42.5, 61.0, 66.7, 70.3, 70.5, 119.1, 128.6, 
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129.8, 131.4, 132.7; m/z 260 (M+H, 100%); HRMS (ES+) 260.2014 calculated for C17H26NO+ 
(M+H+), found 260.2008, Δ= -2.3 ppm. 
 
Diels-Alder adduct 64 
 
The reaction was carried out in accordance to the procedure described by Maranzano et al. 
[121] The N-oxide 62 (12 mg, 0.046 mmol, 1.0 eq.) was dissolved in dry toluene (0.13 mL). the 
reaction mixture was cooled to 0 °C and TFAA (13 µL, 0.092 mmol, 2.0 eq.) was added to the 
solution. The reaction mixture was stirred at RT for 1.5 h before NaOMe (12.4 mg, 0.23 mmol, 
5.0 eq.) was added. The reaction mixture was stirred for another 1 h. The solvent was 
removed under reduced pressure and used crude for the next reaction. The p-methoxy 
tetrahydropyridine 63 (16 mg, 0.05 mmol, 1.0 eq.) and alkyl-substitued N-aryl maleimide 47 
(13 mg, 0.07 mmol, 1.4 eq.) were dissolved in toluene (1 mL). The solvent was degassed 
(freeze-pump-thaw, 3 cycles) the reaction mixture was heated to reflux for 16 h. Purification 
by column chromatography gave the product 64 as a brown oil (3 mg, 0.006 mmol, 13%). Rf: 
0.4 (PE/EtOAc 5:1); δH (CDCl3, 400 MHz) 0.83-1.33 (29H, m, alkyl), 3.11-3.24 (3H, m, NCH, 
NCHCH, NCHCHCH), 3.29-3.41 (2H, NCH2), 4.93-4.97 (1H, m, CH2CH), 5.50-5.64 (2H, m, 
ArCH2), 6.16 (1H, s br, CH=CH), 7.28-7.67 (8H, m, Ar-H); δC (CDCl3, 100 MHz) 11.11 (s), 
14.09 (s), 19.07 (s), 22.66 (s), 29.67 (s), 109.99 (s), 122.17 (s), 129.37-130.01 (m). 
 
Protein Expression 
In an eppendorf tube a stock solution (20 µL) of E.coli bacterial cells was defrosted on ice.  
The plasmid (3 µL) was added and the cells gently mixed. The tube was heated to 42 °C for 
45 seconds and immediately put back on ice for 2 min. Media (700 µL) was added and the 
cells incubated for 30 min at 37 °C. Then, the solution was spread on agar plates, which were 
treated with chloramphenicol and ampicillin, and incubated overnight. From the grown 
colonies a single colony was picked and inoculated in media (2 mL). The falcon tube was 
incubated at 37 °C for 6 h, before the culture was transferred into a 100 mL of media. The 
culture was incubated over night. After that, this culture was divided into 5 times 1L of media. 
The cultures were grown until an optical density of 0.6 was achieved. Then, the cultures were 
induced with IPTG and incubated at 25 °C over night. To obtain the protein the cuture was 
divided into 4 centrifuge flasks and spun for 30 min at 5000 rpm. The supernatant was 
discarded, the obtained cell pellet was resuspended in water. The obtained slurry was 
sonicated in 30 sec intervals with 30 sec breaks for 3 min total sonication time. The resulting 
mixture was spun at 15000 rpm. The protein-containing supernatant was treated with DNAse 
and and MgCl2 and left on ice for 30 min. Then, the protein was loaded onto a Hi-trap column 
i) TFAA
ii) NaOMe 47
Tol, 120 °C, 16 h.
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for purification. The crude protein was purified by FPLC using a Hepes buffer with an 
increasing gradient of imidazole. The protein-containing fractions were conbined and split in 
aliquots of 100 µL.  The aliquots were rapidly frozen in liquid nitrogen and stored at -80 °C.  
 
Determination of the Protein Concentration (Bicinchoninic Acid Assay) 
A stock solution of BSA (10.5 mg in 1060 mL water) was prepared. An aliquot of this solution 
(50 µL) was transferred into the first well of a 96 well plate. Water (25 µL) was added to the 
remaining wells in the row. A 1-in-2 serial dilution was carried out. Bicinchoninic acid (5 mL) 
and CuSO4 (1M, 100 µL) were mixed and added to the wells (200 µL). In the next row of the 
plate the protein solution (25 µL) and a 1 in 10 dilution were added. 200 µL of the bichinoic 
acid/CuSO4 mix were added and the plate was incubated for 30 min. The absorbance was 
measured and the protein concentration calculated from the obtained graph. 
 
AlphaScreen® Assay 
Of all compounds and peptides stock solutions (10 mM in DMSO) were prepared. On a 384 
well plate a 10 point 1-in-3 serial dilution of the compounds was carried out: To the first well of 
the row 15 µL of the compound stock was added. To the remaining wells of the row DMSO 
(10 µL) was added. Then, 5 µL of the compound stock was added to the second well of the 
row and mixed. From that well 5 µL were taken and added to the third well. This procedure 
continued until the last well. The 5 µL excess taken from the 10th well were discarded. 
The compound controls (Whitby’s 5a and Scripps compound) were treated as compounds. A 
baseline control and negative control was implemented into the plate. 
An aliquot (5 µL) of all concentrations was transferred to the assay plate. A dilution of protein 
and the respective peptide were added to each well. Nickel-chelate beads (20 µL beads in 
980 µL buffer) were added to each well and the plate centrifuged for 20 sec to enhance 
mixing. The plate was placed on a shaker in the dark for 30 min at RT. Then, the 
streptavidine beads (20 µL beads in 980 µL buffer) were added. The plate was again 
centrifuged for 20 sec and placed on a shaker in the dark for another 1 h. The fluorescence 
was measured using a Pherastar plate reader (excitation 680 nm, emission 520-620 nm).  
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agreement to comply with and be bound by the following terms and conditions:
You grant to users a non-exclusive, non-transferable license to download and use for non-
 Search
commercial, educational purposes any files that you upload to the Access Excellence Forum on
the World Wide Web.
You acknowledge that The National Health Museum, the entity responsible for maintaining the
Access Excellence Forum, retains the sole discretion over whether to make the files you upload
available on the World Wide Web.
You represent and warrant that: (i) you are fully authorized and possess all rights necessary to
grant a license to World Wide Web users to use the files you upload to the Access Excellence
Forum; (ii) your uploading files to the Access Excellence Forum does not infringe the copyright
or any other proprietary rights of any third party; (iii) the downloading and use by World Wide
Web users of any files you upload to Access Excellence will not infringe the copyrights or other
proprietary or license rights of any third party; and (iv) any files that you upload to Access
Excellence do not contain any material that is obscene, libelous or otherwise in contravention of
law.
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Note: the “Contact us” link did not work any 
longer. 
Melanie Muller <melanie.muller.ic@gmail.com>
AW: Fwd: Phenex Pharmaceuticals AG - Contact Form
2 messages
Thomas Schlueter <Thomas.Schlueter@phenex-pharma.com> 22 January 2014 10:17
To: m.mueller07@imperial.ac.uk
Dear%Melanie,
no%problem,%please%feel%free%to%use%that%picture.
I%also%a7ached%some%more%recent%slides%9%just%in%case.
%
Best
Thomas
%
Phenex Pharmaceuticals AG
Dr. Thomas Schlueter
VP Discovery Services
Waldhofer Strasse 104
D-69123 Heidelberg
Germany
Phone: ++49-(0)6221-65282-21
Fax  : ++49-(0)6221-65282-10
thomas.schlueter@phenex-pharma.com
P Sustainable development – Do you really need to print this email?
Von: Services [mailto:services@phenex-pharma.com] 
Gesendet: Dienstag, 21. Januar 2014 21:38
An: Thomas Schlueter
Betreff: Fwd: Phenex Pharmaceuticals AG - Contact Form
 
> ---------- Ursprüngliche Nachricht ---------- 
> Von: Melanie Muller <m.mueller07@imperial.ac.uk> 
> An: info@phenex-pharma.com 
> Datum: 20. Januar 2014 um 22:39 
> Betreff: Phenex Pharmaceuticals AG - Contact Form 
> 
> Dear Sir or Madam, 
> 
> I currently write my PhD thesis and I was wondering if I could have your permission to use a picture of a FRET
assay I found on your website in my introduction? 
> 
> 
> Many thanks and best wishes, 
> 
> Melanie Müller 
>
Melanie Muller <melanie.muller.ic@gmail.com>
RE: permission to use AlphaScreen pictures from your website
3 messages
LAS-EU CC UK <LAS-EUCCUK@perkinelmer.com> 21 January 2014 14:18
To: Melanie Muller <melanie.muller.ic@gmail.com>
Dear Ms. Muller,
 
I have received the relevant approval, hence you may use the pictures of AlphaScreen
 
 
Kind regards,
 
Magdalena Nocuń | Customer Care UK & Ireland
PerkinElmer | For the Better
cc.uk@perkinelmer.com
Phone:  0800 896 046 |   Fax:  0800 891 714   |
Chalfont Road, Seer Green, Beaconsfield, Bucks, HP9 2FX   
cc.ie@perkinelmer.com
Phone:  1800 932 886 |   Fax:  1800 932 884 |  
C17 The Exchange, Calmount Park, Ballymount, Dublin 12
www.perkinelmer.com
Follow us on facebook and twitter
Please consider the environment before printing this e-mail.
This e-mail message and any attachments are confidential and proprietary to PerkinElmer, Inc.  If you are not the intended recipient of this message, please inform
the sender by replying to this email or sending a message to the sender and destroy the message and any attachments.  Thank you.
!
!
!
From: Melanie Muller [mailto:melanie.muller.ic@gmail.com] 
Sent: Monday, January 20, 2014 10:54 PM
To: LAS-EU CC UK
Subject: permission to use AlphaScreen pictures from your website
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Title: Toward Proteomimetics:!
Terphenyl Derivatives as
Structural and Functional Mimics
of Extended Regions of an α-
Helix
Author: Brendan P. Orner,Justin T. Ernst,
and, and Andrew D. Hamilton*
Publication: Journal of the American
Chemical Society
Publisher: American Chemical Society
Date: Jun 1, 2001
Copyright © 2001, American Chemical Society
  Logged in as:
  melanie muller
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you because no
fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and
translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate
school.
Appropriate credit for the requested material should be given as follows: "Reprinted
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the
capitalized words.
One-time permission is granted only for the use specified in your request. No additional
uses are granted (such as derivative works or other editions). For any other uses, please
submit a new request.
If credit is given to another source for the material you requested, permission must be obtained
from that source.
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Dear Sir or Madam, 
 
I currently write my PhD thesis and I was wondering if I could get permission use 2
explanatory pictures of the AlphaScreen I found on your website?
 
 
Many thanks and best wishes, 
 
Melanie Müller
LAS-EU CC UK <LAS-EUCCUK@perkinelmer.com> 22 January 2014 08:27
To: Melanie Muller <melanie.muller.ic@gmail.com>
Dear Ms. Muller,
!
Following my yesterday’s e-mail please kindly acknowledge the images of PerkinElmer when using them by:
 
Images used with permission of PerkinElmer. © 2014 PerkinElmer.
 
Thank you.
 
 
Kind regards,
 
Magdalena Nocuń | Customer Care UK & Ireland
PerkinElmer | For the Better
cc.uk@perkinelmer.com
Phone:  0800 896 046 |   Fax:  0800 891 714   |
Chalfont Road, Seer Green, Beaconsfield, Bucks, HP9 2FX   
cc.ie@perkinelmer.com
Phone:  1800 932 886 |   Fax:  1800 932 884 |  
C17 The Exchange, Calmount Park, Ballymount, Dublin 12
www.perkinelmer.com
Follow us on facebook and twitter
Please consider the environment before printing this e-mail.
This e-mail message and any attachments are confidential and proprietary to PerkinElmer, Inc.  If you are not the intended recipient of this message, please inform
the sender by replying to this email or sending a message to the sender and destroy the message and any attachments.  Thank you.
!
!
 
!
From: LAS-EU CC UK 
Sent: Tuesday, January 21, 2014 3:18 PM
To: 'Melanie Muller'
Subject: RE: permission to use AlphaScreen pictures from your website
[Quoted text hidden]
Melanie Muller <melanie.muller.ic@gmail.com> 22 January 2014 11:03
To: LAS-EU CC UK <LAS-EUCCUK@perkinelmer.com>
Dear Magdalena, 
Yes I will certainly do this.
Many thanks and best wishes,
Melanie
[Quoted text hidden]
